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THESIS ABSTRACT 
Background: Primary ciliary dyskinesia (PCD) is a rare heterogeneous genetic disorder 
associated with abnormal ciliary structure and function, characterised by progressive sino-
pulmonary disease, with symptoms starting soon after birth. There is no ‘gold standard’ for 
diagnosing PCD, and testing includes genotyping, and analysis of cilia function and 
ultrastructure which requires high levels of expertise and expense. Using the biopsychosocial 
framework, this thesis aimed: to provide an overview of the PCD patient perspective and 
experience of living with PCD, to address some of the complexities in referring and 
diagnosing PCD patients, and to provide age specific, PCD-specific validated health-related 
quality of life (HRQoL) measures to monitor patient outcomes and assess effectiveness of 
treatments and interventions.  
 
Method: A patient survey to capture patient experience of PCD diagnostic testing was 
completed in 25 countries (n=365). This was followed by semi-structured interviews with 20 
participants, which were analysed thematically. A systematic review was conducted to 
synthesise evidence on the experience of living with PCD. Through the analysis of 
prospectively collected data from consecutive patients referred to a PCD diagnostic centre 
(2007-2013), sensitivity and specificity for individual testing strategies were calculated. 
Patient clinical characteristics were correlated with diagnostic outcome and using logistic 
regression, the predictive performance of the best model was simplified into a tool 
(PICADAR), predicting the likelihood of referrals having PCD based on clinical symptoms. 
This was externally validated in a second diagnostic centre.  A PCD-specific HRQoL 
measure for adults (QOL-PCD) was developed following a literature review, an expert panel 
meeting, and semi-structured interviews (n=21) from which content analysis was used to 
 xix 
 
derive saturation matrices. Items were rated for relevance (n=49) and the preliminary 
questionnaire was refined following cognitive interviews. Validation followed with patients 
completing QOL-PCD and generic quality of life measures. Stability and responsiveness to 
change were assessed.  
Results: The most prominent theme in the assessment of diagnostic experiences was the lack 
of awareness among medical practitioners leading to a delayed diagnosis; 35% visited their 
doctor >40 times with PCD related symptoms prior to referral. Only 14 PCD studies have 
presented the PCD patient experience or have used patient-reported outcome measures e.g. 
generic HRQoL measures. PCD was found to have a negative impact on physical, emotional, 
and social functioning, and the need for PCD-specific HRQoL measures was highlighted. 
Outcome data from 641 consecutive referrals for diagnostic testing showed that none of the 
diagnostic testing strategies were 100% sensitive and specific. PICADAR applies to patients 
with persistent wet cough and has 7 clinical predictive parameters; it has been shown to have 
good accuracy and validity to predict diagnostic outcome when validated in a second 
diagnostic centre. The QOL-PCD HRQoL measure for adults has demonstrated good internal 
consistency, test-retest reliability, convergent and divergent validity, and responsiveness to 
exacerbations. 
Discussion: Findings from the international survey and interviews have been used to advise 
on ERS Task Force guidelines for diagnosing PCD. The development of PICADAR will lead 
to earlier referral of patients and improved awareness among medical practitioner of the signs 
and symptoms of PCD. The development and validation of QOL-PCD has provided the first 
disease specific patient-reported outcome measure to allow for the assessment of new and 
existing treatments. Overall this thesis has led to advances in the field of PCD; from 
diagnosis to the treatment and management of patients.
 1 
 
 
1. Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
 
1.1.Introduction 
PCD is a rare heterogeneous genetic disorder characterised by impaired mucociliary 
clearance due to abnormal ciliary function. Symptoms of PCD mostly begin in the first few 
days of life with unexplained neonatal respiratory symptoms ranging in severity (1-3). 
Patients continue to have daily chronic wet cough and recurrent upper and lower respiratory 
tract infections throughout childhood (4). Recurrent infections can lead to bronchiectasis and 
reduced lung function over time (5-7). This can result in end-stage lung disease with long-
term oxygen dependency or require lung transplantation. Male infertility is common in PCD 
since sperm flagella have a similar ultrastructure to cilia, however the incidence of female 
infertility and of ectopic pregnancy is unclear but can be explained by immotile fallopian tube 
cilia. A spectrum of organ laterality defects occur with PCD, including situs inversus totalis 
which is a mirror-image arrangement of the thoracic and abdominal organs (~40%), and situs 
ambiguous (~12%) where organ arrangement falls somewhere between normal and mirror 
image (8). Reported prevalence in PCD varies from 1:2,000 to 1:40,000. Variability in 
prevalence rates is likely attributed to a lack of access to diagnostic facilities, or to 
populations where there are high levels of consanguinity (9-11). A European Respiratory 
Society (ERS) Task Force survey of 26 European countries found that PCD is both under-
diagnosed and diagnosed late, particularly in countries with low health-care expenditure (9). 
Early diagnosis has been associated with improved respiratory prognosis (1, 12). 
 
There is currently no “gold standard” test to diagnose PCD (13). European guidelines 
recommend that PCD be confirmed in a specialist centre using a combination of tests. 
Diagnostic tests include nasal nitric oxide (nNO) screening (4, 14), high-speed video 
microscopy analysis (HSVMA) of ciliary beat frequency (CBF) and pattern (CBP) (15, 16) 
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and transmission electron microscopy (TEM) analysis of ciliary ultrastructure (17, 18). PCD 
diagnostic investigations are complex, requiring expensive infrastructure and an experienced 
team of clinicians, scientists, and microscopists (13, 19, 20). Several articles have reported 
the accuracy of individual diagnostic tests for the diagnosis of PCD, but none have explored 
their accuracy when used in combination. There is also a need to promote early diagnosis 
without overburdening specialist services. As PCD symptoms are variable and non-specific 
(21), physicians need guidelines on whom to refer for diagnostic testing.  
 
No medications to date have specifically been approved by regulatory bodies for PCD. 
Treatment strategies for PCD have been applied from other diseases (22, 23), particularly 
cystic fibrosis (CF). A major obstacle to evaluating new treatments and monitoring disease 
progression is the lack of disease-specific outcome measures (24).  
 
This thesis aims to address some of the challenges faced in referring, diagnosing, and treating 
this rare disease.  
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1.2 Aim 
To contribute to the current evidence base in PCD by developing an understanding of the 
issues that are important for patients with PCD, and by developing and validating tools that 
will aid diagnosing, monitoring, and treating patients (Figure 1).  
 
1.3 Objectives 
The thesis has three main objectives: 
1. To provide an overview of the patient’s perspective and opinion on PCD diagnostic 
testing and the experience of living with PCD through: 
A. An international survey and a series of interviews. 
B. Systematically collating and synthesising evidence on PCD patient reported 
outcomes and experiences. 
 
2. To address some of the complexities in referring and diagnosing PCD patients by 
conducting an analysis of 641 consecutive patients referred to a national reference 
centre: 
A. To describe the accuracy of each diagnostic test when used in isolation, in 
combination, or as a screening tool. 
B. To develop and validate a clinical predictive rule to assess the likelihood of a PCD 
diagnosis based on clinical symptoms. 
 
3. To provide a disease-specific outcome measure which can be used to monitor patients 
and assess effectiveness of interventions by: 
 5 
 
A. Developing a health-related quality of life measure specifically for adults with 
PCD (QOL-PCD). 
B. Perform psychometric testing to assess QOL-PCD for reliability, validity and 
responsiveness to change. 
 
 
1.4. Research Setting 
This research was conducted both from University College Cork in the Republic of Ireland, 
and Southampton University Hospital (UHS)/University of Southampton in the United 
Kingdom. UHS is a national reference centre for the diagnosis and management of patients 
with PCD. Data from consecutive referrals have been prospectively and systematically 
collected here since 2007.  Clinical and diagnostic data collected between the years of 2007-
2013 was cleaned, collated, and analysed to calculate diagnostic accuracy and to develop 
PICADAR. To externally validate the predictive score, data was extracted from patient 
records of nearly 200 referrals at a separate PCD diagnostic centre at the Royal Brompton 
Hospital in London.   
Semi-structured interviews were conducted with a large body of patients to generate the items 
for the HRQoL measures. Patients were recruited and interviewed in PCD clinics in UHS and 
in various locations across the UK including Bristol, London and Leeds/Bradford. The author 
also interviewed patients in their homes both around Southampton, the Isle of Wight and the 
Republic of Ireland.  
Recruitment of patients for the validation of the PCD HRQoL measures required the author to 
travel to clinics across the UK and attend PCD Family Support Information days to inform 
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patients of the research that was taking place and to provide them with an opportunity to 
participate. 
 
1.6. Thesis Outline 
The thesis comprises six papers which describe and address some of the complexities of 
referring, diagnosing, and treating patients with PCD. The patient experience of diagnosis, 
daily living and quality of life will also be provided. Chapter 2 provides a brief introduction 
about PCD and the gaps in the knowledge base. 
 
In Part 1 the patient experience is explored.  
Chapter 3 provides an overview of the PCD diagnostic journey from referral to follow-up, 
from the perspective of the patient. Findings are presented from an international survey and 
thematic analysis of semi-structured interviews. The findings from this study have 
contributed to an ERS Task Force developing guidelines for diagnosing PCD. 
Chapter 4 provides a systematic overview of the literature on the patient experience, health-
related quality of life and perspectives of the PCD patient. Perspective from various countries 
and age groups are presented; comparisons between groups, and factors affecting quality of 
life are explored.  
In Part 2 the challenges of referring high risk patients for diagnostic testing are explored in 
addition to the accuracy of diagnostic tests.  
Chapter 5 provides a detailed analysis of the sensitivity and specificity of each diagnostic test. 
The accuracy of each test when used in isolation and in combination is presented. This study 
highlights the challenges of diagnosing PCD which requires highly specialised equipment 
and expertise, not available in most countries.  
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Chapter 6 will examine how well a PCD diagnosis is predicted by clinical features and past 
medical history. The development of PICADAR, a clinical predictive rule for diagnosing 
PCD is described in addition to the external validation of this rule.  
Chapter 7 includes a letter to the editor which was published in the European Respiratory 
Journal following publication of these two papers. The response to this letter is provided 
further highlighting the complexities and challenges faced in research of this rare disease 
where there is no ‘gold standard’ diagnostic method available. 
 
Part 3 shows the process of developing and validating the first patient-reported outcome 
measure for PCD.  
Chapter 8 presents the developmental phase of this HRQoL measure for PCD adults: QOL-
PCD.  
Chapter 9 presents the results from the psychometric validation of this measure showing its 
reliability, validity, and responsiveness to change.  
 
Chapter 10 integrates the main findings of these studies. The main findings are discussed 
according to the biophysical, psychological, and social impact of PCD. The implications of 
these findings are provided. Conclusions are drawn and the limitations of the studies outlined. 
Recommendations are made for future research. 
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1.7. Author’s Contribution 
I was lead author of the research papers in Chapters 3, 4, 6 and 9 and co-first author for the 
papers in Chapters 5 and 8. This involved developing the study protocols, conducting 
literature searches, data cleaning, data analysis, and drafting of each of these manuscripts. 
  
In Chapter 3, the research question was generated to inform a European Respiratory Society 
(ERS) Task Force who were developing guidelines for diagnosing PCD. It is important that 
these guidelines are patient centred. This provided me with an international platform to 
establish the patient perspective from countries where it has not been investigated before. 
Supported by my supervisors, I developed the survey based on literature searches and 
analyses of transcripts of previous interviews with PCD patients. Once developed, members 
of the ERS Task Force (international) and patient support groups (UK and USA) were 
contacted for their opinions on the survey and to suggest interactive changes. Once amended, 
I organised the translation and back translation of the survey into 9 European languages and 
enlisted the help of members of the taskforce, international patient support groups, and the 
European Lung Foundation (ELF) to disseminate the survey internationally. I performed 
descriptive analysis of the survey findings. Dr Bruna Rubbo (a PhD student in the University 
of Southampton) conducted an analysis of the survey results by country to allow comparisons 
to be made. I completed 20 semi-structured interviews focusing on the participant’s 
experience of the referral and diagnostic process. Telephone interview were completed with 
participants from Europe, Australia and the USA. I conducted a thematic analysis of the 
transcripts and drafted the manuscript. I presented the findings to the ERS Task Force at 
committee meetings and at the European Respiratory Society Congress in 2015 as a poster 
presentation. In Chapter 4, I formulated the research question, wrote the protocol, conducted 
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the data synthesis and wrote the manuscript. I was assisted by Dr Bruna Rubbo who 
completed the search and data extraction independently to ensure accuracy of reporting. 
 
For Chapter 5 and Chapter 6, I prepared and cleaned the database used for both studies, 
conducted the data analysis and presented the results. For Chapter 6, I collected the data for 
the external validation of the score by extracting the data from 200 patient records at the 
Royal Brompton Hospital. I was responsible for drafting the manuscript. 
I participated in discussions and contributed to the writing of the response letter in Chapter 7.   
 
Chapter 8: As a senior research assistant on the BESTCILIA FP7 study, my main task was to 
develop, validate, and translate age-specific HRQoL measures for PCD patients. These have 
been developed for adults, adolescence, children and parent-proxy; the adult version is 
presented in this thesis. I completed semi-structured interviews and cognitive interviews with 
all age groups in the UK as part of the work package protocol. I conducted the content 
analysis of transcripts and developed saturation grids for all domains of interest. This has 
been a major collaboration with partners in North America and throughout Europe; I 
conducted the co-ordination of the project. I presented the results from the UK interviews, 
and findings from the clinical relevance scores to our colleagues in North America, who had 
followed this study protocol in parallel. Results from both countries were triangulated to 
generate the HRQoL measures (QOL-PCD). This ensured the measures were cross-culturally 
valid across English speaking populations. I led the comprehensive translations of the QOL-
PCD questionnaires into a number of European languages (German (adapted for Swiss 
German), Dutch, Danish and French).  The English, German, Danish and Dutch QOL-PCD 
measures have been included as a secondary outcome measure in the BESTCILIA 
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international clinical trial. For this paper, I was responsible for data collection, analysis, 
reporting the results, and drafting the manuscript.  
 
Chapter 9: Following on from the development of the adult measures, I was responsible for 
developing the protocol for the longitudinal psychometric validation of the QOL-PCD 
measures. I recruited patients in the UK and regularly updated the team on the status of the 
study. I performed the analyses and drafted the manuscript. Throughout this research project 
of developing, validating, and translating the HRQoL measures for PCD, I have presented 
findings from each stage of the developmental process at BESTCILIA conferences and 
meetings, at BEAT-PCD Cost Action training schools and annual conference, and as a poster 
presentation at the European Respiratory Society Congress. 
 
Recognising the importance of international collaboration in rare diseases such as PCD, for 
the past three years, I have fully immersed myself in international PCD collaborations such as 
the European Respiratory Task Force (I am a member of the management committee), 
BESTCILIA and the Cost Action project: BEAT-PCD, where I am the early-career 
researcher representative on the Steering Group as well the Irish representative on the 
management committee. In March 2015, I co-organised The First Young Researchers 
Conference in PCD, which was held in Bern, Switzerland, bringing together early-career 
researchers from across Europe with the aim of developing collaborations and providing a 
platform for early-stage researchers to present their work to peers as well as a panel of PCD 
experts and to received feedback and recommendations. 
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Figure 1. Overview of thesis including aim and objectives 
 Aim: To understand the issues that are important to patients with primary ciliary dyskinesia and to develop tools that will improve diagnosis, 
monitoring and treatment of patients. 
 
   
Objective 2 (B) 
To develop and 
validate a clinical 
predictive rule to 
assess the likelihood of 
a PCD diagnosis to aid 
referral of patients to 
diagnostic services 
 
  
Objective 1 (B) 
To provide an 
overview of the 
patient experience of 
living with PCD 
through 
systematically 
collating and 
synthesising evidence 
on PCD patient 
outcomes  
 
Objective 2 (A) 
To analyse and 
describe the accuracy 
of each diagnostic 
test when used in 
isolation, in 
combination, or as a 
screening tool   
 
Objective 3 (A) 
To develop a health-
related quality of life 
measure specifically 
for adults with PCD 
(QOL-PCD) 
 
 
Objective 3 (B) 
To perform 
psychometric testing to 
assess QOL-PCD for 
reliability, validity and 
responsiveness to 
change 
“An international 
study on PCD 
patients’ diagnostic 
experience calls for 
earlier referral & 
access to specialist 
services” Published 
in the European 
Respiratory Journal 
 
 “The patient’s 
experience of living 
with primary ciliary 
dyskinesia: a 
systematic review” 
To be submitted to 
Quality of Life 
Research 
 
Objective 1 (A) 
To provide an 
overview of the 
patient perspective 
of PCD diagnostic 
testing through an 
international survey 
and a series of 
interviews 
 
“Combination 
testing in PCD 
diagnosis remains 
the most accurate 
approach, but 
standardisation is 
needed” Published in 
the European 
Respiratory Journal 
“PICADAR is a 
simple diagnostic 
prediction tool for 
PCD with good 
accuracy and 
validity that is now 
ready for testing” 
Published in the 
European 
Respiratory Journal 
“QOL–PCD: quality 
of life measure for 
primary ciliary 
dyskinesia is ready 
for multi-national 
psychometric 
testing” Published in 
the European 
Respiratory Journal 
“QOL-PCD is short 
and easy to use tool for 
evaluating new 
therapies and for 
measuring symptoms, 
functioning and 
HRQoL during 
routine care.” 
Submitted to the 
American Journal of 
Respiratory and 
Critical Care Medicine 
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BACKGROUND 
This chapter provides an overview of primary ciliary dyskinesia (PCD). It describes the 
history of PCD, the symptoms, and prevalence rates. Secondly, the pathophysiology of PCD, 
and the methods used to diagnose this illness are examined. Thirdly, disease progression and 
prognosis are discussed. The importance of health-related quality of life (HRQoL) in PCD is 
highlighted and the approaches used for developing and applying tools to measure this multi-
dimensional concept. Finally the biopsychosocial model is presented and the need for an 
integrated approach for diagnosing and treating PCD patients across this three tiered 
framework is presented.    
2.1. Description of the illness 
PCD represents a clinically and genetically heterogeneous group of respiratory ciliopathies 
with absent mucociliary clearance of the airways. Simply explained, the normal bronchial 
tree, upper respiratory tract, and fallopian tubes are lined by small extrusions from the cell 
body (cilia) which beat in a coordinated fashion to remove mucus and secretions (often 
containing bacteria and allergens) from the lungs and sinuses (Figure 2). When cilia are 
immotile or beat in a dysfunctional or uncoordinated way, secretions build up causing 
inflammation and leading to recurrent infections (22). Eventually permanent damage occurs 
to the airway structure, a condition known as bronchiectasis.  In addition to recurrent 
infections, the predominant symptoms of PCD are chronic daily productive cough and 
chronic persistent rhinitis (1, 10). As the middle ear, paranasal sinuses and nasal pharynx also 
are lined with ciliated epithelium, defective mucociliary clearance leads to persistent chronic 
rhinitis, sinusitis, recurrent otitis media and hearing impairment (22, 25). 
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Figure 2: Ciliated epithelium lines the upper and lower airways. The coordinated beating of 
the cilia (at 12-18Hz) sweeps mucus and any debris or pathogens via the ‘mucociliary 
escalator’ to the pharynx, where it can be swallowed (26). 
 
2.2. Pathophysiology of PCD 
The ultrastructure of motile cilia found in the upper and lower respiratory airways and 
fallopian tubes consists of a highly organised ‘9+2’ arrangement: 9 microtubule doublets 
located around the periphery of the cell which surround a single pair of central microtubules 
(Figure 3). The structure of the axoneme is maintained by protein cross-links with each 
doublet microtubule linked to the adjacent by nexin links and to the central pair by radial 
spokes. The central pair of microtubules are connected together by a bridge. Attached to the 
microtubule doublets are inner and outer dynein arms. In 70-80% of PCD cases, the 
ultrastructural defect is a result of missing inner and/or outer dynein arms. Other 
ultrastructural defects include a loss of microtubule arrangement (radial spokes defect) or 
where the central pair microtubules are missing and are replaced by a peripheral doublet of 
microtubules (transposition defect) (17, 27-30). Ultrastructural defects are associated with 
various types of cilia dysfunction. As dynein is a mechano-chemical protein, it generates 
force for ciliary beating and bending (28). Abnormalities of the dynein arm affect ciliary 
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beating i.e. an outer dynein arm defect results in static or extremely slow beating cilia. A 
transposition defect leads to ineffective circular beat patterns (16).  
 
Figure 3: Diagram of the transverse section of a respiratory cilium axoneme (right) and a 
transmission electron photomicrograph of cilia ultrastructure, with ultrastructure features 
labelled.  Both diagram and micrograph show normal cilia ultrastructure (31).  
 
 
In addition to sinopulmonary disease, infertility or subfertility is common (32). For males, 
infertility occurs since sperm flagella have a similar ultrastructure to cilia so there is often an 
absence of the sperm tail or impaired motility of the sperm tail (33, 34). The incidence of 
female infertility and of ectopic pregnancy is less clear and is explained by immotile fallopian 
tube cilia (32, 35).  
Situs inversus totalis or mirror-image organ arrangement is found to be present in nearly half 
of PCD patients, and at least 12% of patients present with heterotaxy (8, 36, 37). This is a 
result of cilia dysfunction in embryonic nodal plate cells which results in laterality defects. 
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This can also lead to complex congenital cardiac defects which is found in 5% of patients 
(37).  
 
2.3. History of PCD 
Primary ciliary dyskinesia was first described by Siewart in 1904 where an association 
between bronchiectasis and situs inversus was made in a 21 year old male. Kartagener (in 
1933) reported on 11 cases with situs inversus and bronchiectasis that were all associated 
with sinusitis, and described a condition as being made up of a triad of these symptoms (38). 
He also described this as a hereditary condition which became referred to as ‘Kartagener’s 
Syndrome’. It was in the 1970s that Afzelius found infertility was also a feature. He 
described 4 subjects with immotile sperm, three of whom had frequent bronchitis and 
sinusitis. He noted the absence of mucociliary transport (Figure 2) and indicated (through 
electron microscopy) that cilia from the cells of these patients lacked dynein arms (39, 40). 
Pedersen continued this work to confirm the unifying role of respiratory tract symptoms in 
patients with Kartagener’s Syndrome and abnormality in cilia at the sub-structural level  (41) 
(Figure 3). Later work by Afzelius found that cilia were immotile (39) and he proposed and 
defended that ‘Kartagener’s Syndrome’ be changed to ‘Immotile Cilia Syndrome’.  Later 
work found that not all patients have immotile cilia, with a proportion of patients having 
dysfunctional cilia motility (42, 43).  
In 1980, Sleigh, supported by 23 researchers, advocated for the name to be changed to 
‘primary ciliary dyskinesia’ (44). ‘Primary ciliary dyskinesia’ would be the term used for 
patients with the congenital disease and ‘secondary cilia dyskinesia’ would be a diagnosis for 
those who acquired the disease as a result of infection, pollutants or inflammation.  
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Further work has indicated more levels of heterogeneity in the diagnosis of this condition. 
Ultrastructural abnormalities in cilia are not confined to the absence of outer dynein arms.  
Radial spokes (45) and central pair (46) have been found to be missing in some cases. Later 
again it was found that patients with PCD could have normal cilia ultrastructure but abnormal 
beating (47). While advances in the diagnosis of PCD continue to be made, the contributions 
of this early work on identifying PCD through analysis of cilia ultrastructure and cilia 
motility remain as recommended diagnostic tests in European guidelines (22).  
PCD is a heterogeneous disorder. Advances in genotyping have led to the discovery of over 
30 mutations causing genes which identify approximately 65% of PCD cases. Cilia consist of 
more than 250 proteins and thus many genes are involved in ciliary structure and function. 
The first PCD gene isolated was dynein axonemal intermediate chain 1 DNAH5, identified in 
1999 (48). The second gene, isolated in 2000, was dynein axonemal heavy chain 5 (DNAI1) 
(49).  These are the most common mutations and are found to be present in up to 38% of all 
PCD patients (50). It has been found that DNAH5 mutations are associated with outer dynein 
arm defects, left–right asymmetry, and male infertility. In patients with this gene defect, cilia 
are completely immotile. DNAI1 mutations have been shown to cause either immotile cilia or 
a reduced cilia beat frequency (51).  
 
2.4 Obstacles in diagnosing PCD 
Diagnostic challenges begin early with symptoms of PCD being non-specific and although 
PCD is a rare disease, symptoms such as recurrent upper and lower respiratory tract 
infections are extremely common, especially in the paediatric population. Therefore, an 
important but complicated task for clinicians is to identify patients suffering from this 
condition. Physicians need guidance of whom to refer for diagnostic testing and large multi-
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national studies are ongoing to identify the more prominent clinical features to predict PCD 
diagnosis (21).  
Diagnostic testing in PCD requires expensive infrastructure and an experienced team of 
clinicians, scientists, and microscopists (13, 19, 20). Guidelines recommend that PCD should 
be confirmed in a specialist centre using appropriate diagnostic testing (22). Diagnosing PCD 
is difficult with no single ‘gold standard’ test currently available (52).  A combination of 
complex techniques was recommended in European consensus guidelines in 2009 (22) which 
include high-speed video microscopy analysis to identify abnormal ciliary function 
(HSVMA) (15, 16, 29), and transmission electron microscopy (TEM) to define ciliary 
ultrastructural defects (17, 18). Nasal nitric oxide (which is extremely low in patients with 
PCD) (14, 53) was recommended as a screening test for PCD. These tests are not readily 
available or standardised (54) and various models exist to deliver diagnostic services. Up to 
now, genetic testing has taken a prominent position in some countries such as the USA. In the 
UK, while genetic testing has recently been introduced, the main diagnostic strategies include 
measuring nNO, HSVMA, and TEM (21, 55). In the UK, generally there is a network of 
satellite screening centres accessing a specialist centre (14, 20, 21). 
No diagnostic test for PCD is 100% accurate and therefore combinations of tests must be 
available. Each test has its own limitations. HSVMA is a qualitative test with potential 
subjectivity. Both false negative and false positive results can occur. False positive results 
can occur due to recent infection or damage during sampling leading to a proportion of cilia 
presenting as dyskinetic (62). Therefore PCD scientists require significant experience to 
distinguish between PCD samples and non-PCD samples.  
TEM has been shown to be unreliable when used in isolation as approximately 20% of 
patients have normal cilia ultrastructure (56, 57). TEM often requires the support of nNO and 
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HSVMA to make a diagnostic assessment. However, it is a vital part of the diagnostic 
portfolio in both supporting HSVMA findings and in providing a diagnosis when HSVMA 
results are inconclusive or when results are not available.   
Nasal nitric oxide (nNO) is extremely low in patients with PCD however there is much 
debate of the best cut-off values for nNO testing. An arbitrary nNO value in the diagnostic 
centre in Southampton is set at 30 nL·min
−1
. This was determined based on prior experience, 
however more recent evidence suggests that higher cut-offs may be more useful (53). A USA 
diagnostic centre has recommended that the cut-off value of 77 nL·min
−1
 be used (14). While 
nNO is a useful screening test for symptomatic patients (53, 58), UHS uses nNO in parallel to 
TEM and HSVMA, to support a positive diagnosis. Without a standardised agreed cut-off 
value, it is considered a risk to exclude a PCD diagnosis if a patient has a nNO measurement 
of >30 nL·min
−1
.   
Although the rate of discovery of new PCD genes has accelerated during the past number of 
years, clinically available genetic testing is only available for a subset of individuals with 
PCD as it is estimated that known PCD-causing mutations account for approximately 60% of 
cases (31). Disease-associated mutations have been identified in over 30 genes with strong 
correlations between genotype and cilia ultrastructure defect (20, 59).  
A more recent European Task Force (2014-2016) for which the author was a junior member, 
has developed updated evidence based guidelines for diagnosing PCD (Submitted for 
publication to ERJ, May 2016) (Appendix 8)).  The guidelines recommend genotyping to be 
included in the diagnostic protocol, where a positive test has been diagnosed by other means 
(e.g. HSVMA, TEM). In the case where a mutation in a PCD causing gene is found in 
addition to an identified hallmark ciliary ultrastructure defects, a conclusive positive 
diagnosis can be provided. As genetic testing only identifies approximately 60% of PCD 
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patients, a negative genetic test cannot exclude PCD.  It is now recommended that only a 
‘highly likely’ diagnosis can be provided in patients with a combination of a compatible 
history of PCD, very low nNO, and HSVMA findings (static or circling cilia) consistently 
suggestive of PCD, or where a very low nNO is found plus HSVMA consistent with PCD 
following cell culture.  
In more recent times, tests such as immunofluorescence (IF) of ciliary proteins (60, 61) and 
pulmonary radioaerosol mucocliliary clearance (PRMC) (62) are becoming more increasingly 
available which may lead to greater accuracy of diagnostic testing in the future. IF of ciliary 
proteins was developed as a research tool to improve understanding of the impact of disease-
causing genes on ciliary proteins. PRMC is a method that draws on the fact that patients with 
PCD have impaired mucociliary clearance as a result of abnormal ciliary motility. Abnormal 
clearance patterns can be visualised for the entire lung using a gamma camera to follow the 
movement of an inhaled radioaerosol (63). Evidence on the sensitivity and specificity of IF 
and PRMC is too limited for these tests to be included alongside some the more mainstream 
diagnostic tests, however application of these tests is recommended in patients where the 
diagnosis is highly likely or remains inconclusive following other investigations. 
 
2.5. Prevalence of PCD 
There is limited representative international data on the prevalence of this illness. Estimates 
of prevalence vary from 1:2,000 to 1:40,000. The highest prevalence rate (1:2,265) has been 
reported in a South Asian population living in the UK with relatively high levels of 
consanguinity (11). A survey of 26 countries across Europe examined prevalence rates in 
pediatric respiratory centres and found that prevalence of PCD varied considerably between 
countries. The highest rate was reported in Cyprus (1:10,000), Switzerland (1:20,000) and 
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Denmark (1:20,000). Lower rates were found in countries such as Findland and the Czech 
Republic, where prevalence rates were approximately 1:200,000. This may reflect true 
variability or it could be due to under-diagnosis or late diagnosis of patients.  It could also be 
due to a lack of access to PCD diagnostic services in some countries (9).  
 
2.6. Disease progression and prognosis of PCD 
There is little known about the clinical severity or the natural progression of this illness (1, 22, 
64). Symptoms of PCD mostly begin in the first few days of life with unexplained neonatal 
respiratory symptoms; these can range in severity from mild transient tachypnoea to 
pneumonia and significant respiratory failure requiring prolonged respiratory support (1-3). 
Patients continue to have chronic wet cough and recurrent upper and lower respiratory tract 
infections throughout childhood. Reduced lung function i.e. mean FEV and forced vital 
capacity (FVC) have been shown over time in a large number of patients showing the 
progressive nature of this illness over time (1, 4, 65). Recurrent infection invariably leads to 
bronchiectasis which has been reported in 25-55% of children (66) and in virtually all adults 
(6, 7). Severity of bronchiectasis has been shown to correlate with increasing age, decreased 
lung function, and colonisation with pseudomonas aeruginosa (6, 7). The progression of 
hearing and upper airways disease is unknown however it has been reported that hearing 
impairment in PCD children can lead to speech delay and impaired learning at school if not 
picked up and manged correctly (25, 67, 68). 
 
PCD can lead to end stage lung disease with one study reporting that 25% of adult PCD 
patients in the USA require long term oxygen or lung transplantation. A USA cross-sectional 
study showed that FEV1 (% predicted) decreases with age at a rate of 0.8% per year (1), 
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however it is unclear if this is influenced by age at the time of diagnosis. An early study has 
suggested that lung function can improve over time once a diagnosis has been made and 
treatment has initiated (64). A more recent longitudinal study however, by Marthin et al. (4) 
described the long term outcome of 74 patients of all age groups, followed over a 9.5 year 
period. Despite the initiation of state of the art treatments, only 10% showed an improvement 
of ≥10% FEV1 in the 10 year period following diagnosis, 57% remained stable and 34% had 
a decline in lung function of ≥10%. Change in lung function over time was also not 
correlated with age at diagnosis, although a decrease in lung function did slow-down 
following diagnosis and initiation of treatment. 
 
2.7. Treatment, management and outcome measures in PCD 
There is little evidence to inform PCD management practice. As an orphan disease, PCD has 
historically been absent from clinical trials evaluating medicines and therapeutic treatments. 
Most treatment recommendations are extrapolated from cystic fibrosis and non-cystic fibrosis 
bronchiectasis guidelines, subjective experience of experts, and small observational studies. 
Due to the underlying impairment of mucociliary clearance, routine daily therapies including 
regular airway clearance are considered the backbone of prescribed treatments (1). By ridding 
the airway of excess mucus, the patient is also removing pathogenic debris. Exercise is 
recommended for aiding physiotherapy and general wellbeing as exercise intolerance has 
been correlated with decreased lung function in PCD (1).  
Routine clinical visits are recommended 2-4 times annually. This allows for review by the 
multidisciplinary team including physiotherapists and ENT (Ear, Nose Throat) specialists. At 
routine visits lung function measurements are also taken, as are sputum cultures for the 
surveillance of microbial organism growth (59). Staphylococcus aureus, Streptococcus 
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pneumonia, Haemophilus influenza, and Pseudomonas aeruginosa are the most common 
microbial organisms grown by PCD patients (1, 64, 69).  While mild exacerbations are 
treated with oral antibiotics and increased airway clearance, severe exacerbations can require 
intravenous antibiotics and inpatient hospitalisation (69). Inhaled antibiotics are often 
prescribed for patients with Pseudomonas aeruginosa infection or when Pseudomonas 
aeruginosa is grown in airway sputum culture (70).  Other less routine case-by-case 
treatments include chronic suppressive oral or inhaled antibiotics, DNase, inhaled 
hyperosmolar agents and inhaled bronchodilators (70).  
The use of cystic fibrosis guidelines for the management of PCD has its limitations. PCD has 
been shown to be clinically distinct from cystic fibrosis with different underlying genetics 
and pathophysiology. Patients are therefore likely to benefit from different treatment 
strategies (23).  Randomised control trials are needed in PCD. These will allow for treatment 
efficacy and side effects to be determined and guidelines on treatment plans to be tailored for 
this disease specifically. The first PCD randomised controlled clinical trial is currently 
ongoing as part of the BESTCILIA FP7 Study. This trial is evaluating the use of prophylactic 
Azithromycin.  
Assessment of new treatments is challenging without the availability of a highly sensitive 
disease-specific outcome measure. Outcome measures used to assess disease severity in PCD 
to date include spirometry (4), chest computed tomography (66, 71), magnetic resonance 
imaging (5) and lung clearance index (72-75). These physiological and radiological measures 
all have limitations in terms of their sensitivity or feasibility to monitor disease progression. 
Although spirometry is easy to perform, it is an insensitive marker of lung function decline. 
Normal spirometry has been found in cases where there are substantial structural lung 
changes as shown by chest computed tomography (CT). Spirometry has also been shown to 
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be less accurate in detecting changes associated with the progression of lung disease. 
Assessment of disease severity using high-resolution computed tomography (HRCT) has 
been shown to be a sensitive method of assessment, however HRCT cannot be used for 
regular monitoring because of radiation risks (66). Magnetic resonance imaging (MRI) 
protocols have been developed showing good agreement with HRCT for determining the 
extent and severity of lung disease in non-CF bronchiectasis. Although MRI is inferior to 
HRCT with regard to speed, image contrast, and spatial resolution, it is a useful radon-free 
tool (5). Lung clearance index (LCI) is a measure of abnormal ventilation distribution derived 
from the multiple breath inert gas washout (MBW) technique. Similar to cystic fibrosis, LCI 
has shown to be more sensitive than spirometry in detecting pulmonary disease in PCD 
patients (76). However  it has been reported not to be so sensitive in detecting changes in 
advanced PCD (73). In PCD, longitudinal data for each of these physiological outcomes is 
either absent or of poor quality. This highlights the need for a sensitive disease-specific 
outcome measure. 
 
2.8. Psychosocial factors in PCD 
Few studies have reported on the psychological and social burden of PCD. However a small 
case-control study of 10 PCD children and 32 healthy children (77), who underwent the 
Wechsler Intelligence Scale for Children-III edition and the Child Behaviour Check-List 
questionnaire (CBCL), suggests that PCD children were more likely to be withdrawn, 
experience anxiety or depression, and internalise more problems than their healthy peers. 
PCD has also been found to be associated with higher scores in the Parenting Stress Index-
Short Form in mothers of children with PCD compared to mothers of healthy children. 
Qualitative research findings have shown the emotional impact this illness can have, with 
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prominent themes including anger and frustration on account of the constant symptoms, 
treatment burden, and frequent exacerbations associated with PCD. Patients reported feeling 
anxious when thinking about their future health (78). Feelings of embarrassment were 
prominent and were attributed to the need to cough or blow nose in public or when producing 
sputum in social contexts (79). Patients also spoke about not being able to physically keep up 
with other family members and peers due to fatigue caused by PCD (78). 
 
2.9. Health-Related Quality of Life (HRQoL) 
 
The term ‘quality of life’ itself has no strict definition, however the World Health 
Organisation (WHO) defines it as an “individual’s perception of their position in life in the 
context of the culture and value systems in which they live, and in relation to their goals, 
expectations, standards and concerns” (80). Thus, quality of life assesses physical health, 
psychological state, levels of independence and social relationships, but also a broader range 
of conditions such as environment, wealth, safety, crowding etc. (81).  
HRQoL is a less general term than quality of life. This term was intended to narrow the focus 
to the effects of health, illness, and treatment on quality of life. Cella et al’s (82) definition 
for HRQoL is ‘the extent to which one’s usual or expected physical, emotional, and social 
well-being are affected by a medical condition or it’s treatment.’ The US Food and Drug 
Administration (FDA) defines HRQoL as the patient’s perception of how they “survive, feel, 
and function”(83).  HRQoL is a multi-dimensional construct evaluating physical, 
psychological, and social components that may be impacted by a disease or medical 
condition. HRQoL is evaluated from the patient perspective. 
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There are two main types of HRQoL instruments: generic and disease-specific. Generic 
HRQoL instruments are not specific to any particular disease and are therefore useful for 
comparing HRQoL across different conditions. They are however, more ‘general’ and less 
sensitive to the particular problems associated with a condition. Disease-specific HRQoL 
questionnaires focus on issues pertinent to one disease and provide an in-depth picture of the 
day-to-day concerns of patients (84). They also have an improved ability to capture small 
changes in HRQoL that may occur as a result of clinical or therapeutic treatment (84, 85). 
Disease-specific HRQoL measures have become an increasingly important tool for measuring 
outcomes, particularly in the context of chronic diseases (13).  
Data is sparse in PCD regarding disease progression and life expectancy. It is important that 
medical interventions not only focus on preventing disease progression but also focus on 
improving the patient’s HRQoL. With healthcare moving more and more towards a patient-
centred approach, the utilisation of PROMs such as HRQoL measures have become 
increasingly important. While traditional medical models focus merely on the etiology, 
pathogenesis, signs, symptoms, treatment and prognosis of the disease (86), the 
biopsychosocial approach focuses on the psychological and social components of health and 
disease. The biopsychosocial model does not provide a straightforward testable model to 
explain interactions or causal influences by each of the three components (biological, 
psychological, social) but it does provide a general framework to guide theoretical and 
empirical exploration (87, 88).  
 
2.10. Measuring heath related quality of life 
Substantial progress has been made in the past three decades in defining and measuring 
HRQoL. There is extensive agreement that assessment of HRQoL should encompass a 
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minimum of physical, social and emotional well-being which allow for a multidimensional, 
systematic measure of the impact that the illness and its treatments have on the individual 
(89, 90). Measures should be capable of capturing changes in disease progression over time. 
They must also be able to discriminate between subjects with varying levels of severity of 
symptoms and other criteria such as age differences (91). 
The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) 
strongly promote the use of PROMs in clinical trials in addition to physiological measures 
(92-94).  There are several recommended stages in the development and testing of a HRQoL 
measure. For example, Kirshner and Guyatt described six stages of development: (1) 
choosing an initial item pool, (2) selection of the "best" items from that pool, (3) reduction of 
the number of items, (4) questionnaire format, (5) pretesting the instrument and 
demonstrating the reproducibility of the instrument, and 6) assessing the validity of the 
instrument and it’s responsiveness to change (91). Guyatt et al. (95) describes these stages as 
either involving a rigorous process (termed the ‘Rolls-Royce model’) that will establish the 
clinical relevance, responsiveness and validity of the instrument, or a less costly approach 
that does not test for reproducibility, responsiveness and validity (the ‘Volkswagan’ model). 
The FDA guidelines for developing PROMs for use in clinical trials (83) recommend an 
iterative process consisting of: (1) hypothesising the conceptual framework, (2) adjusting 
conceptual framework and draft instrument, (3) confirming the conceptual framework and 
accessing other measurement properties, (4) collecting analysing and interpreting data, and (5) 
modifying the instrument. For this study we aimed to adopt a rigorous and time consuming 
approach and ensured that FDA guidelines were adhered to in the development of the PCD 
HRQoL measure. This will allow for the assessment of special states and concerns unique to 
this diagnostic group and will be an important asset in trials evaluating the effectiveness of 
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treatments and interventions. The EMA recommends that PROMs are validated in therapeutic 
exploratory trials before their implementation in therapeutic confirmatory trials. The PRO 
instrument should be validated by testing and documenting validity, reliability, 
responsiveness and interpretability for the specific condition/setting.   
 
2.11. Cross-cultural approach to HRQoL 
In rare diseases a leading problem can be the recruitment of a requisite number of study 
participants. To overcome this, international collaborations are often required (96). It is 
important that PROMs used in these trials are translated and tested comprehensively in each 
language. Even within countries, there may be differences in dialects and in what is 
considered culturally acceptable. It is important that steps be taken in the translation process 
to ensure that validity and reliability remains intact (97). In 2005, recommendations for good 
practice for the translation and cultural adaptation of PROMs from an International Society 
for Pharmacoeconomics and Outcome Research (ISPOR) Task Force were released. ISPOR 
proposed a 10 step process of translation. These steps include (1) preparation, where an 
outline is provided on what this work involves, (2) forward translation using more than one 
forward translator (a native speaker of the language to be translated) who would translate 
their versions independently, (3) reconciliation, a translation panel consisted of project 
manager and translators would discuss discrepancies between measures and arrive at a 
consensus forward translation version, (4) back translation of the measure into its original 
language by a native speaker of the translated language, (5) back translation review, (6) 
harmonisation, a panel consider all versions and all changes to the translation with the 
original version, (7) cognitive debriefing, where a number of patients complete the measures 
and are asked to provide feedback on the items included, (8) review of cognitive debriefing 
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results and finalisation: a review of the cognitive debriefing results against the original 
version of the instrument is completed to ensure cultural relevance, (9) proofreading to ensure 
minor mistakes are corrected early on, and (10) final reports: to provide a report on all 
translations and decisions which may be useful when interpreting datasets or informing other 
translation of the same instrument (98). QOL-PCD have been translated to ensure all these 
steps are taken.  
 
2.12. Summary 
PCD is a rare heterogeneous genetic disorder characterised by impaired mucociliary 
clearance due to abnormal ciliary function. Diagnosis is difficult with no single ‘gold 
standard’ test available. A combination of complex techniques is recommended including 
HSVMA to identify abnormal ciliary function, TEM to define ciliary ultrastructural defects, 
and measurement of nNO levels. Standardised testing is needed. 
Symptoms of PCD mostly begin in the first few days of life with unexplained neonatal 
respiratory symptoms ranging in severity. The most predominant symptoms of PCD are 
chronic daily productive cough, chronic persistent rhinitis, sinusitis, recurrent otitis media 
and hearing impairment.  As these symptoms are extremely common, especially in the 
paediatric population, physicians often miss the signs and symptoms of PCD. Patients are 
often diagnosed late. Guidance to physicians of whom to refer for diagnostic testing is 
required. 
Living with PCD has been found to have an impact on physical, emotional and social 
functioning across the age groups.  Associations between HRQoL and increasing age, and 
age at diagnosis have been reported. While it is suggested that diagnosis and subsequent 
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commencement of treatment can lead to health improvements, there are no sensitive outcome 
measures to confirm this.  
Outcome measures that have been used to assess disease severity in PCD to date include 
spirometry, chest computed tomography, magnetic resonance imaging and lung clearance 
index. These physiological and radiological measures all have limitations in terms of their 
sensitivity or feasibility to monitor disease progression. There is a need for a sensitive PCD 
specific outcome measures to evaluate new treatments and monitor disease progression.  The 
Food and Drug Administration (FDA) and the European Medicines Agency (EMA) strongly 
promote the use of PROMs in clinical trials.  
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Author's Contribution 
The research question was generated to inform a European Respiratory Society (ERS) Task 
Force who were developing guidelines for diagnosing PCD. It is important that these 
guidelines are patient centred. This provided me, the lead author, with an international 
platform to establish the patient perspective from countries where it has not been investigated 
before. Supported by JSL and ADG, I developed the survey based on literature searches and 
analyses of transcripts of previous interviews with PCD patients. Once developed, members 
of the ERS Task Force (international) and patient support groups (UK (FC) and USA (MM)) 
were contacted for their opinions on the survey and to suggest interactive changes. Once 
amended, I organised the translation and back translation of the survey into 9 European 
languages and enlisted the help of members of the taskforce, international patient support 
groups and European Lung Foundation (ELF) to disseminate the survey internationally. I 
performed descriptive analysis of the survey findings.  BR conducted an analysis of the 
survey results by country to allow comparisons to be made. I completed 20 semi-structured 
interviews focusing on the participant’s experience of referral and diagnostics. Telephone 
interview were completed with participants Europe, Australia and the USA. I conducted a 
thematic analysis of the transcripts and drafted the manuscript. I presented the findings to the 
ERS Task Force at committee meetings and at the European Respiratory Society Congress in 
2015 as a poster presentation.  
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3.1. Abstract  
Background: Primary ciliary dyskinesia (PCD) is a rare genetic disorder characterised by 
progressive sino-pulmonary disease, with symptoms starting soon after birth. An ERS Task 
Force aims to address disparities in diagnostics across Europe by providing evidence-based 
clinical practice guidelines. We aimed to identify challenges faced by patients’ when referred 
for PCD diagnostic testing. 
Method: A patient survey was developed by patient representatives and healthcare specialists 
to capture experience. Online versions of the survey were translated into 9 languages, and 
completed in 25 countries (n=365) of which 74% were PCD positive, 5% negative and 21% 
uncertain/ inconclusive. We then interviewed 20 parents/patients. Transcripts were analysed 
thematically.  
Results: 35% of respondents visited their doctor >40 times with PCD related symptoms prior 
to referral for testing. Furthermore, the most prominent theme among interviewees was a lack 
of PCD awareness among medical practitioners and failure to take past history into account 
leading to a delayed diagnosis. Patients also highlighted the need for improved reporting of 
results and a solution to the “inconclusive” diagnostic status 
Conclusion: The greatest frustrations related to delayed referrals and the need for improved 
communication when receiving results. These findings will be used to advise on ERS Task 
Force guidelines for diagnosing PCD.  
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3.2. Introduction  
Primary ciliary dyskinesia (PCD) is a rare heterogeneous condition. Genetic mutations cause 
abnormal ciliary function which is associated with abnormal ciliary ultrastructure in 70% of 
cases (16, 40). PCD is characterised by impaired mucociliary clearance of upper and lower 
airways. Symptoms usually present soon after birth and range in severity from mild transient 
tachypnoea to significant neonatal respiratory failure requiring prolonged respiratory support 
(1-3).  Chronic and progressive chest symptoms persist throughout life and include daily wet 
cough and recurrent chest infections which almost consistently lead to bronchiectasis (1). 
Upper airway symptoms include rhinosinusitis and recurrent serous otitis media with hearing 
impairment (99). Situs inversus is seen in approximately 40% of cases and situs ambiguous is 
seen in approximately 10% of cases (3).  
Reported prevalence varies from 1:2,000 to 1:40,000 which could be due to a true variability 
across demographics but is likely to reflect differences in access to diagnostic facilities (9-
11). A European Respiratory Society (ERS) Task Force survey of 26 European countries 
found that PCD is under-diagnosed or diagnosed late, particularly in countries with low 
health-care expenditure (9). In addition to improving respiratory prognosis (4, 12, 64) early 
diagnosis also facilitates appropriate management of the associated upper airway disease 
since management is different to non-PCD related serous otitis media and sinusitis (21). 
Diagnosis also allows genetic counselling for the family.  
 
There is no “gold standard” test to diagnose PCD and diagnostic pathways vary 
between/within countries (13, 100, 101). European guidelines recommend that PCD should 
be confirmed in a specialist centre using appropriate diagnostic testing (22).  PCD diagnostic 
investigations are complex, requiring expensive infrastructure and an experienced team of 
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clinicians, scientists and microscopists. Due to inadequate samples or inadequate results, 
several samples may need to be taken until a conclusive result is achieved and the time until a 
conclusive result is reached can vary greatly between patients (13, 19, 20). Various models 
exist to deliver diagnostic services for this rare disease, generally with a network of satellite 
screening centres accessing a specialist centre (14, 20, 21).  
  
A European Respiratory Society (ERS) Task Force was established in September 2014 to 
develop clinical practice guidelines on diagnosing or refuting the diagnosis of PCD. An 
important element to consider in developing practice guidelines is the patient perspective and 
experiences of the diagnostic process. There has been no previous international research 
evaluating PCD patients’ experiences and their perspective on the diagnostic process. This 
study was therefore undertaken to address this gap and to inform the Task Force. 
 
Over 25 years ago the authors of a pioneering study to characterise PCD concluded “All 
children with unexplained chronic respiratory disease, in particular those with symptoms 
starting in the neonatal period should be investigated for ciliary dyskinesia” (102). However, 
access of patients with these symptoms to diagnostic services remains problematic. The 
present study used a mixed methods (qualitative and quantitative) approach to more fully 
understand the perspectives of patients and to identify the most prominent issues and 
concerns arising for patients at any stage in the diagnostic pathway.  
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3.3.Methods  
The study combined an international web-based survey and semi-structured interviews, 
ensuring both breadth and depth. Ethical approval for semi-structured interviews was 
provided by Southampton and South West Hampshire Research Ethics Committee A 
07/Q1702/109. Audio-recorded and/or written consent was obtained from interviewees and 
electronic consent recorded for survey participants.  
We conducted an international survey to investigate the patients’ perspectives on diagnosis 
between April and November 2014. We designed the survey based on findings and expertise 
from three sources: (1) semi-structured interviews with patients from a previous study to 
understand factors impacting on quality of life in patients with PCD (103); (2) consultation 
with patient representatives in the UK, USA and Switzerland; and (3) consultation with the 
European Lung Foundation (ELF). Survey topics included measures of demographics, age of 
diagnosis, methods of diagnosis, the patient opinions on their diagnostic experience and how 
diagnostic services should be delivered (Box 1). To ensure it reflected wider international 
issues, the prototype survey was amended by ERS Task Force panel members from 7 
countries (UK, France, Switzerland, Germany, Italy, Ireland and Belgium). The finalised 
online survey (Appendix 1) was translated into 9 European languages (Italian, Polish, 
Russian, Portuguese, Czech, Dutch, German, French and Greek) using forward and back 
translations. Translation and dissemination of the survey was done according to countries 
with established PCD diagnostic services in addition to advice from the ELF and ERS 
Taskforce. Links to the survey were distributed by patient organisations, clinicians and 
through the ELF via newsletters, targeted emailing and social media channels. The survey 
was hosted by University of Southampton (https://www.isurvey.soton.ac.uk). 
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Survey topics: the survey allowed participants to rate the importance of topics relating 
to their diagnostic experience 
The ability to meet, discuss and have their samples analysed by PCD experts 
Repeat testing for inconclusive results 
The availability of information before testing   
The availability of information after diagnosis  
Travelling long distances for diagnostic testing  
The level of agreement on whether their condition, treatment and quality of life had 
improved since diagnosis 
A free text option to allow for comments was provided at the end of the survey 
 
The survey sought the opinions of patients with PCD and parents of children with PCD. We 
included all patients who had been considered for PCD testing irrespective of their diagnostic 
outcome i.e. positive /negative/inconclusive or by their diagnostic protocol and the tests that 
they received if any i.e. nasal nitric oxide (nNO), transmission electron microscopy (TEM), 
high speed video microscopy (HSVM), genetic, diagnosis based on symptoms etc.   
The survey was anonymous; however, respondents were invited to provide their email 
address if they wished to take part in a telephone interview. Over 80 participants provided 
their email address and expressed interest to be interviewed. Twenty of these respondents 
were recruited. Participants had to be able to speak English to be included in the interviews. 
Measures were taken to ensure interviewees represented different age groups, different 
diagnostic status and countries. The semi-structured interviews were conducted by the lead 
author (L.B.) who is trained and experienced in semi-structured/ open-ended interviews and 
qualitative analyses. Topics of discussion included: when they first heard of PCD, medical 
providers seen, experience with diagnostic services and any problems encountered. 
Telephone interviews were used to ensure a geographical representation, to provide a degree 
of anonymity and to relieve pressure on participants to provide the socially acceptable answer 
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(104) i.e. discussing challenges experienced with diagnostic services and medical 
professionals.  
3.3.1. Data analysis 
We used simple descriptive statistics to investigate comparisons of the demographic 
characteristics across the range of diagnostic outcomes and between countries. Data were 
checked for normality and two-tailed parametric (t-test) or non-parametric (Mann-Whitney) 
tests were used to assess differences among mean and median values for the group as a whole 
and across each diagnostic outcome. Positively skewed data were transformed, were 
appropriate, prior to performing statistical analysis. Categorical variables were presented by 
frequency and percentage. Statistical analyses were performed with IBM SPSS Statistics 
(IBM Corp. Released 2012. IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: 
IBM Corp). 
Semi-structured interviews were recorded, transcribed, verified for accuracy, and identifying 
information was removed. In order to maintain thoroughness, a COREQ checklist was used 
throughout the study (105). Notes were maintained at all times to track decisions and help to 
verify the link between the original data and the findings (105). Thematic analysis was used 
where patterns within data were identified using an inductive or ‘bottom up’ approach. By 
using an inductive approach, the themes identified were strongly linked to the data 
themselves (106).  The interview transcripts were single-coded by L.B. Themes and 
subthemes were discussed with the senior author J.S.L. in order to confirm the validity of the 
interpretations that were being developed. Data was coding using NVivo qualitative data 
analysis Software (QSR International Pty Ltd. Version 10, 2012).  Themes and subthemes 
were presented in three stages, pre-diagnosis, diagnosis and post-diagnosis (Figure 4).  
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3.4. Results  
3.4.1. Study population 
The survey was completed in 9 European languages by 365 participants from 25 countries. 
The majority of respondents had been diagnosed with PCD (74.3%), with a smaller 
percentage of respondents distributed across other diagnostic outcome groups. 54.5% of the 
respondents were parents of children and 41.6% were adults who had been tested for PCD.  
49.8% of PCD positive respondents had situs inversus and 11.8% were born with a cardiac 
defect. Only 1 (6%) of the PCD negative respondents had situs inversus and 0% had a cardiac 
defect (Table 1).  
Respondents were resident in Germany (21%), United States (18%), France (15%), United 
Kingdom (13%), Belgium (11%), Denmark (5%) and others (17% including Italy, Australia, 
Switzerland, Canada, Cyprus, Ireland, Greece, South Africa, Austria, Chile, Portugal, Qatar, 
Poland, Iran, Norway, Spain, Portugal and Algeria). Semi-structured interviews were 
conducted with 20 participants from 7 countries (40% from United Kingdom) and were 
diverse in age group, diagnostic testing, and diagnostic outcomes (25% were 
negative/inconclusive/still waiting). 25% were parents of children between the ages of 0-4 
years, 35% were parents of children 5-17 years, and 40% were patients tested at ≥18 years. 
The majority (70%) were from English speaking countries (Appendix 1; Table A1). 
Saturation was reached after the 14
th
 interview.  
3.4.2. Pre-diagnosis: journey to referral  
Most survey respondents had repeatedly visited medical professionals with PCD related 
symptoms prior to referral; 37% of positive patients had >40 visits and only 3% had been 
referred soon after birth. 61% of PCD negative respondents had ≤20 visit prior to referral for 
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testing. 76.4% of respondents were older than one year of age when they were tested for 
PCD. The overall median age at testing was 6 years (IQR =11) (Table 2). The mean age at 
testing slightly younger for those with situs inversus with the mean age at testing slightly 
younger for those with situs inversus (mean 2.38 +/-2.04  vs 2.97 +/-1.76 for those without, 
p=0.016) and congenital cardiac defect (mean 2.01 +/-1.78 vs 2.76 +/-1.91 for those without, 
p=0.036). The most common reasons for diagnostic referral of interviewees was an episode(s) 
of pneumonia i.e. x-rays and CT-scan showing changes (6/20), and self-referral following 
reading about PCD online (3/20).  
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Interviewees attributed a delay in referral for diagnostic testing to a lack of awareness and a 
poor attitude among healthcare professionals (14/20) (Figure 4). 11/12 parents reported that 
their child had respiratory distress at birth but 8/11 were not referred until repeated visits to 
their physicians sometimes over many years. Participants felt that the underlying cause of 
symptoms was not considered nor was past medical history taken into account. Adult 
participants felt they were not taken seriously while parents reported being treated as over-
cautious and over-protective. Many participants were continually treated for other common 
conditions e.g. asthma and hay-fever, despite treatments not having any effect. (Box 2: A, B, 
C, D). Older participants (>30 years at diagnosis) felt the cause of their illness was not seen 
as a priority for investigation due to their age with focus instead being on the treatment of 
COPD/bronchiectasis (Box 2: A, B). 99% of survey respondents felt that an improvement in 
PCD awareness amongst general practitioners (GPs) and local doctors is needed to encourage 
early referral (Figure 5). 
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Box 2: Sub-themes and example participant quotes regarding experiences prior to 
diagnostic testing: journey to referral 
Past medical history was not considered 
A: It was a wait, but it was more the fact that no-one was looking at the history….she’d been in 
neonatal for eleven days when she was born, she was full-term…she couldn’t get her sats 
up….how many times I’d been in, you know and no one put two and two together. Participant 
010, parent, positive PCD 
Symptoms not taken seriously – parents treated as fussy/over protective 
B: ....and all this time you know…time’s going on…I don’t think that I was listened to as a 
mum, it was a bit like, I was you know maybe of over worrying, things like that. Participant 
004, parent, positive PCD 
C: I think the lateness in the diagnosis has caused the bronchiectasis and…other problems and I 
think that could have been prevented if someone would have taken me a bit more seriously. 
Participant 010, parent, positive PCD 
Mistreated for other illnesses 
D: ...he treated her for asthma, but the picture never made sense, and she didn’t look like an 
asthmatic child. Participant 015, parent, positive PCD 
Older patient treated without investigation for route cause 
E: There seems to be, among pneumologists, that they think in adult people or at least people 
who are more than forty years old, it doesn’t matter anymore which is the reason for this COPD, 
and they don’t even think about testing it. Participant 011, adult, positive PCD 
 
3.4.3. Diagnosis: experience and impact of diagnostic testing 
The most common diagnostic procedures experienced by survey respondents were nasal 
scraping (79%), nasal nitric oxide testing (44%) and genetic testing (37%). 88% of survey 
participants rated it as important to have multiple tests if this ensured an accurate result and to 
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see a PCD expert even if it means travelling long distances (Figure 5). This was echoed 
overall in the interviews (Box 3: A-C); however, some age-specific variances emerged with 
parents describing nasal scraping as a moderately distressing experience. This distress was 
heightened if their child needed a repeat brushing (Box 3: B, C). Participants reported that 
testing was carried out in an efficient and empathetic manner with the appropriate amount of 
information provided once they reached specialist services (8/20) (Box 3: D, E). 
Box 3: Sub-themes and participant quotes for diagnosis: Experience of diagnostic 
testing 
Importance of meeting a PCD expert to be tested and to discuss results 
A: And everything just went really smooth for us when we were over there.  Having to go over 
there, it wasn’t great, but you know it’s the facilities are not in Ireland, so you just have to do it. 
Participant 003, parent, inconclusive PCD 
Distress from nasal scrape 
B: ...it’s a little bit distressing for parents….it’s got to be done…. you know you’re holding a 
child still and you don’t want to do it, but you have to, for their best. Participant 004, parent, 
positive PCD 
C: It was a bit uncomfortable… I mean I don’t think she was expecting it to be quite as 
uncomfortable as it was, but having said that she went along with it okay, she knew she had to 
get it done. Participant 002, parent, positive PCD 
Communication of testing procedure 
D: First of all it was an absolutely painless experience and the people doing it explained it so 
well, I wouldn’t change a thing at all.  Participant 001, adult, positive PCD  
E: I mean it’s all very new for me…but… the amount of information that I got… which 
explained the process and explained what was being done and how it was going to be achieved, I 
think was very well done, and the staff involved were very empathetic, very sympathetic. 
Participant 008, adult, inconclusive PCD 
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3.4.4. Diagnosis: awaiting and receiving results 
A total of 67% of survey respondents received their result within a 6 months period and 12% 
reported that they received confirmatory results within 1 week of testing (Table 2). Opinions 
varied on what was deemed to be a ‘long time’ to wait for results (Box 4: A, B). Ninety-four 
percent of survey participants rated having samples analysed by a PCD expert as important or 
very important and 97% rated the as important or very important the opportunity to discuss 
results with a PCD expert (Figure 5). 
Participants referred to encountering problems when results for tests such as transmission 
electron microscopy (TEM) and genetics were received much later than others e.g. high 
speed video microscopy and nNO test. Explanations of what the results mean in combination 
were incorrectly relayed back to the patients. To overcome this, participants recommended 
that it would be helpful if they could receive an overall report explaining what the results 
mean in combination and to have the opportunity to discuss this with a PCD expert (Box 4: 
D, E). 
 
Box 4: Sub-themes and participant quotes for Diagnosis: awaiting and receiving results 
Long-time taken to receive results 
A:  I had to ring up months after, chasing up the results… we should have got the results sooner 
than what we did….like the testing was done in the January and probably should have got the 
results probably March, April. Ended up being like June, July, because I had to actually chase up 
myself to get the results. Participant 019, parent, positive PCD 
B: No, definitely a month is a long time to wait. To know what’s wrong with your child or 
significant other or something, but it takes as long as it takes; I have gotten used to that. 
Participant 017, parent, positive PCD  
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Experience of communication of diagnostic results 
C: And I got the results, let’s say in drops, maybe one year later I got the information about the 
electron microscopy was or maybe it was eighteen months later. Participant 011, adult, positive 
PCD 
D: I got the information from my doctor that my son…probably has PCD….the cilia didn’t 
move…about already one month later…the report that the electron microscopy was normal, and 
the report from the electron microscopy said we cannot prove primary ciliary dyskinesia based 
on this.  The doctor told me, ‘well then it’s not primary ciliary dyskinesia’. Survey participant, 
open text response 
E: Before they did any testing we had a good discussion about what it was and what it meant, 
and then when we got the results they explained what it was that wasn’t working….It’s usually 
better if somebody talks to you rather than it being written down. Participant 010, parent, 
positive PCD 
 
3.4.5. Post-Diagnosis: impact of diagnosis 
Participants who experienced an inconclusive diagnostic result discussed the practical 
constraints of such an outcome e.g. insurance constraints and not being included in research 
(Box 5: A, B). The emotional impact of a positive diagnosis was described by many as 
leading to a profound sense of validation that their symptoms were down to a specific named 
condition (Box 5: C, D). Participants also reported feeling some distress that their/their 
child’s diagnosis process took such a long time and felt that an earlier diagnosis could have 
made a significant difference to the state of their current and future health; relief was 
expressed once they had a label and could pursue getting the correct treatment (Box 5: E, F).  
Relief was also described when a negative diagnosis was received (Box 5: G). 
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Box 5: Sub-themes and participant quotes for Diagnosis: Impact of diagnosis 
Impact of an inconclusive diagnostic result 
A: I have suffered from serious upper and lower respiratory infections all my life. I have an 
‘inconclusive’ status re: diagnosis of PCD….there must be a category of PCD that includes a 
variant of PCD as a diagnostic category. This is crucial for people who have insurance challenges. 
Survey participant, open text response 
B: I hate the probable PCD diagnosis. 4 years ago my 3 kids were given that. All classic symptoms 
with bronchiectasis and low nasal nNO. But cilia appeared normal. It infuriates me they can't be 
included in research. Survey participant, open text response 
Emotional response to positive diagnosis: feeling of validation 
C: Like to have the confirmed diagnosis…well I am just really excited they were finally able to 
prove it’s not in my head. You know like I didn’t make it up. Participant 016, adult, positive PCD 
D: I actually felt like shouting Alleluia once she was diagnosed, because it was just years and years 
of worry and thinking what’s going on and why, and I just, you kind of doubt yourself as a mum. 
Participant 010, parent, positive PCD 
Emotional response to positive diagnosis: relief but a sense of sadness that diagnosis wasn’t 
sooner 
E: You know that’s kind of like oh wow, finally I’m no longer a bookcase.  But then I have all this 
damage that you know at least, you know at least I have a diagnosis, twenty years later, but it’s a 
little late. Participant 009, adult, positive PCD 
F: Well it was a certain relief, first of all in that you know we can explain now…. we can help her 
in the way that she needs.  So really it was just a huge kind of relief really, just knowing that we 
have an explanation now.  Along with you know a bit of sadness that we didn’t catch onto it 
earlier. Participant 002, parent, positive PCD 
Impact of a negative diagnosis: relief 
G: I was very relieved of course.  I didn’t know anything at all about it until I was told by the 
consultant I was going to be sent for the test.  And then I received some documentation in advance 
with the appointment.  And I also read a little bit about it online…I was quite concerned, because 
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one of the things I heard was that it could affect your hearing and you can go deaf…. I was quite 
anxious, so the length of time being referred and actually having the tests, I was very worried. 
Participant 007, adult, negative PCD 
 
3.4.6. Post diagnosis: follow up care and support available 
Participants expressed a sense of being overwhelmed by the prescription of medication, 
treatments and clinic appointments following a positive diagnosis, particularly when newly 
diagnosed. The benefits of a diagnosis to the reported current state of health varied among 
survey participants with 21% reporting no improvement to health since diagnosis (Figure 5). 
There was a significant difference was found between those who were diagnosed in 
childhood (0-12 years) and those who were diagnosed in adolescences/adulthood (>13 years) 
on the level of agreement that health has improved since diagnosis (p=0.041).  Similar 
variability was found among the interviewees with some participants feeling that their/their 
child’s health had benefited greatly since starting treatments (Box 5: A-C) and others 
reporting no major change since diagnosis despite adhering to the prescribed treatments (Box 
5: D).  
In the survey 91% of respondents strongly agreed/agreed that it is important to have a patient 
organisation in each country (Figure 5). The role of PCD patient support groups following 
referral was further elaborated in the interviews as important in terms of meeting other 
families affected by PCD and having an opportunity to share experiences (Box 6: E, F). 
Participants in countries without a PCD support group spoke of the need for support services 
enabling discussions about experiences specific to their country’s health system and in their 
native language (Box 6: G- I). 
 
 49 
 
Box 6: Sub-themes and participant quotes for Post diagnosis: Follow up care and 
support available 
Treatment burden and effect on condition 
A: “It was a bit of a shock…. I was probably in my mid-thirties then, to suddenly be told, right, 
you’ve got to do twenty minutes of physio twice a day, you’ve got to take this blue puffer, and 
the brown puffer… as soon as you get a chest infection you’ve got to take really strong 
antibiotics, I rebelled against that, just because it was too much all at once.”  Participant 006, 
adult, positive PCD 
B: “For me it made a huge difference in my treatment when I finally knew the diagnosis. And I 
am certain that I wouldn’t be as well as I still am when I would have continued in the way as I 
did before it” Participant 011, adult, positive PCD 
C: “She was sick every month.  Once we had a diagnosis… she gets sick, but not as severe as… 
before. Definitely milder…you know we have a treatment plan and even when she starts to get 
sick; those medications are changed so we tend to catch that right away rather than after that. 
Participant 015, parent, positive PCD  
D: “It’s strange, since being diagnosed we are now bombarded with a very heavy burden of care, 
she uses the nebulisers three times a day, and she has physio twice a day…and yet she’s not 
clinically, she’s no different to before she was diagnosed. Participant 004, parent, positive PCD 
Support from PCD patient organisations 
E: Well we go, after the diagnosis…through the PCD Foundation, and that was a huge support.  
Also there is like chat groups that we go on.  We’ve gone to family days.  So we’ve met quite a 
few other families that also have PCD…yeah, it’s a huge, huge help really.  Sometimes it’s even 
just finding out what they did in certain situations.  So things you can bring up to your doctor, so 
that’s helpful as well. Participant 015, parent, positive PCD 
F: I got connected with the PCD group online …without the people in this group… I would be 
terribly lost…they’ve been my life support. Participant 009, adult patient, PCD positive 
Need for PCD patient organisations in each country 
G: In Spain, we would like…a Patients Association…., in the UK there will be one of these, you 
know this association, but in Spain we don’t know anything about the illness and the patients. 
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Participant 013, parent, PCD positive  
H: There isn’t any in Ireland….I don’t know anybody else that has it, and if I did know 
somebody that would be handy…. like you could see…what does the future hold for us in a few 
years’ time, really we’re only going day-by-day, and I know every case is different, but it would 
be nice to kind of know other issues some people have experienced.  And the mistakes I made, 
maybe you could try this, which might help. Participant 003, parent, inconclusive PCD 
I: I think it’s difficult.  There is no information in Bulgarian for example….and I would speak 
English so I can get a lot of information from the internet, but if you are a Bulgarian and you do 
not speak English, it’s very, very hard for you to get that information. Participant 012, adult 
patient, probable PCD 
 
3.5. Discussion  
This study represents findings from an international survey and in-depth semi-structured 
interviews specifically designed to understand the experiences, concerns and needs of 
patients requiring diagnostic testing for PCD. It describes the experiences and perspectives of 
365 adult patients and parents from 25 EU and non-EU countries, 20 of whom were 
interviewed to obtain an in-depth insight to their experiences and opinions of being tested for 
PCD.  
 
When discussing the journey to referral, the overarching theme was the lack of PCD 
awareness by medical professionals thus leading to a delayed diagnosis. This was also 
reflected in the survey, with 34% of the total respondents reporting that they visited their 
doctor on >40 occasions for PCD related symptoms before PCD was considered a possible 
diagnosis. There is a clear need to reiterate to non-expert clinicians the guidelines (102) 
published a quarter of a century ago, which stated that individuals with chronic upper and 
lower airway symptoms should be investigated for PCD. Previous research has found a sense 
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of isolation and mistrust in medical care among PCD patients which is heightened by a lack 
of PCD awareness by the patient’s GP (79). Participants were concerned that delayed 
diagnosis had adversely affected their health.  All adult interviewees were diagnosed late in 
life (>30 years of age) and felt that their current state health might have been better had they 
been diagnosed earlier. This finding supports previous research that found that delayed PCD 
diagnosis led to poorer subsequent quality of life (107). To prevent a delayed diagnosis, 
participants felt that medical professionals need be to be better informed about PCD, its signs 
and symptoms and relevance of past medical history.  
 
When receiving a diagnosis, patient and parent interviewees who visited specialised 
diagnostic centres were satisfied with their experience. The implications of normal electronic 
microscopy wrongly being interpreted as negative diagnosis (101) by non-PCD experts was 
highlighted. Respondents felt that being able to discuss their test results with a PCD expert as 
well as receiving a written report of all test results was important and contributed to a sense 
of certainty and assurance. 
 
Due to the importance of societal, health and cultural differences between countries, we 
aimed to recruit participants from diverse geographical regions. We first examined the results 
from all participants and then analysed countries separately. A quantitative comparison of 
countries grouped by general government expenditure on health (the sum of outlays for 
health maintenance, restoration or enhancement paid for by government entities) or grouped 
by countries with and without specialist diagnostic services was prevented due to the limited 
numbers of respondents from some areas. We have, however, included the analyses from the 
UK, Germany and the USA to show comparisons with differing approaches to delivery of 
diagnostic services and availability of tests. The percentage of respondents who had 40 or 
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more visits to their doctor with symptoms related to PCD before being referred for testing 
was significantly higher in the USA (44%) compared with the UK (24%) and Germany 
(35%) (Appendix 1: Table A2). The interviews also revealed country-specific variances. 
Participants from non-English-speaking countries strongly advocated that support groups be 
set up in their country and for information to be available online in all languages. The 
inconclusive PCD diagnosis also had country-specific implications, with participants from 
countries including the USA requiring a definitive diagnosis in order to access insurance for 
treatments. A resolution to the problems associated with an inconclusive result or a 
“probable” PCD diagnosis was called for. 
 
3.5.1. Strengths and Limitations 
This is the first international study of the perspective of patients referred for PCD diagnostic 
testing. Questions for the survey involved the contribution of an international panel of PCD 
experts and patient representatives. However, our study does have limitations: response 
varies from country to country with the main percentage of respondents from countries with 
established diagnostic centres i.e. UK, US, Germany and France.  
The survey also aimed to include patients who were referred and still waiting for results, who 
were negative for PCD or who have been found to be inconclusive for PCD and are still 
going through testing however 74.3% of survey respondents were PCD positive with PCD 
negative representing only 4.9%, inconclusive 8%, and still waiting 3%. It is especially low 
considering that international results have found that between 11.5%-18.6% of referrals are 
eventually diagnosed with PCD (29, 58, 101, 108). It is perhaps not surprising that patients 
with ongoing interest in the disease (PCD-positive) were more likely to respond to the 
survey. This limits our capacity to assess the perspective of the population with an 
inconclusive or negative outcome. 
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Although participants were asked about the tests that had been performed, their results cannot 
be verified and there is therefore diagnostic uncertainty. In addition, a number of participants’ 
diagnoses were based on tests that are not considered robust, e.g. the saccharine test. It is 
therefore likely that some patients may have been diagnosed who do not have PCD and vice 
versa. Since we were interested in the experiences and outcomes of patients from diverse 
clinical settings it was important to include groups where diagnostic status was uncertain. 
This inherently means that allocation of patients to diagnostic outcome groups was defined 
by the participants’ understanding rather than the diagnosis that might be provided by a 
highly specialist centre; this is at the same time a strength and a weakness of the study. 
 
3.5.2. Implications and conclusion 
This study concludes that there are a number of recommendations for the improvement of 
PCD diagnosis from the patient’s perspective and that are needed across Europe and 
internationally. (1) Samples should be analysed by PCD experts. (2) Results should be 
delivered by a PCD expert. Patients should have the opportunity to discuss their results with a 
PCD expert and to ask questions. (3) Repeat testing should be completed if needed, to ensure 
an accurate result. (4) Measures must be introduced to prevent late diagnosis such as better 
knowledge of PCD by medical practitioners, including relevance of past medical history. (4) 
A resolution to the “inconclusive” diagnosis result status. (5) Establishment of a patient 
support group in each country. (6) Availability of online translated information on PCD in all 
European languages. 
 This is the first international study evaluating PCD patients’ experiences and their 
perspective on the diagnostic process. The findings from this study will be used to advise the 
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ERS Task Force (TF-2014-04) as they develop clinical practice guidelines on diagnosing or 
refuting the diagnosis of PCD. We anticipate that the results will inform stakeholders with 
responsibility for improving existing diagnostic provision and for expanding services for this 
rare disease. It should feed into the new European Reference Networks (ERNs) for rare 
diseases, particularly the PCD ERN. 
3.6. Conclusion 
This is the first international study evaluating PCD patients’ experiences and their 
perspectives on the diagnostic process.  The findings from this study will be used to advise 
the ERS Task Force TF-2014-04) as they develop clinical practice guidelines on diagnosing 
or refuting the diagnosis of PCD.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Themes and subthemes from semi-structured interviews 
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Figure 5: Survey findings on patient opinion of diagnostic effect on health and the 
importance of expert service provision 
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Table 1: Characteristics of participants in the survey stratified by PCD disease status 
Disease status 
 Total 
365 (100%) 
PCD positive 
271 (74.3%) 
PCD negative 
18 (4.9%) 
Inconclusive    
29 (8.0%) 
Other* 
47 (12.9%) 
Respondent’s status 
Patient tested for PCD 152 (41.6%) 115 (42.4%) 8 (44.4%) 8 (27.6%) 21 (44.7%) 
Parent of child tested for 
PCD 
199 (54.5%) 152 (56.1%) 10 (55.6%) 21 (72.4%) 16 (34.0%) 
Missing 14 (3.8%) 4 (1.5%) - - 10 (21.2%) 
Gender 
Male 156 (42.7%) 114 (42.1%) 8 (44.4%) 14 (48.3%) 20 (42.6%) 
Female 195 (53.4%) 154 (56.8%) 7 (38.9%) 14 (48.3%) 21 (44.7%) 
Missing 14 (3.8%) 3 (1.1%) 3 (16.7%) 1 (3.5%) 6 (12.8%) 
Age of suspected PCD patient at time of survey 
< 5 years 54 (14.8%) 38 (14.0%) 2 (11.1%) 8 (27.6%) 6 (12.8%) 
5-12 years 88 (24.1%) 61 (22.5%) 7 (38.9%) 10 (34.5%) 10 (21.2%) 
13-17 years 52 (14.3%) 42 (15.5%) 1 (5.6%) 4 (13.8%) 5 (10.6%) 
18-35 years 70 (19.18%) 58 (21.4%) 3 (16.67%) 2 (6.9%) 7 (14.9%) 
36-50 years 52 (14.25%) 45 (16.61%) - 2 (6.9%) 5 (10.6%) 
51-65 years 26 (7.12%) 19 (7.01%) 1 (5.56%) 1 (3.45%) 5 (10.6%) 
> 65 years 11 (3.01%) 4 (1.48%) 4 (22.22%) 2 (6.9%) 1 (2.1%) 
Missing 12 (3.29%) 4 (1.48%) - - 8 (17.0%) 
Situs inversus  157 (43.0%) 135 (49.8%) 1 (5.6%) 6 (20.7%) 15 (31.9%) 
Congenital heart 
defect  
41 (11.2%) 32 (11.8%) - 4 (13.8%) 5 (10.6%) 
*Other includes participants still waiting for results and those who received a false positive result as 
well as missing values. 
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Table 2: Age at testing, time taken to receive test results, and number of visits to doctor before 
referral stratified by disease status for survey participants. 
Disease status 
 Total 
365 (100%) 
PCD positive 
271 (74.3%) 
PCD 
negative 
18 (4.9%) 
Inconclusive 
29 (8.0%) 
Other* 
47 (12.9%) 
Age at initial testing 
< 1 year old 42 (11.5%) 30 (11.1%) - 4 (13.8%) 8 (17.0%) 
> 1 year old 279 (76.4%) 229 (84.5%) 14 (77.8%) 20 (69.0%) 16 (34.0%) 
Missing 44 (12.1%) 12 (4.4%) 4 (22.2%) 5 (17.2%) 23 (48.9%) 
Median age (IQR) 6 years (11) 
(n = 226) 
Number of visits to doctor before diagnosis 
Referred soon after 
birth 
12 (3.3%) 9 (3.3%) - 2 (6.9%) 1 (2.1%) 
1-10 visits 64 (17.5%) 46 (17.0%) 6 (33.3%) 5 (17.3%) 7 (14.2%) 
11-20 visits 56 (15.3%) 45 (16.6%) 5 (27.8%) 3 (10.3%) 3 (6.4%) 
21-40 visits 68 (18.6%) 52 (19.2%) 4 (22.2%) 8 (27.6%) 4 (8.5%) 
>40 visits 123 (33.7%) 101 (37.3%) 1 (5.6%) 8 (27.6%) 13 (27.7%) 
Other 22 (6.03%) 13 (4.8%) 1 (5.6%) 3 (10.3%) 5 (10.6%) 
Time to diagnosis after testing for PCD 
<1 week 45 (12.3%) 39 (14.4%) 1 (5.6%) 1 (3.5%) 4 (8.5%) 
1-4 weeks 76 (20.8%) 61 (22.5%) 8 (44.4%) 3 (10.3%) 4 (8.5%) 
1-6 months 122 (33.4%) 105 (38.8%) 8 (44.4%) 4 (13.8%) 5 (10.6%) 
6-12 months 10 (2.7%) 8 (3.0%) - 1 (3.5%) 1 (2.1%) 
> 1 year 28 (7.7%) 24 (8.9%) 1 (5.6%) 2 (6.9%) 1 (2.1%) 
Still waiting 28 (7.7%) - - 15 (51.7%) 13 (27.7%) 
Not sure 36 (9.9%) 31 (11.4%) - 2 (6.9%) 3 (6.4%) 
Missing 20 (5.5%) 3 (1.1%) - 1 (3.5%) 16 (34.0%) 
Diagnostic procedures 
Nasal nitric oxide 157 (43.0%) 110 (40.6%) 14 (77.8%) 17 (58.6%) 16 (34.0%) 
Nasal scraping 283 (77.5%) 221 (81.6%) 16 (88.9%) 28 (96.6%) 18 (38.3%) 
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Bronchoscopy 134 (36.7%) 102 (37.6%) 6 (33.3%) 12 (41.4%) 14 (29.8%) 
Genetics 134 (36.7%) 105 (38.8%) 1 (5.6%) 13 (44.8%) 15 (31.9%) 
Saccharine test 19 (5.2%) 14 (5.2%) 1 (5.6%) 2 (6.9%) 2 (4.3%) 
Nuclear medicine scan 25 (6.9%) 19 (7.0%) 2 (11.1%) 1 (3.5%) 3 (6.4%) 
X-ray or CT scan alone 8 (2.2%) 2 (0.7%) - - 6 (12.8%) 
Symptoms only 12 (3.3%) 6 (2.2%) - - 6 (12.8%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Other includes participants still waiting for results and those who received a false 
positive result as well as missing value. 
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4.1 Abstract 
Background: Primary ciliary dyskinesia (PCD) is a rare genetic disorder characterised by 
progressive sino-pulmonary disease, with symptoms starting soon after birth. The aim of this 
study is to critically review, analyse, and synthesise the literature, in order to understand the 
experiences of patients with primary ciliary dyskinesia (PCD) and the impact on health-
related quality of life (HRQoL).  
Method: MEDLINE, EBSCO, Cumulative Index to Nursing and Allied Health Literature 
(CINAHL), PsycINFO and EMBASE were searched according to the inclusion criteria. A 
qualitative analysis of 14 studies was conducted. 
Results: Fourteen studies were included in the review, five with qualitative methodologies. 
Studies originated from the UK, USA, Italy, Denmark and Belgium, one study included a 
survey distributed internationally.  Significant relationships were found between age and 
worsening of respiratory symptoms, physical, and mental domains of HRQoL, with a greater 
decline compared with reference populations. Variations between the UK and Italy were 
found for HRQoL and its correlation with time since diagnosis. PCD was found to have a 
physical impact in all age groups: patients found it difficult to keep up with others, and found 
energy levels were easily depleted compared to family or peers. In terms of social impact, 
symptoms lead to embarrassment and a sense of isolation, with patients concealing symptoms 
and/or their diagnosis. In turn, isolation was also linked with the lack of public and medical 
knowledge.  In relation to emotional impact, anxiety was reported in a number of qualitative 
studies; patients were anxious about getting sick or when thinking about their future health. 
The burden of treatment and factors influencing adherence were also discussed in depth. 
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Conclusion:  HRQoL decreases with age in patients with PCD. For all age groups, PCD was 
found to greatly impact physical, emotional, social functioning, and treatment burden. More 
research needed on the psychosocial impact of the illness, disease burden, and its effect on 
quality of life. 
 
4.2. Background 
Primary ciliary dyskinesia (PCD) is a rare, inherited lung disease affecting cilia motility such 
that mucociliary clearance is impaired. Individuals with PCD often present with unexplained 
neonatal symptoms such as neonatal cough, rhinitis transient tachypnoea, and pneumonia, 
often requiring respiratory support (1, 3, 109). Patients continue to have persistent sino-
pulmonary symptoms in infancy. Chronic and progressive chest symptoms persist throughout 
life and include daily wet cough and recurrent chest infections which almost consistently lead 
to bronchiectasis (4, 66). By adulthood, bronchiectasis is present and some patients develop 
respiratory failure (1). Upper airway symptoms include rhinosinusitis and recurrent serous 
otitis media with hearing impairment (37). Situs inversus is found in approximately 50% of 
cases and situs ambiguous is seen in approximately 10% of cases (8, 37).  
Assessment of the prevalence, burden of disease, and prognosis of PCD patients is difficult to 
determine due to a lack of representative international data. Reported prevalence varies from 
1:2,000 to 1:40,000; this could reflect true variability or could be a result of poor access to 
diagnostic facilities in some areas and countries (110-112). A European Respiratory Society 
(ERS) Task Force survey of 26 European countries found that PCD is both under-diagnosed 
and diagnosed late (110).  
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As in most orphan diseases, research has focused on describing the pathophysiological 
mechanisms of the illness and improving diagnostics. Few studies have examined the 
psychosocial impact of the illness, disease burden, and its effect on health-related quality of 
life. This was highlighted by McManus back in 2003 (113), where a systematic search found 
that no studies reporting data from the patient perspective or on the impact of PCD on daily 
functioning, mental health and well- being.  
The overall aim of this study was to synthesise the results from both qualitative and 
quantitative studies which examine the psychosocial impact of PCD. Through this synthesis, 
we evaluated qualitative studies documenting the experiences and views of PCD patients, the 
impact of the condition on their daily lives, in addition to HRQoL and any influencing factors.  
We included all age groups (adult, child, adolescent) and parents of PCD children. The 
qualitative studies allowed us to identify the most salient themes among age groups through 
interviews and focus groups analysis. The quantitative studies allowed us to compare patient-
reported outcome PROMs and factors influencing variability. Finally, through this synthesis, 
we assessed the quality of the studies and made recommendations on future research needs.  
4.3. Method  
4.3.1. Search Strategy 
The systematic review was conducted using the Preferred Reporting Items for Systematic 
Review and Meta-Analyses Approach (PRISMA)(114). The following electronic databases 
searched for papers published in the English language from inception until September 2015: 
MEDLINE –EBSCO, Cumulative Index to Nursing and Allied Health Literature (CINAHL), 
PsycINFO and EMBASE. Key words and subject headings/MeSH terms searched in titles 
and abstracts using various combinations included: “ciliary dyskinesia, primary”, “ciliary 
motility disorder”, “Kartagener’s syndrome”, "primary ciliary dyskinesia", “perspective”, 
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“perception”, “knowledge”, “opinion”, “psychological”, “experience”, “attitude”, “impact”, 
“view”,  “idea”, “quality of life”, “QOL”, “HRQL”, “patient report”, “belief”, and 
“awareness”. 
4.3.2. Inclusion and Exclusion Criteria 
Inclusion criteria were primary studies that reported on experiences and perspective of PCD 
patients of all age groups, or where patients completed patient reported outcome measures 
(PROMs) as primary or secondary outcomes. Quantitative, qualitative, and mixed 
methodologies were considered equally. PROMs were operationalised as generic HRQoL 
questionnaires, e.g. Short-Form-36 (SF-36), and disease-specific HRQoL questionnaires, e.g. 
St George’s Respiratory Questionnaire (SGRQ), Leicester Cough Questionnaire (LCQ). 
Measures of psychological distress, e.g. Child Behaviour Checklist questionnaire and 
Parenting Stress Index-Short Form were also included.  Qualitative studies and mixed-
methods studies with a significant qualitative component were considered for inclusion if the 
number of participants was greater than one, and if sufficient methodological details and data 
were provided. Non–primary research articles (letters, commentaries, and reviews) were 
excluded. 
 
4.3.3. Search Outcome 
The initial database search generated records from which articles were initially identified 
through screening of titles and abstracts (LB and BR). Following removal of duplicates, full 
text papers were read by two authors (LB and BR) to determine eligibility for inclusion. 
Discrepancies about whether a paper met the inclusion criteria were discussed with a third 
author (JSL) and a final decision was based on consensus. References of the full text articles 
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assessed for eligibility were hand checked to identify further papers that satisfied selection 
criteria. 
4.3.4. Data Extraction and analysis 
The following data from included papers were extracted: author, date and location of study, 
aim, sample, design and methods, data collection and analysis, and results. 
Data from included studies were systematically extracted using a standardised tabulated form 
(Table 4) by LB and BR independently, and then discussed and combined. Data was 
extracted on the results from HRQoL measures and PROMs. For qualitative studies, extracted 
data was compared across studies and grouped into themes to describe the issues pertinent to 
PCD patients.   
 
4.3.5. Quality Appraisal 
Quality appraisals of data from both the qualitative and qualitative studies were 
independently assessed by LB and BR. The criteria for assessing the quality of quantitative 
studies as previously used by researchers (115-117) included: study design, participants and 
recruitment, comparison group, number of participants, and quality of instrument used (Table 
3). The total quality score ranged from 0-15 with each of the 5 criteria being scored from 0 to 
3. Quality assessment of qualitative studies was performed using the Consolidated Criteria 
for Reporting Qualitative Health Research (COREQ) (105). 
 
4.4. Results 
4.4.1. Study selection 
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The initial database search generated 260 records from which 32 articles were initially 
identified through screening of titles and abstracts as potentially relevant (Figure 6). Removal 
of duplicates resulted in 26 papers of full text. Fourteen papers were identified for inclusion, 
two of which were conference abstracts where the full results were not available. No further 
papers were identified where references of the full text articles were hand checked.  
Studies included samples from the UK (78, 79, 113, 118), Italy (77, 107, 119, 120), Denmark 
(121), and Belgium (122, 123) with a collaborative study including participants from the UK 
and North America (103, 124) and an international study including participants from 25 
countries (112). Six studies consisted of cross-sectional surveys, two of which compared the 
PCD sample results with reference population norms (107, 113, 118, 119, 122, 123), one was 
a longitudinal survey given at two time points (120), two were case-control design including 
health samples for comparison (77, 121). Four used a qualitative approach (78, 79, 103, 124) 
and one used a mixed method approach (112). Three of the UK studies (79, 113, 118) were 
carried out using the same study population. The two Belgian studies were also conducted on 
a shared sample. Sample sizes ranged from 5 to 270. Apart from one study, gender was 
reported and all studies included both male and female participants. 
 
4.4.2. Methodological quality 
Quality appraisal of the quantitative studies points to deficits, in particular to study design, 
and recruitment and inclusion of a comparison group (Table 5). Psychometric properties of 
the measures were cited in five of the quantitative studies; however the internal reliability of 
the measures, i.e. Cronbach’s alpha within the sample population was not reported in any of 
the studies. The application of the measures was not clear for all studies. For some studies, 
measures used were not developed/adapted and validated specifically for younger children. 
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Most studies were surveys (with one being longitudinal) and although it was apparent that 
these studies were cross-sectional, this was not stated explicitly in all. The study which 
ranked the highest had a score of 8 out of 15 points; this was a cross-sectional survey study 
where 78 patients completed a questionnaire which collected information on age of diagnosis, 
symptoms and likely PCD-specific problems, in addition to disease specific and general 
HRQoL (using the St George’s Respiratory Questionnaire and the Medical Outcomes Study 
Short Form-36 (SF-36)). Use of the SF-36 allowed for scores to be compared with the healthy 
Italian population. 
 For the five qualitative studies, criteria of the COREQ-32 item checklist were generally 
adhered to (Table 4). The main deficits in reporting were: the characteristics of the research 
team and the relationship between interviewee and interviewer, description of the coding tree, 
and the provision of feedback to the interviewee following transcription (Table 6). 
 
4.4.3. Methodologies of Quantitative and Qualitative Studies 
Six studies assessed HRQoL in PCD patients. HRQoL measures are generic or disease 
specific. Disease-specific measures assess special states and concerns of different diagnostic 
groups and are important for the detection of small clinically important changes. The most 
commonly used disease specific HRQoL measure in this review was the St George’s 
Respiratory Questionnaire (SGRQ) for chronic obstructive pulmonary disease (n=6). Other 
disease-specific outcome measures used included the HRQoL measure for cystic fibrosis 
(CFQ-R) (n=1), a HRQoL measure for sinonasal conditions: The Sino-Nasal Outcome Test 
(SNOT-22) (n=1), and the Leicester Cough Questionnaire (LCQ) (n=1). To assess the impact 
of PCD on HRQoL, related to mental health and wellbeing, the Medical Outcomes Study 
Short Form 36 (SF-36) was used in five of the studies.  
 69 
 
Other patient-reported measures other than HRQoL included the Wechsler Intelligence Scale 
for Children, the Child Behaviour Checklist questionnaire, the Parenting Stress Index-Short 
Form, and the Self-reported Physical Activity Measure. One study included a questionnaire 
measuring Stigma  (118). This was developed by the author and stigma was assessed by the 
patient’s response to 11 items on embarrassment about symptoms, feeling a nuisance to 
friends or family, concealment of condition etc. Four of the studies were cross-sectional, 
single-occasion, single-centred studies. One study was a cross-sectional, single-occasion, 
single-centred case-control study, and one was a longitudinal, single-centred study with 
measures repeated after 1 year.  
 
4.4.4. Main themes 
4.4.4.1. Factors influencing HRQoL 
In a cross-sectional UK survey (113), a slight decline in HRQoL was found for all three 
domains of the SGRQ  (Activity, Impacts and Symptoms) until the age of 25 years after 
which a more rapid decline occurred. The physical component score of the SF-36 also 
showed a continual decline with age so that by the age of 40 onwards, the health status of 
PCD patients was one and a half standard deviations below the population mean. In contrast, 
the mental component score also declined with age however the declining health status 
broadly parallels that found in the general population as a whole, and was, at the most, one 
third to one half a standard deviation below the population norms. Age was also an important 
factor in an Italian cross-sectional survey study (107), where all three subscales of the SGRQ 
and the physical and mental component scores of the SF-36 declined significantly greater 
than norms for the corresponding Italian population. These declines, however, were found to 
be earlier in age than those reported in the UK study (113), where deterioration mainly 
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occurred prior to and during adolescence. In the UK study, little abnormality was found for 
the childhood and adolescence study population when compared to standard measures of the 
SF-36. 
  
Both studies found that patients with an earlier diagnosis had better scores for the SGRQ 
Impact and Activity subscales, suggesting the importance of early medical intervention for 
HRQoL. The Italian group found a clear majority of patients (71.8%) considered their 
HRQoL significantly or slightly improved after diagnosis; however there remained a 
progressive worsening of the disease over time. This was in contrast to the UK group who 
reported stable scores for patients after diagnosis.  
 
4.4.4.2. Physical Impact 
Ten studies addressed the impact of PCD on physical functioning (78, 103, 107, 112, 113, 
118-121, 124). The physical impact of PCD was reported by children, teenagers, and their 
parents in a qualitative study using phenomenological analysis methods (78). Coughing was 
regularly mentioned by all participants in their accounts of daily activities, as was the impact 
of their cough on activities when both well and unwell. Symptomatic relief of chest 
symptoms was reported as leading to a sense of freedom at being able to undertake activities 
without restrictions. Patients reported feeling limited in their ability to keep up with peers 
because of coughing, breathlessness, fatigue and low energy levels. Similar themes arose in 
two collaborative qualitative studies, which included interviews with patients from the UK 
and North America (103, 124). Children and teenagers reported they became tired quickly 
when engaging in physical exercise and needed to request more breaks than their peers. This 
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theme relating to the physical impact of PCD was also found in adult interviewees, where 
patients reported not being able to keep up with others when walking or exercising (Box 1). 
Box 1: Patient experiences of the physical impact of PCD 
A: “I go running again and then cough a bit and then I’ll stop” Child (78) 
B: “I had to tell the group not to worry because I start huffing and spluttering as I’m walking.” 
Adult (103) 
“My air goes out because I’m running and I can’t speak and then I’m not speaking and 
sometimes my air goes down a bit and then I can’t, and then I just can’t, I can’t, I can’t take it.” 
Child (78) 
 
“…if he’s playing in school and …he needs to run around, then he gets more tired than other 
kids and they’re still running around and he’s stopping.” Parent (124) 
 
In a quantitative study, 10% of patients were found to be moderately-to-highly limited by 
respiratory symptoms in everyday activities, and 52% of cases had moderate-to-severe 
limitations in performing vigorous activities (119). This was in contrast to a Dutch study 
where 34% of patients reported being moderately-to-highly limited by sinopulmonary 
symptoms in activities of everyday-life, and 39% reported moderate-to-severe limitations in 
performing vigorous activities. None of the healthy controls reported any limitations in 
physical abilities.  
As reported previously, a continual decline according to age in scores on the physical domain 
of the SF- 36 reflected a moderate degree of morbidity on normal physical functioning which 
is progressive across the lifespan (113). Cough, on almost all days of the week in the last 12 
months, was the most frequently reported symptom (48.7% of patients) regardless of age, 
together with excessive sputum (57.7% of patients) (107).  
 
4.4.4.3. Emotional impact: Frustration, anxiety and stress 
The emotional impact was explored in depth in three of the five the qualitative studies (78, 
103, 124). Interviews in the UK and North America, explored the emotional impact of PCD 
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in all age groups (103, 124).  In the paediatric group, frustration relating to treatment burden 
was a prominent theme. Children and adolescents reported feeling frustrated about getting 
sick regularly and about the chronic nature of their symptoms.  In addition, a sense of 
injustice and sadness about having this condition was reported. A UK qualitative study (78) 
found that children and teenagers became anxious when thinking about their health in the 
future. The positive changes which had arisen from their diagnosis and effective health care, 
while appreciated, induced a level of doubt and anxiety as to how these improvements could 
be sustained.  Such feelings of anxiety were also found in a series of interviews with adult 
patients (103). This was especially the case when thinking about their future and future health. 
They reported feeling anxious about being able to conceive children as well as being well 
enough to care for their family (Box 2).   
 
Box 2: Patient experiences of the emotional impact of PCD 
A: “I was sick on and off…it’s just frustration.  Because there’s no cure.” Adolescent (124) 
B: “Sometimes, when he sees his friends running around and he can’t tag them, then he feels like 
‘why do I have PCD?’ Parent (124) 
C “It…just wastes all of my energy, it makes me feel like I don’t want to wake up in the mornings” 
Child (124) 
D “I’m so frustrated with this illness, I just want it to go away, but, unfortunately, that’s how I have 
to live.”  Adult (103) 
E “…if you go to the doctor [and] you’re feeling pretty good and you know your numbers are not 
good; that can be a big cause of anxiety.” Adult (103) 
F “Finding out that I possibly can’t have kids; that are when it started to panic me a little bit.” Adult 
(103) 
G “I’m still very uncertain if I ever wanna have children because I don’t know how me having this 
illness will affect them.” Adult (103) 
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Carotenuto et al., conducted a behavioural and psychological evaluation of children with 
PCD and compared the results to healthy children (77). The findings showed no clinically 
relevant scores for both healthy and PCD groups. However, higher scores were found in the 
PCD group for factors such as withdrawnness, somatic complaints, anxious/depressed items, 
attention span, and internalising problems items (p<0.05). This study also found that total 
stress levels (assessed through the parenting stress index-short form (PSI/SF)) in mothers 
were significantly higher in the PCD group than in mothers of healthy controls (p<0.01), and 
that all PCD mothers had high levels of stress.  
 
4.4.4.4. Social impact: Stigma, embarrassment and concealment 
In the qualitative studies, symptoms such as coughing, sputum production, and ear drainage 
were reported as causing embarrassment among paediatric patients (78, 103, 124). 
Acceptance of coughing was found to be variable among participants and depended on 
severity.  There was also a sense of revulsion from coughing up sputum. Symptom relief led 
to patients feeling ‘normal’(78) (Box 3). Paradoxically reluctance to adhere to treatments was 
also attributed to wanting to feel normal (122, 123). Adult patients also reported feelings of 
embarrassment (79). In a study assessing stigma (measured using a questionnaire developed 
for this study) (118), 75% of the sample agreed that their coughing or breathing was 
embarrassing in public. It also found that stigma correlated with symptoms and impact of 
illness from the SGRQ but not with activities. It also correlated with the mental health 
component scores of the SF-36 but not for the physical component scores.  
Paediatric patients were found to be reluctant to share their PCD diagnosis with teachers and 
peers or even to talk about their condition at home (78). In a separate UK study of patient ≥10 
years, 45% of patients agreed in a study specific questionnaire that they have sometimes felt 
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they had to hide their condition from other people (118). Following on from this, a qualitative 
study (79) found that some patients felt frustrated by lack of knowledge of PCD in the 
general public. While some interviewees were keen to educate others and were open to 
discuss their illness, others were more censored, and avoided describing their symptoms. The 
likelihood of disclosure may be dependent on context, since some patients felt under pressure 
to disclose their diagnosis, for example to teachers or work managers on an account of 
needing time off when ill. There were other patients who reported avoiding open disclosure, 
particularly when at school (Box 3). 
 
 
 
 
 
 
 
 
 
 
 
 
4.4.4.5. Lack of PCD awareness among medical practitioners 
A mixed method study (112) reported the accounts of 20 adult patients and parents of 
children and teenagers from 9 different countries on their experience of being diagnosed with 
PCD or going through the diagnostic process. The most prominent theme reported among 
interviewees was frustration due to the lack of PCD awareness among medical practitioners, 
Box 3: Patient experiences of the social impact of PCD 
A: “actually coughing up mucus isn't a very nice thing. It's not, it's quite a sort of...frowned on 
in society kind of thing isn't it so I kind of, yeah, I don't think it's very nice, sort of, to do it in 
front of people” Adult (78) 
 
B: ‘Sometimes I raise my hand and then say, ‘I have to blow my nose.’  And then I go in the 
bathroom…and shut the door because I don’t want anyone to hear me [because] it’s 
embarrassing.” Child (118) 
 
C: “I feel like I’m being judged by other people because I constantly sniff and…cough.”  
Teenager (118) 
D: “If she has a speech problem or…coughing constantly…when they’re in school, it might 
become embarrassing.” Parent (118) 
E: When I cough . . . it feel a bit more, erm. . . like I’ve got PCD, but when I don’t cough I just 
feel normal. Child (78) 
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manifesting initially in the failure of general practitioners (GPs) to refer them for PCD 
diagnostic testing. This was also found in a UK based qualitative study, using grounded 
theory analytical methods (79) where failure to diagnosis PCD until later in life left some 
patients feeling distrustful of medical care. Themes such as distrust in GPs, difficulty getting 
antibiotics, and isolation due to poor communication between GPs and specialists was 
reported by both studies (79, 112).  
 
4.4.4.6. Treatment adherence and treatment burden 
Barriers to completing treatments included being too busy, forgetting about treatments, 
family issues, and treatments taking too much time. A range in the levels of agreement were 
found between self-reported and prescribed treatment, ranging from 39% for eardrops, to 
71% for antibiotics, and 89% for physiotherapy (122, 123). For adolescents, 57% agreed that 
their PCD team do not understand how difficult it is to follow treatments, and 43% felt that 
having to follow the PCD treatments meant less freedom in life. The difficult of fitting 
treatments in on a daily basis was reported by 12/20 adolescences interviewed across the UK 
and North America (124). Interviews with adult PCD patients also reported the challenges of 
completing their treatments (103, 112) (Box 4).  
There was also agreement among parents of children with PCD (76%) that barriers to 
completing treatments meant less freedom in life (122). Parents expressed how other 
commitments, such as siblings and employment, could limit their ability to complete daily 
treatments (78, 124) (Box 4).  
Patients did report that following a PCD diagnosis, treatments could reduce symptoms 
providing sensations of relief. There was a subjective perception of physiotherapy treatments, 
corresponding to fluctuating levels of motivation. There was also a variance in the different 
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levels of PCD health literacy knowledge in the preventative nature of physiotherapy among 
children and teenagers (78). In a cross-sectional survey study (122), 86% agreed that they had 
difficulty complying with treatments because they made them feel physically worse; however 
96% of patients acknowledged their health would decline without treatments. In the mixed 
methods study by Behan et al. (112), in a study specific survey a significant difference was 
found between those who were diagnosed in childhood (0-12 years) and those who were 
diagnosed in adolescences/adulthood (>13 years) on the level of agreement that health has 
improved since diagnosis (p=0.041).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Box 4: Patient experiences of treatment burden 
A: “I think it just requires more planning. I need to wake up earlier or start getting ready for 
bed earlier, I need to come home from work and do this; it's just more planning.” Adult (103)  
B: “It was a bit of a shock…. I was probably in my mid-thirties then, to suddenly be told, 
right, you’ve got to do twenty minutes of physio twice a day, you’ve got to take this blue 
puffer, and the brown puffer… as soon as you get a chest infection you’ve got to take really 
strong antibiotics, I rebelled against that” Adult (118) 
C: “She was sick every month.  Once we had a diagnosis… she gets sick, but not as severe 
as… before.” Parent (112) 
D: Definitely milder…you know we have a treatment plan and even when she starts to get 
sick; those medications are changed so we tend to catch that right away rather than after that.” 
Adult (118) 
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4.5. Discussion 
This systematic review identified 14 studies focussing on the perspectives, opinions, and 
attitudes of patient with PCD. Most of the quantitative studies consisted of small cross-
section surveys and the methodological quality of these studies was generally low (Table 5). 
While the qualitative studies provided a deeper insight into the patient experience, only a 
small number of these studies exist, and mostly include patients from the UK and North 
America.  Notwithstanding these weaknesses, the evidence assembled from the studies makes 
an important contribution to understanding the PCD patient experience and associated 
influences relating to quality of life.   
Two cross-sectional studies suggested a correlation between age and worsening of respiratory 
symptoms, general physical and mental quality of life. Within these two studies, variances 
exist with Pifferi et al.(107) reporting an early decline in HRQoL and McManus reporting 
little abnormality in standard measures of SF-36 during childhood and adolescence. Also the 
variances between the two studies could be due to differences in the age of participants 
involved or a result of their limited sample size.  It could also be due to cultural differences 
between the countries (UK and Italy), access to specialist diagnostic, and management 
services or treatment adherence may also account for differences. Caution must be exercised 
in the interpretation of these findings. Cross-sectional studies do not take into account 
confounding factors such as differences between adult and child participants and experience 
which may affect changes over time i.e. diet, tobacco smoke exposure etc.  The progressive 
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nature of PCD and the deterioration of health have been described in other studies through 
physiological methods such as spirometry (4). Werner et al. (2016)(65) has shown the 
percentage predicted forced expiratory volume in 1 s (FEV1 % pred) values versus age 
exhibited a mean annual decline of 0.59%. The results show interesting trends however 
highlight the need for large longitudinal international studies before more reliable 
conclusions can be made. The Genetic Disorders of Mucociliary Clearance Consortium 
(GDMCC), the iPCD cohort and the BESTCILIA registry are examples of ongoing large-
scale studies that will contribute to this aim.  
 
The physical impact of PCD was a prominent theme in both the qualitative and quantitative 
studies. This was defined by the most prominent feature of this illness: coughing. Coughing 
was regularly mentioned by interviewees of all age groups (78, 103, 124). It was the most 
frequently reported symptom in a survey of 78 participants, where 48.7% reported having to 
cough nearly all days of the week for the past 12 months (107). Persistent presence of cough 
was found to be far less prevalent that in other studies (112, 125) where it was found to be as 
high as 93%-100%. This could be as a result of the way in which the question was phrased or 
the method of data collection used, i.e. patient reporting at home or reporting to a clinician in 
a hospital setting. Severity of symptoms might also reflect different data collection points, 
with patients on their first referral appointment prior to diagnosis and commencement of 
treatments exhibiting more severe symptoms. The physical impact of PCD was expressed by 
patients in the qualitative studies, as not being able to keep up with other family members and 
peers due to fatigue (78, 103, 124).  
Questionnaire findings (77) showed that PCD children were more likely to be withdrawn, 
experience anxiety or depression, and internalise more problems than the healthy population. 
PCD was found to affect the parent also with significantly higher stress being reported in 
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mothers of children with PCD. No other PCD study reports on these factors however studies 
in children and parents with cystic fibrosis have also reported elevated levels of depression, 
stress and anxiety compared to healthy populations (126, 127). The synthesis of the 
qualitative studies allows the researcher to conclude possible reasons for this. PCD impacts 
greatly on the emotional functioning of patients in all age groups. Children described the 
frustration of having constant symptoms and recurrently getting sick. Patient anxiety was 
expressed, especially when thinking about the near and distant future. Children reported 
feeling worried about their health and of getting sick. A sense of sadness was reported 
because of their awareness of being different from other children. There is a need for further 
exploration on how PCD causes stress in developmental ages and the psychological effects of 
PCD on intra-familiar relationships.  
 
Concealing PCD symptoms such as cough and blowing nose in public were reported across 
the qualitative studies (78, 79, 103, 124). Embarrassment was mostly from coughing and 
producing sputum in public however ear drainage was also reported as an embarrassing 
symptom in one of the paediatric studies(124). The stigma questionnaire (which included 
items on embarrassment from symptoms and concealment) correlated with mental health and 
the social impact of symptoms. Although the impact of PCD on school functioning were 
expressed by patients (103, 124), no differences in educational level or IQ were found 
between PCD children and healthy children. School functioning instead could be related to 
patients’ reluctance to disclose their PCD diagnosis with teachers and peers. Such 
concealment of symptoms and illness disclosure has been reported across chronic illness 
(128-131). Results from a cystic fibrosis study (131) found patients were more likely to 
disclose to romantic partners and close friends than to casual friends, bosses, or co-workers 
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and disclosure was associated with higher social support, social functioning, and medication 
adherence self-efficacy.   
Poor adherence to treatments can often be a conscious decision in PCD, however it can be the 
result of not making any decisions at all e.g. worry about having PCD could lead to attempts 
to avoid thinking about it. Poor adherence however is likely to lead to raised anxiety about 
the consequences, which often leads to attempts by the individual to minimise the risks (132). 
This process is known as cognitive dissonance which refers to the widespread observation 
that in any situation where people who feel uncomfortable about a choice they have made, 
also hold a strong desire to resolve this discomfort. Its’ resolution is central to motivating 
patients to change (133). Cognitive dissonance has been reported in cystic fibrosis and has 
been shown to be the case in PCD through this synthesis of literature.  It was reported that 
symptom relief led to patients feeling ‘normal’(78) but there was  paradoxically reluctance to 
adhere to treatments which was also attributed to wanting to feel normal (122, 123).  
 
Patients reported in one study that treatments could reduce symptoms providing sensations of 
relief. In a cross-sectional survey study (122), 85.7% agreed that they had difficulty 
complying with treatments because they made them feel physically worse; however 96% of 
patients acknowledged their health would decline without treatments. There was also a 
variance different levels of PCD health literacy knowledge in the preventative nature of 
physiotherapy among children and teenagers (78). The perception of physiotherapy 
treatments, which corresponding to fluctuating levels of motivation, highlighted the need for 
patient centeredness and personalised medicine. 
4.5.1. Limitations 
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The review has limitations. Papers included were limited to those published in the English 
language. It is possible that there are relevant studies published in other languages. Overall 
the evidence of this review is based on a small number of heterogeneous studies (n=14) that 
are limited in size. The quality assessment of the quantitative studies revealed them to be of 
low quality with scores no greater than 8 points. Until recently, no disease-specific age 
appropriate HRQoL measures were available for PCD patients (103, 124) and to date, studies 
have used general HRQoL tools such as the SF-36 and disease specific tools for cystic 
fibrosis and COPD. These studies have also included child participants to complete measures 
that are not age appropriate without psychometric validation. Studies have included results 
where young children had help from a parent to complete these measures which may lead to 
bias (129). Only one of the studies performed analyses with and without the children who 
needed help completing the questionnaire. In addition, limited psychometric data was 
presented on the validity of the HRQoL used, with some studies reporting validity but never 
for all of the scales. As with any review, the quality of studies included can only be assessed 
by what was reported in the final manuscript; e.g. missing information on any of the adopted 
criterion might reflect unclear reporting as opposed to a limitation in study design.  
 
4.5.2. Recommendations 
To date, no medications to treat PCD have been approved by regulatory bodies (125)  and 
current physiological outcome measures, such as spirometry, chest computed tomography, 
and lung clearance index have been reported to have limitations in terms of their sensitivity 
and feasibility for evaluating new therapies or disease progression (66, 74, 76, 134). These 
physiological measures also do not reflect the impact of the disease on patients' daily 
symptoms or functioning (e.g., physical, respiratory, social) as required by the Food and Drug 
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Administration (94) and the European Medicines Agency (92, 93). This study has highlighted 
the need for large multi-national and longitudinal studies to be conducted using PCD specific 
HRQoL measures (103). Studies are underway and QOL-PCD has been translated 
comprehensively into five European languages. These tools have been included in the first 
international RCT azithromycin study(65). The measures are also being included in an 
international PCD registry developed as part of the BESTCILIA FP7 study, providing an 
international platform to systematically collect data on incidence, clinical presentation, 
treatment, and disease course. Qualitative studies that reflect different ethnicities and cultures 
are important and necessary to establish the needs and opinions specific to these groups. 
 
4.6. Conclusion 
The findings of this review indicate the physical impact, emotional and stigmatising impact 
of PCD. They highlight the need for well designed, quantitative studies using PCD specific 
health-related quality of life measures to accurately determine the factors that impact PCD. 
There is also a need for the experience of patients to be further examined across ethnicities to 
evaluate various nuances between cultures. This will lead to better care, management, and 
outcomes for PCD patients.   
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Figure 6: PRISMA Flow Diagram for search to investigate PCD from the patients’ 
perspective.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Results  
 
Abstracts read 
Initial Search: 
N=260 
 
 
N=32 
 
 
Duplicates Removed 
N=26 
 
 Full Text Reads 
Studies for Inclusion: 
N=14 
 
 
12 studies were excluded: 
 2 studies were commentaries 
 1 study was a case report 
 9 were irrelevant as they did not report 
findings from patient reported outcome 
measures, quality of life or qualitative data 
on patient experience 
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Table 3: Criteria for Rating Methodological Quality of Quantitative Studies 
Study parameter Rating Criteria 
Study design 3 Longitudinal prospective design (explicitly stated) 
2 Retrospective or mixed design (explicitly stated) 
1 Cross-sectional (explicitly stated) 
0 Survey or did not report 
Participants and 
recruitment 
3 Description of the population, (2) Eligibility of participants, (3) 
precise details of the recruitment process, (4) accounted for the 
number recruited, (5) loss to follow up. 
 
2 Minimal description of at least four criteria 
1 Two criteria missing 
0 More than two criteria missing 
Comparison group 3 Healthy, age appropriate comparison (i.e. adolescents/young 
people 13-25 years) 
2 Reference sample 
1 Other comparison group (i.e. adults) 
0 No comparison group 
Number of participants 3 n>100 
2 n=50-100 
1 n<50 
0 Did not report 
Instruments used 3 Psychometrically sound report of instruments used 
2 Some weak psychometric properties reported 
1 Psychometric properties of instruments reported as inadequate for 
measuring HRQoL or IQ, physical functioning etc.  
0 No psychometric properties reported 
Adapted from previously reported studies (115-117) 
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Table 4: Summary of the 14 studies included in this systematic review, including the 
aims, study design, analysis, and findings
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Study, Year, 
Country Aims Sample Design Data collection and Analysis Findings 
Behan et 
al.(112) (2015) 
International 
 
Investigate patient opinions 
about the PCD diagnostic 
process internationally. 
-Survey: 270 PCD 
patients from 25 
countries.                         
- Age: not specified. 
- Gender: 114/271 
males 
- Interviewed 20 
parents/patients.           
- Gender: 6/20 males - 
Age: not specified. 
Survey, cross 
sectional and 
semi-structured 
interviews  
-A patient survey was developed by 
patient representatives and healthcare 
specialists to capture experience.                         
- Information collected included age, 
gender, age at diagnosis, time since 
diagnosis, diagnostic procedures, number 
of visits to GP before referral, questions 
relating to patient's perception on 
diagnostic process.                                   -
Semi-structured interviews were 
conducted and fully transcribed and 
thematically analysed 
-35% of respondents visited their doctor >40 times with PCD related 
symptoms prior to referral for testing.                                                                
-Lack of PCD awareness among medical practitioners and failure to take 
past history into account leading to a delayed diagnosis.                                
-In the diagnostic process, improved reporting of results and a solution the 
‘inconclusive’ diagnostic status were considered as needs.                             
-A significant difference was found between those who were diagnosed in 
childhood (0-12 years) and those who were diagnosed in 
adolescences/adulthood (>13 years) on the level of agreement that health 
has improved since diagnosis (p=0.041)                                                                                                         
-Difficulty getting antibiotics, and isolation due to poor communication 
between GPs and specialists was reported after diagnosis. 
Carotenuto et 
al.(77) (2013) 
Italy 
To perform behaviour and 
psychological evaluation of 
children with PCD compared to 
controls of healthy children. To 
assess if PCD effects and 
impacts the quality of family 
functioning and the 
psychological equilibrium of 
children. 
-10 PCD and 34 
healthy school-aged 
children 
-PCD: 7/10 males. 
-PCD Age range: 8-16 
years 
-Healthy: 24/34 males  
-Healthy Age range: 
6-16 years 
Survey; case-
control, cross-
sectional  
-Standardised questionnaires  
-Children completed Wechsler 
Intelligence Scale  
-Parents completed Child Behaviour 
Checklist questionnaire and Parenting 
Stress Index-Short Form 
-No significant differences between age, gender or BMI, or mother’s age 
and educational level between the 2 groups.  
-No difference in IQ (WISC-III) between the two groups.  
-For CBCL no clinical relevant scores were found for both group   
-Higher scores were found in the PCD group compared to the healthy 
group for withdrawn, somatic complaints, anxious/depressed items, 
attention and internalising problems items (p<0.05).  
-Parent Stress Index Short-Form mean scores relating to parental distress, 
child parent interaction and total stress in mothers was significantly higher 
in the PCD group 
-All PCD mothers had high levels of stress.  
*Dell et al. 
(124) (2014) 
To develop harmonised (North 
America, Europe) paediatric 
HRQoL questionnaires for 
children (6-12 years), 
adolescents (13-18 years), and 
parent respondents. 
Age range: 6-17 years 
Gender: 20/40 males 
Focus groups 
and open-ended 
interviews.  
-Literature review, focus groups (clinician 
and patient) and semi-structured 
interviews with children, adolescents and 
their parents.                                                   
-Transcripts were content-analysed.          
-item relevance survey.      -
Questionnaires refined following 
cognitive interviews. 
-This led to the development of four age-specific preliminary instruments 
measuring HRQoL in PCD patients.  
-These consist of a: 1) Child version (6-12 years) (37 items); 2) Adolescent 
version (13-17 years) (43 items); and 3) Parent version (children aged 6-12 
years) (41 items).  
-Measures consisted of 8-10 scales including: Impact to Physical, 
Emotional and Social functioning, Vitality, School Functioning, Lower 
and Upper Respiratory Symptoms, Impact of ear symptoms/hearing loss, 
Impact of treatment burden, Impact to Eating and Weight. 
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*Lucas et 
al.(103) (2015) 
UK and North 
America 
To develop a PCD-specific 
HRQoL instrument for adults 
with PCD 
-21 PCD adults  
-3/21 males 
-Age range: ≥18 years 
Focus groups 
and open-ended 
interviews.  
-Open-ended interviews                    
- Content analysis yielded the most 
important items for each of the 10 
domains based on the frequency 
with which they were mentioned. 
Saturation confirmed when no new 
themes emerged.                                                       
- Item relevance survey.                    
- Questionnaires were refined 
following cognitive interviews. 
-10 domains based on frequency with which they were mentioned across 
adult group.  
-Cognitive interviews provided 6 additional items.  
-The final prototype instrument contained 49 items across ten domains and 
included impact of respiratory symptoms, impact of sinus symptoms, 
impact of ear symptoms/hearing loss, impact to physical functioning, 
impact to emotional functioning, impact to social functioning, vitality, 
health perception, role functioning, impact of treatment burden. 
Madsen et al. 
(121) (2013) 
Denmark 
To assess peak oxygen uptake 
(VO2peak) to compare these 
values with those of healthy 
subjects; and assess if VO2peak 
is associated with parameters of 
pulmonary function, self-
reported physical limitations, 
and weekly physical activity. 
-44 PCD adults and 
children matched with 
33 healthy controls.  
-PCD: 17/44 males.          
-PCD age range: 6.0-
29.7 years.  
- Healthy: 17/33 
males      
-Healthy age range: 
6.2-28.8 years 
Survey, cross-
sectional, case 
control study 
 
 
-3 questions about physical activity and 
limitations were extracted from 
standardised questionnaires; St George's 
Respiratory Questionnaire, Cystic 
Fibrosis Questionnaire, Sino-Nasal 
Outcome Test-22 and the Medical 
Outcomes Study Short Form-36 
-In response to questions relating to physical activity, 34% of patients 
reported being moderate to highly limited, 44% were slightly limited while 
21% were not limited at all by sino-pulmonary symptoms in activities of 
everyday life.  
-39% reported moderate to severe limitation in performing vigorous 
activities, while 30% only reported only slight difficulties and 30% denied 
having any difficulties.  
-VO2peak was significantly lower in patients reporting severe limitations 
in performing vigorous activities compared to patients without limitations.  
-VO2peak was significantly lower in patients who reported being highly 
limited by sino-pulmonary symptoms in everyday-life compared to 
patients who were not limited at all.  
Maglione et al. 
(2014) Italy 
To verify HRQoL in respiratory 
disorders correlate with 
spirometry or a 6-minute walk 
test. 
-20 PCD patients.         
-Gender not specified.  
-Age range: 12.0-33.4 
years 
Survey, 
longitudinal. 
-Standardised questionnaires were 
completed by patient: St George's 
Respiratory Questionnaire, Leicester 
Cough Questionnaire, Medical Outcomes 
Study Short Form 36 at two time points.         
- Data on spirometry and the 6-minute 
walk test at 2 time points also collected. 
-Spirometry and 6 minute walk test were not significantly related to any of 
the HRQoL assessment tools at baseline or 12 months later.  
-Over the 12 month period, no significant changes were found in any of the 
HRQoL outcomes or in spirometry of 6 minute walk test.  
-HRQoL tools used reported as suboptimal to longitudinally track HRQoL 
in PCD. 
ƚMcManus et al. 
(113)(2003) UK 
To examine the effect of PCD 
on the overall health status of 
patients. 
-93 members of UK 
PCD Family Support 
Group.  
-34/93 males.  
-Mean age = 22.7 (SD 
16.8) and median 16.5 
(IQR 10.8 - 31.3) 
Survey, cross-
sectional   
-Standardised questionnaires were 
completed by patient; St George's 
Respiratory Questionnaire and Medical 
Outcomes Study Short Form 36. 
-Separate versions of the questionnaire 
were provided for adults and children 
(<16 years). 
-SGRQ domains; Symptoms, Activity and Impact scores correlated 
significantly with age and declined more rapidly after 25 years and more 
rapidly than population norms.  
- SGRQ domain: Impact and Activity show effect of time since diagnosis. 
-Almost all patients reported 'a runny nose and nasal congestion', 'pain 
over my sinuses' and 'a headache' affected patients a few days a month.   
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ƚMcManus et 
al.(118) (2006) 
UK 
To describe the influence of 
demographic factors, 
respiratory symptoms, physical 
and mental health status and 
stress upon stigma experienced 
by patients and their 
relationship with the Big Five 
measures of personality.  
-71 members of UK 
PCD Family Support 
Group. 
-23/71 males. 
-Mean age = 27.7 (SD 
16.2) and median 20.1 
(IQR 15.6 - 38.7). 
(Only respondents’ 
≥10 years were 
included.) 
Survey, cross 
sectional 
Standardised questionnaires were 
completed: St George Respiratory 
Questionnaire, Medical Outcomes Study 
Short Form 36 General Health 
Questionnaire, personality ('Big Five'). 
Stigma using the authors own 
questionnaire was also. Separate versions 
were provided for adults and children 
(under16 years).  
-Stigma had no association with age or age of diagnosis. 
-It correlated significantly with the SGRQ Symptom and Impact of Illness 
Score but not with Activity Score.  
-Stigma correlated with the GHQ stress score and with the Mental 
Summary of the SF-36 although not the Physical Summary scores.  
-The stigma score correlated with neuroticism measure 
-Stigma did not differ between males and females or between those with 
situs inversus and situs solitus.  
-High Impact measure on the SGRQ and good mental health (SF-36) and 
Low Activity (SGRQ) are predictors of Stigma. 
Mirra et al.(119) 
(2015) 
To investigate if levels of 
Vitamin D are associated with 
quality of life and self-reported 
activity level, among other 
outcome parameters. 
-22 PCD patients,  
-15/22 males.  
-Age range: 2-34 
years 
Survey, cross-
sectional   
-Standardised questionnaires were 
completed: St George's Respiratory 
Questionnaire and Self-reported Physical 
Activity levels.  
Patients underwent serum vitamin D 
levels measurement, pulmonary function 
tests, deep throat and sputum culture.  
-SGRQ score was 19 (9-65).  
-For physical activity, 10% of patients reported moderately-to-highly 
limited, 26% were slightly limited and 63% were not limited at all by 
respiratory symptoms in everyday activities.  
-52% of cases reported moderate-to-severe limitations in performing 
vigorous activities, while 26% had only slight difficulties, 21% had no 
difficulties at all.  
Pifferi et al. 
(107)(2009) 
Italy 
To assess the impact of PCD on 
HRQoL in Italian patients. To 
identify the unmet needs of the 
patients and the potential 
diagnostic and therapeutic 
pitfalls.  
-78 PCD patients. 
-34/78 males. 
-Age range: 1.7 - 48.5 
years 
Survey, cross-
sectional  
-Standardised questionnaires were 
completed: St George Respiratory 
Questionnaire, Medical Outcomes Study 
Short Form-36.  
-Information on age, gender, age at 
diagnosis, time since diagnosis, clinical 
features, compliance with treatment, 
diagnostic procedures, incidences of 
surgery in patients, PCD in family 
members also collected.  
-A questionnaire on clinical course of the 
disease management, including a question 
on the patient's perception on quality of 
life after diagnosis was completed.  
-Separate age specific versions used.  
-All 3 subscales of SGRQ correlated with age. 
-Cough on almost all days a week was the most frequent reported 
symptoms (48.7% of patients).  
-Significant correlation between time since diagnosis and impacts subscale 
but not for symptoms subscale (SGRQ).  
-Breathlessness increased with age.  
-There was a decline in physical and mental component scores (SF-36) in 
relation to age in PCD patients, significant only for mental component 
scores.  
-Age at diagnosis influence on symptoms, activity and impacts (SGRQ) 
and mental health (SF-36). 
-Reduced compliance with treatment is associated with mental component 
scores (SG-36) and age at diagnosis and time since diagnosis. - The 
majority (71.8%) considered their quality of life to have significantly or 
slightly improved after diagnosis. 
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Schofield et al. 
(78) (2014) UK 
To explore the physiotherapy 
experiences of patients and 
their parents within the 
paediatric PCD population in 
the UK. To identify patients' 
needs and to make 
recommendations for future 
service developments.  
-3/5 males, 
-Age range: 8-15 
years (all Asian 
ethnicity). 
Semi-structured 
interviews. 
-Interpretative Phenomenological 
analysis.  
-Pilot interview conducted: themes based 
on concepts from existing literature. 
-Subsequent interviews involved the 
participant recounting their daily routine. 
-A second validation interview discussed 
key points of the first interview. 
-Experience of day to day life with symptoms and treatment burden.         -
Diagnosis led to symptoms perceived as abnormal  
-Symptoms reduced since treatment began. Coughing was variable in its 
acceptance and depended on severity.  
-Embarrassment from coughing. Revulsion from coughing up sputum. 
Anxiety looking towards the future and how long-term improvements 
could be sustained fuelled anxiety. Freedom emerged from being able to 
engage in activities without limitation.  
-Participant’s self-awareness and self-assessment of symptoms. 
Knowledge of condition and the preventative nature of physiotherapy 
varied. Limited sharing of PCD with teachers and peers and even at home. 
-The role of the family, carers and health specialists in nurturing personal 
mastery skills. Clinics provide knowledge and treatment skills which were 
then refined into practices that were personally enjoyable and effective.  
*Taelman et 
al.(122) (2014) 
Belgium 
This study aims to investigate 
and identify attitudes and 
barriers related to treatment 
adherence in children with PCD 
and their parents. 
-25 parents of PCD 
children (<18 years) 
-7 PCD adolescents  
-Age range: 14-18 
years. 
 
Survey, cross 
sectional 
-A questionnaire consisting of 
demographic information and treatment 
related questions. 
 -A list of 18 barriers and 10 statements of 
attitudinal patterns.  
-Adolescents completed questionnaire 
independently. 
-The most commonly reported barriers to treatment were too busy, 
forgetting, family issues, wanting to be normal, takes too much time. 
- For adolescents, attitudes influencing non-adherence include PCD team 
does not understand how tough it is to follow treatments (57.1%), wanting 
to follow my treatments but sometimes just forget (71.4%), trouble 
sticking to treatments because they make teenager feel worse (85.7%), 
having to follow treatments means less freedom in  life (42.9%).  
*Taelman et 
al.(123) (2014) 
Belgium 
 
To examined the impact of 
PCD on daily life by comparing 
self-reported and prescribed 
treatment; investigating barriers 
and attitudes to treatment and 
exploring coping styles. 
-39 PCD patients  
(25 parents) 
-13/39 males. 
-Mean age=33 years. 
Survey, cross 
sectional 
- A questionnaire consisting of treatment 
related questions. 
- Age, gender, FEV1, types of treatment 
completed also completed                              
-Frequency of treatments varied with 82% parents reported daily use of 
nebulizer; 64% patients reported daily use of nose spray and 46% reported 
physiotherapy.  
-Agreement between self-reported and prescribed treatment ranged from 
39% for eardrops to 71% for antibiotics and 89% for physio.  
- Most patients (96%) did not agree that their health will be OK, even if 
treatments are not done and parents (76%) agreed that having to follow 
treatments means less freedom in life.  
-Burden of treatment is related to time and wanting a normal life. 
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ƚWhalley et al. 
(79)(2006) UK 
Depth-qualitative interviews 
aimed to explore themes 
surrounding the psycho-social 
impact of PCD. A quasi -
experimental design was used 
for directly validating the 
stigma questionnaire. 
-6 pairs (n=12) of 
PCD patients.  
-2/12 males.  
-Aged range: 27-65 
years 
Depth 
qualitative 
interviews 
followed by 
stigma rating.  
-Grounded theory analytical approach.    -
Interviews conducted and fully 
transcribed.  
-Initial themes under investigation 
included diagnosis, symptoms and social 
perspectives surrounding PCD, including 
the possibility of stigma. 
- Before each interview, the previous was 
transcribed and loosely open-coded, with 
emerging themes compared with the 
previous interview data. 
- Comprehensive open-coded once data 
collection was complete. 
- Other people’s lack of knowledge of PCD led to frustration in some but 
other understood this was due it being a rare disease. Some educate others 
and are open. Others were more censored avoiding describing the 
stigmatised symptoms such as productive cough. Some were under 
pressure to disclose while others at some point avoided disclosure 
particularly when at school.  
-Most had at some stage tried to conceal symptoms  
-Embarrassment from symptoms led to behavioural change  
- Failure to diagnosis PCD until later in life left some feeling mistrust of 
medical care. Mistrust in GPs; difficulty getting antibiotics and isolation 
due to poor communication between GP and specialist. However praise of 
tertiary specialist centre.  
-Ratings of stigma scales were in complete concordance. 
Ƚ Same UK study population 
* Same Belgian study population 
* Both publication are part of the same study with UK and US participants however different age groups, therefore separate study populations 
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Table 5: Summary of the quality of the data and studies contributing to the quantitative studies included in this systematic review. Scoring was 
according to Criteria for Rating Methodological Quality of Quantitative Studies adapted from previous studies (115-117) 
 Study design Participants & recruitment Comparison group Number of participants Instruments  Total 
Behan et al.(112) (2015) International 0 2 0 3 0 5 
Carotenuto et al.(77) (2013) Italy 0 0 3 1 2 6 
Madsen et al. (121) (2013) Denmark 1 2 3 1 0 7 
Maglione et al. (2014) Italy 3 0 0 1 0 4 
ƚMcManus et al.(118) (2006) UK 0 1 0 2 2 5 
ƚMcManus et al. (113)(2003) UK 0 1 2 2 2 7 
Mirra et al.(119) (2015) 1 0 0 1 2 4 
Pifferi et al. (107)(2009) Italy 1 1 2 2 2 8 
*Taelman et al.(123) (2014) Belgium 0 0 0 1 0 1 
*Taelman et al.(122) (2014) Belgium 0 1 0 1 0 2 
ƚSame UK sample  
*Same Belgian sample
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Table 6: Summary of completeness of reporting for the qualitative studies included in this 
systematic review using the Consolidated Criteria for Reporting Qualitative Health Research 
(105) 
Reporting criteria No (%) n=5 References of studies 
reporting each criterion  
Characteristic of research team:   
Interviewer/facilitator identified 4 (80%) 23, 24, 35, 36 
Credentials 2 (40%) 23, 35,  
Occupation 2 (40%) 23, 35 
Gender 0 (0%) - 
Experience and training 2 (40%) 23, 35 
Relationship with participants:   
Participation knowledge of the 
interviewer 
2 (40%) 23, 35  
Interviewer characteristics 3 (60%) 23, 24, 35 
Methodological orientation and 
theory 
5 (100%) 23, 24, 34-36 
Participant selection:   
Sampling method (for example, 
snowball or purposive) 
5 (100%) 23, 24, 34-36 
Method of approach 5 (100%) 23, 24, 34-36 
Sample size 5 (100%) 23, 24, 34-36 
Non-participation 2 (40%) 23, 24 
Setting:   
Setting of data collection 4 (80%) 23, 34-36 
Presence of non-participants 1 (20%) 23 
Description of sample 5 (100%) 23, 24, 34-36 
Data collection:   
Interview guide 5 (100%) 23, 24, 34-36 
Repeat interviews 1 (20%) 23 
Audio/visual recording 5 (100%) 23, 24, 34-36 
Field notes 3 (60%) 23, 24, 36 
Duration 2 (40%) 23, 24 
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Data saturation 4 (80%) 24, 34-36 
Transcripts returned to participant 0 (0%) - 
Data analysis:   
Number of data coders 5 (100%) 23, 24, 34-36 
Description of the coding tree 0 (0%) - 
Derivation of themes 5 (100%) 23, 24, 34-36 
Protocol for data preparation and 
transcription 
5 (100%) 23, 24, 34-36 
Software 4 (80%) 23, 34-36 
Participants’ feedback or member 
checking 
3 (60%) 23, 34, 35 
Reporting:   
Participant quotations presented 5 (100%) 23, 24, 34-36 
Data and findings consistent 5 (100%) 23, 24, 34-36 
Clarity of major themes 5 (100%) 23, 24, 34-36 
Clarity of minor themes 5 (100%) 23, 24, 34-36 
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5.1. Abstract  
 
Background: Diagnosis of primary ciliary dyskinesia (PCD) lacks a ‘gold standard’ test and 
is therefore based on combinations of tests including nasal nitric oxide (nNO), high-speed 
video microscopy analysis (HSVMA), genotyping and transmission electron microscopy 
(TEM). There is little published data on the accuracy of this approach.  
 
Method: Using prospectively collected data from 654 consecutive patients referred for PCD 
diagnostics we calculated sensitivity and specificity for individual testing strategies. 
Accuracies of combination testing strategies were compared in a subset of 180 patients who 
underwent all tests. 
 
Results: HSVMA had excellent sensitivity and specificity (100%, 93%), TEM was 100% 
specific but 21% of PCD patients had normal ultrastructure. nNO (30nL/min cut-off) had 
good sensitivity and specificity (91%, 96%).  Simultaneous testing using HSVMA and TEM 
was 100% sensitive and 92% specific.   
 
Conclusion: Combination testing was found to be a highly accurate approach for diagnosing 
PCD.   HSVMA alone has excellent accuracy but requires significant expertise and repeated 
sampling or cell culture is often needed. TEM alone is specific but misses 21% of cases. nNO 
(≤30 nL/min) contributes well to the diagnostic process. In isolation nNO screening at this 
cut-off would miss ~10% of cases but in combination with HSVMA could reduce 
unnecessary further testing.  Standardisation of testing between centres is a future priority. 
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5.2. Introduction 
Recent advances in the diagnosis of patients with primary ciliary dyskinesia (PCD) have 
included networks of specialists developing protocol-driven testing (14, 19, 20, 135) 
international consensus guidelines (22), and rapid expansion of known PCD-related genes 
(20). 
 
There is no ‘gold-standard’ test for PCD, hence European consensus guidelines (2009)(22)  
recommend a combination of tests including nasal nitric oxide (nNO) screening (14, 58), 
high-speed video microscopy analysis (HSVMA) of ciliary beat frequency (CBF) and pattern 
(CBP)(16, 29, 136, 137), and transmission electron microscopy (TEM) analysis of ciliary 
ultrastructure (17, 18).   
 
Reanalysis following submerged  (138) or air-liquid interface (ALI) (139) culture may be 
useful to exclude secondary ciliary dyskinesia or confirm PCD when analysis of the primary 
sample is abnormal and may provide additional cilia if the primary sample is inadequate.  The 
2009 guidelines (22) also suggest potential adjuncts to diagnosis including 
immunofluorescence labelling of cilia proteins (60), pulmonary radioaerosol mucociliary 
clearance (62, 140) and genotyping.  Since 2009 there have been rapid advances in the 
discovery of genes responsible for PCD (20, 135) allowing genetic testing to take a 
prominent position in some countries, but it is currently not funded in the English public 
healthcare system.  The English PCD service (135, 141) diagnoses PCD using nNO, HSVMA 
and TEM, with reanalysis following ALI-culture for inconclusive and positive samples.   
 
Several manuscripts have reported the accuracy of individual tests for the diagnosis of PCD, 
but none have considered all available diagnostic data.  Most reports have failed to include 
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the significant numbers of ‘inconclusive’ results (142).  The aim of this study was to 
determine accuracy of PCD diagnostic tests (nNO, HSVMA, TEM) when used singularly or 
in combination based on a large prospective study of consecutive patients referred for 
diagnostic testing.   
 
5.3. Methods  
Local and national research and development and ethical approvals were obtained 
(Southampton and South West Hampshire Research Ethics 07/Q1702/109).  
 
5.3.1. Participants 
Eight hundred and sixty-eight consecutive subjects were referred to the national PCD centre 
at University Hospital Southampton (UHS) for diagnostic testing between 2007 and 2013; 
654 had adequate data and samples for inclusion. The population served by the centre is 
predominantly White and non-consanguineous. Patients attended UHS or samples were 
couriered to UHS from satellite referral centres, with no pre-screening of nNO.   
 
5.3.2. Diagnostic testing  
The pathway leading to diagnostic outcomes is summarised in Figure 7. Details of the 
method are provided in Appendix 2. 
 
5.3.2.1. Patients and samples 
Patients were required to have been free of infection for ⩾4 weeks. At UHS, demographic 
and clinical history was recorded using a standard form. At UHS nNO was measured using a 
chemiluminescence analyser (NIOX Flex; Aerocrine, Solna, Sweden) aspirating nasal air 
from the nostril at 0.3 L·min−1 during a breath-hold manoeuvre. Based on experience, since 
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2007 we have considered an arbitrary cut-off of ⩽30 nL·min−1 . Following nNO 
measurement, a nasal brush biopsy provided epithelial cells for HSVMA, TEM and ALI 
culture. Satellite centres completed patient proformas and brush biopsies were couriered to 
UHS. Cells for HSVMA and ALI culture were transported in buffered medium within 3 h, 
while fixed samples for TEM were accepted with longer transportation times. 
 
5.3.2.2. Laboratory analyses  
HSVMA and TEM were analysed in blinded fashion by PCD-specialist microscopists 
(Appendix 2). At least six healthy strips of ciliated epithelium were recorded at 500 frames 
per second (fps). Sequences were played back at 30 fps to observe the CBP and calculate 
CBF. CBP was qualitatively assessed as normal, dyskinetic (static, uncoordinated, rotational, 
reduced beat amplitude, slow or hyperfrequent), valid-inconclusive despite adequate sample 
or invalid-inconclusive due to inadequate sample. HSVMA was only reported normal if both 
CBF (normal range 11–20 Hz) and CBP were normal. TEM analysis was carried out if 
HSVMA was abnormal or inconclusive. ⩾100 cilia were imaged in transverse section at 
×60000 magnification for the assessment of axonemal structure. Using in-house normative 
data, quantitative analysis determined ciliary ultrastructure as normal, abnormal, valid-
inconclusive or inadequate-inconclusive. HSVMA and/or TEM were reanalysed following 
ALI-culture or repeat biopsy unless results were normal.   
 
5.3.2.3. Diagnostic decisions  
Data were reviewed at multidisciplinary team meetings, attended by a clinician, an HSVMA 
microscopist and a TEM microscopist. All clinical and diagnostic data were considered when 
agreeing the diagnostic outcome as PCD-positive, PCD-negative or inconclusive. Positive 
diagnosis was reported in patients with typical clinical history, usually with at least two 
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abnormal diagnostic tests (TEM, HSVMA and nNO), but in patients with a strong history 
(e.g. sibling with PCD or “full” clinical phenotype (e.g. neonatal respiratory distress at term 
followed by daily wet cough, persistent rhinitis and glue ear, often associated with episodes 
of upper and lower respiratory tract infection)), we occasionally reported a positive diagnosis 
based on “hallmark” TEM or repeated HSVMA consistent with PCD. CBP was considered 
positive if the pattern was typical of PCD rather than secondary ciliary dyskinesia, 
determined either from two brushing biopsies or from one brushing biopsy with reanalysis 
following ALI culture. Negative diagnosis was reported if 1) HSVMA with or without TEM 
was normal or 2) HSVMA and TEM abnormalities were consistent with secondary rather 
than primary dyskinesia and normal nNO (if available). A valid-inconclusive diagnosis was 
reported if, on repeated testing, adequate samples had subtle abnormalities not “classical” for 
PCD but outside the range of our experience of secondary defects. It was considered that 
these patients might have subtle or rare variants of ciliary phenotype. Patients were therefore 
told that the diagnosis was equivocal, with the recommendation that they received 
appropriate treatment (e.g. airway clearance or treatment of exacerbations). They were 
investigated for other causes of their symptoms (e.g. cystic fibrosis genotype and 
immunology) and were kept under review for further testing as new tests become available 
(e.g. new PCD-associated mutations). 
 
If TEM and HSVMA were inconclusive due to inadequate samples, e.g. sparse cilia, 
diagnostic outcome was invalid-inconclusive and patients were invited for repeat testing.  
Patients with normal TEM in isolation were considered invalid-inconclusive, since TEM 
misses 20-30% of PCD (143).  Patients with nNO ≤30 nL/min were deemed likely to have 
PCD, but it was never accepted as a lone diagnostic test.  
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5.3.3. Statistical analysis 
Data were prospectively recorded in an Access database (Microsoft, Redmond, WA, USA) 
and exported to SPSS Statistics 21 (IBM Corp., Armonk, NY, USA) and GraphPad Prism 6 
(La Jolla, CA, USA) for analysis. Additional details are listed in Appendix 2.  
 
The distribution of clinical data was examined by univariate analysis. Prevalence of 
categorical variables was presented as percentages and Chi-squared and Fisher’s exact tests 
assessed proportional differences. For continuous variables mean±SD with two-tailed 
parametric (t) or nonparametric (×2, Mann–Whitney) tests were presented. P<0.05 was 
considered statistically significant. 
For repeated sampling, the most recent test result was used, although all data were considered 
by the multidisciplinary team when deciding final diagnostic outcome (Figure 7). Patients 
with inadequate inconclusive outcomes were excluded for analysis of test accuracy. The 
sensitivity and specificity of the individual tests were determined firstly based on definite 
positive or negative diagnostic outcome, and then assuming all valid-inconclusive outcomes 
to be truly positive or negative (using multidisciplinary diagnosis as a reference standard). 
Receiver operating characteristic (ROC) curves were constructed for nNO and CBF. Further 
accuracy analysis was completed using HSVMA and TEM as the reference standards.  
 
Additionally, sensitivity, specificity and predictive values were calculated for those who 
underwent all diagnostic tests (n=180) and compared with the whole study population (using 
multidisciplinary diagnosis as a reference standard); the whole population was then further 
stratified into: 1) the full protocol at UHS or 2) partial protocol when samples were couriered 
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to UHS (nNO measurements not taken). We also allowed for the fact that those aged <5 years 
did not have nNO readings measured. 
 
For those who underwent all three tests (n=180), theoretical combination testing approaches 
(144) were used to determine net sensitivity and specificity of simultaneous (>2 tests in 
parallel; positive result if any test was abnormal) and sequential (second test only performed 
if first test(s) abnormal) diagnostic protocols.  Net sensitivity/specificity used the addition 
rule of probability for simultaneous tests and the multiplication rule of probability for 
sequential tests. 
 
5.4. Results  
5.4.1. Study population 
We assessed 868 patients between April 2007 and December 2013 (48% male; median 
(range) age 7 (0–79) years). 517 (60%) attended the UHS clinic in person (Figure 8a) and 351 
samples were delivered by courier (Figure 8b). 75 (9%) patients had a positive diagnosis, 566 
(65%) had a negative diagnosis and 13 (1%) had inconclusive diagnostic outcome despite 
adequate samples. 214 (25%) patients had invalid-inconclusive results due to inadequate data 
at the time of the study, of whom 113 (13%) patients had only TEM samples sent from 
satellite clinics. Invalid-inconclusive outcomes were excluded from the analyses, resulting in 
a study population of 654, of which 641 had a definitive positive or negative outcome. The 
characteristics of the positive, negative and inconclusive patients are shown in Table 7. 
 
5.4.2. Accuracy of individual diagnostic tests  
Analysis was dependent on the quality of the sample and many patients required repeat 
biopsies: 17% (113 out of 654) required one repeat; 2% (11 out of 654) required two repeats; 
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and 0.4% (three out of 654) required three repeats. Analysis of diagnostic accuracy was based 
on the final successful test completed. 
5.4.2.1. Nasal nitric oxide 
nNO was measured in 301 (47%) patients with a positive or negative diagnosis. nNO was 
significantly lower in PCD-positive patients (17±20 nL·min
−1
 , 95% CI 10–23 nL·min−1) than 
negative patients (172±94 nL·min
−1
, 95% CI 160–183 nL·min−1) ( p<0.001) (Appendix 2, 
Figure A2). ROC curve analysis showed low nNO to be a strong predictor of a 
multidisciplinary diagnosis of PCD (area under the curve 0.97, 95% CI 0.94–1.00) (Figure 9). 
A cut-off of 30 nL·min
−1
 was sensitive (0.91, 95% CI 0.76–0.98) and specific (0.96, 95% CI 
0.93–0.98) (Table 8). Inclusion of eight valid-inconclusive results as PCD-positive 
(109.7±119 nL·min
−1
, 95% CI 10–209 nL·min−1) reduced sensitivity to 0.78 (95% CI 0.62–
0.89) (Appendix 2, Table A3). 
 
5.4.2.2. High-speed video microscopy analysis  
HSVMA was performed in 625 (98%) patients including 60 PCD-positive and 565 PCD-
negative cases. HSVMA was abnormal in all 60 positive patients tested. Of 565 PCD-
negative patients, 39 had abnormal or equivocal HSVMA results (17 had abnormal CBF and 
22 had abnormalities of CBP). HSVMA had excellent sensitivity (1.00, 95% CI 0.94–1.00) 
and specificity (0.93, 95% CI 0.91–0.95) (Table 8). Since our definition of PCD includes 
abnormal ciliary function (pattern or frequency), sensitivity would be expected to approach 
1.00. Inclusion of valid-inconclusive results as PCD-positive kept sensitivity high at 0.97 
(95% CI 0.90–1.00) (Appendix 3, Table A3). 
Subgroup analysis (e.g. UHS versus courier-delivered or age <5 years) made little difference 
to the sensitivity, specificity or predictive values (Tables 8 and 9). The mean CBF for PCD-
positive patients (2.3±5.2 Hz, 95% CI 0.4–4.3 Hz) was significantly lower than for PCD-
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negative patients (15.4±2.3 Hz, 95% CI 15.2–15.6 Hz) (p<0.001) (Appendix 3, Figure A3). 
ROC curve analysis showed CBF to discriminate well between PCD-positive and -negative 
patients (AUC 0.92, 95% CI 0.79–1.00) (Figure 9). However, it was not possible to derive a 
reliable CBF for 31 (41%) PCD positive patients with variable CBP. 
 
5.4.2.3. Transmission electron microscopy  
TEM was performed on samples from 368 (57%) patients including 72 PCD-positive and 297 
PCD-negative cases. 57 (79%) out of 72 PCD-positive patients had hallmark ultrastructural 
defects of PCD: 31% with outer dynein arm (ODA) and inner dynein arm (IDA) defects; 26% 
with an ODA defect; 10% with an ODA defect and suspected IDA defect; 7% with 
microtubule disarrangement and IDA defect; 4% with an intermittent central pair microtubule 
defect; and 1% with a microtubule transposition defect. 21% had “normal” ciliary 
ultrastructure. None of the 297 PCD-negative patients had ultrastructural changes suggestive 
of PCD, but secondary changes (e.g. swollen membranes or compound cilia) were fairly 
frequent. TEM sensitivity was 0.79 (95% CI 0.68–0.88) and specificity was 1.0 (95% CI 
0.99–1.00) (Table 8). Again, subgroup analysis made little difference to the sensitivity, 
specificity or predictive values (Tables 8 and 9). 
 
5.4.2.4. Air-liquid interface culture  
ALI culture was done on 808 samples and 241 ciliated (30%).  Ciliary function was 
reanalysed following ALI-culture in 152 (24%) patients.  ALI-samples confirmed a persistent 
abnormality of CBP in 21 out of 21 PCD-positive patients.  Out of 124 PCD-negative 
patients, 123 had a normal CBP following ALI culture, and one patient had uncoordinated 
cilia, perhaps due to variable cell health.   
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5.4.3. Accuracy of combinations of tests 
Various combinations of diagnostic tests are undertaken at our centre (Figure 2) whilst 
alternative combinations are used in other centres (23). We calculated accuracy for the 
combinations of tests in 180 patients who had undergone all diagnostic tests, allowing us to 
consider theoretical scenarios (Table 10). If nNO had been used as a screening test followed 
sequentially by TEM, 36 patients would have proceeded to TEM, but three out of 31 PCD 
patients would have been “missed” by not proceeding to further testing due to false negative 
nNO results; TEM would have subsequently failed to identify nine PCD patients. The net 
specificity for this combination of tests was excellent (100%), but net sensitivity was poor, 
failing to identify PCD in 12 (39%) out of 31 patients. Alternatively, if nNO had been used as 
a screening test followed sequentially by HSVMA, three out of 31 PCD patients would not 
have proceeded to HSVMA; however, HSVMA would have subsequently identified all 28 
positive patients. Therefore, the net sensitivity and specificity were 90% and 100%, 
respectively. Excellent net sensitivity and specificity were achieved upon simultaneous 
testing of HSVMA with nNO (100% and 87%, respectively) or HSVMA with TEM (100% 
and 92%, respectively) or all three tests (100% and 87%, respectively). 
 
5.4.3.1. Accuracy of individual tests using HSVMA or TEM as the ‘reference standard’ 
We calculated the accuracies of individual tests assuming HSVMA and TEM to be the 
reference standard for diagnosing PCD. When TEM analysis was considered as the reference 
standard, HSVMA sensitivity and specificity were 1.00 and 0.78, respectively, and nNO 
(⩽30 nL·min−1) sensitivity and specificity were 0.95 and 0.89, respectively. When HSVMA 
was considered as the reference standard, TEM sensitivity was 0.37 (95% CI 0.29–0.47) and 
specificity was 1.00 (95 % CI 0.98–1.00); nNO (⩽30 nL·min−1) sensitivity was 0.50 and 
specificity was 0.96 (Appendix 2, Table A4). 
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5.5. Discussion  
Our large cross-sectional study provides prospectively collected outcome data following a 
comprehensive range of PCD diagnostic tests.  Our diagnostic algorithm varies from some 
centres, (13) but the findings may contribute to the development of international consensus.   
 
A strength of this study was analyses of consecutive referrals within a national diagnostic 
program, as this is likely to yield the most valid estimates of diagnostic accuracy.  Although 
not all patients underwent all tests, this pragmatic study reflects the real patient journey.  The 
major limitation is the lack of a ‘gold reference standard’; we therefore used a surrogate 
standard of expert multidisciplinary consensus. Since each test contributes to the final 
decision, sensitivity and specificity might be over-estimated. Also, genetic testing does not 
currently form part of our diagnostic pathway and this is a rapidly expanding area that is used 
for diagnosis in many countries. 
 
11.5% of patients with adequate samples were diagnosed as PCD-positive, which is slightly 
lower than some centres,(29, 58, 145), but is similar to or higher than others (Switzerland, 
Amsterdam and London (Claudia Kuehni, Institute of Social and Preventive Medicine, 
University of Bern, Bern, Switzerland; Eric Haarman, VU University Medical Center, 
Amsterdam, the Netherlands; and Claire Hogg, Royal Brompton & Harefield NHS 
Foundation Trust, London UK; personal communications). Higher positive rates may be seen 
at centres with nNO pre-screening, in consanguineous populations (11) or if access to testing 
is restricted to those who are extremely likely to have PCD. The prevalence in referral 
populations will not affect the sensitivity or specificity but will alter the positive and negative 
predictive values of the tests.  
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5.5.1. High-Speed Video Microscopy Analysis 
HSVMA was sensitive and specific for diagnosing PCD; however, if used as a reference 
standard, this would lead to a high number of false positive results. In line with many 
European centres we consider HSVMA a first-line test, which might inflate the sensitivity; 
this needs further investigation in blinded studies. Since HSVMA is a qualitative test with 
potential subjectivity, results are regularly validated by external experts, but this does not 
exclude the possibility of some false negative findings. PCD-negative patients all had 
predominantly normal HSVMA, but often included a proportion of dyskinetic cilia probably 
due to recent infection or damage during sampling (146). Some PCD patients had areas of 
apparently normal ciliary function, highlighting that PCD-scientists require significant 
experience of the qualitative and quantitative range of PCD and non-PCD samples.  
 
HSVMA standardisation is challenging, and robust training, data validation, external audit 
and continued learning is in place. Our data cannot be generalised to centres where different 
standards apply. HSVMA requires expensive high-speed video equipment, high optical 
magnification and digital resolution for accurate CBP analysis, without which errors are 
likely. CBF is pH and temperature dependent, and we conduct analyses using pH-stable 
medium equilibrated to 37°C (147, 148). 
   
Inadequate samples and inconclusive results were a common issue for HSVMA.  Recent 
reports of PCD-causing genes associated with subtle changes at HSVMA and TEM (149, 
150) have confirmed our suspicion that some inconclusive results might represent disease.  
Moreover, samples providing inadequate cilia, may be caused by mutations causing a 
syndrome similar to PCD associated with sparse but normal cilia.(151, 152)  It is possible 
that some patients excluded from analyses due to inadequate samples will fall into this 
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category.  However, in our experience, inadequate samples are commonly adequate on repeat 
brushing following antibiotics and when patients are well.  We always recommend repeat 
testing for inadequate samples; some invalid-inconclusive cases did not return for testing 
because symptoms had resolved or an alternative diagnosis was identified. 
 
5.5.2. Transmission Electron Microscopy 
Approximately a fifth of PCD patients had apparently normal ciliary ultrastructure 
confirming that TEM is unreliable in isolation (143, 153).  However, it is a vital part of the 
diagnostic portfolio, supporting HSVMA findings and providing a diagnosis when HSVMA 
is not available or inconclusive. Analysis of ciliary ultrastructure requires expensive 
equipment and electron microscopists experienced in the range of normality and abnormality. 
Some abnormalities are straightforward (e.g. ODA defect), but we have diagnosed several 
patients with subtle abnormalities of microtubules, supported by nNO and HSVMA, that 
would only be detected by an experienced microscopist analysing sufficient numbers of cilia 
in transverse and longitudinal section. 
 
5.5.3 Nasal Nitric Oxide  
 nNO is a recommended screening test for symptomatic patients, (22, 53, 58).  At the outset 
of the prospective data collection in 2007, a cut-off of 30 nL·min
−1
 was arbitrarily set based 
on prior experience. Recent evidence suggests that higher cut-offs may be more useful (14, 
53), and the accuracy of nNO cut-offs for screening/diagnostics needs to be standardised 
based on emerging evidence.  30 nL·min
−1
 was used clinically throughout data collection and 
so it is on this basis that we have analysed the data. The sensitivity and specificity of this cut-
off were 0.91 and 0.96, respectively. Therefore, 9% of cases might be missed if further 
testing was excluded on the basis of this test in isolation. 77 nL·min
−1
  has recently been 
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recommended as a cut-off (14); this cut-off improved sensitivity in our population to 96%, 
but reduced specificity to 83%. In Leigh et al’s study (14) sensitivity to detect patients with 
PCD diagnosed by TEM or genetics was 0.98 whilst specificity was >0.75, similar to our 
findings. In our centre we are confident to use a cut-off of 30 nL·mL
−1
 because it is always 
alongside a HSVMA result. In our opinion, if nNO is used by referral centres to decide who 
to refer for testing, the higher cut-off with greater sensitivity should be used, but it is notable 
that 4% of cases might still be missed. We use nNO to support a positive diagnosis in patients 
with consistent subtle abnormalities of CBP who might otherwise be labelled inconclusive. 
We would be cautious to exclude a diagnosis of PCD in patients with nNO ⩽30 nL·min−1, 
and these patients are more likely to be considered inconclusive and therefore undergo 
repeated testing. Only 47% of the study population underwent nNO testing, because it is not 
available at satellite centres and the breath-hold manoeuvre is usually technically acceptable 
only in those aged >5 years. However, the present article reports nNO data from 301 
participants, which constitutes the largest study to date in a PCD diagnostic clinic population. 
 
5.5.4. Accuracy of combinations of tests 
Data from patients who had undergone all tests (n=180) was used to calculate the accuracy 
for possible combinations of tests.  Two-stage testing based on nNO pre-screening followed 
by TEM potentially missed ∼40% of PCD cases, because both tests were required to be 
positive for a positive diagnosis (144). However, our 30 nL·min
−1
 cut-off is probably too low 
for use as a screening threshold [34] and the previously discussed subjectivity of HSVMA 
needs to be taken into account.  Simultaneous testing requires one positive test result for a 
positive diagnosis and conversely all tests to be negative for a negative outcome (144). Using 
all three tests simultaneously (where any abnormal test leads to a positive result) sensitivity 
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was 100%, but specificity reduced to 87%, compared to our multidisciplinary approach where 
no test was considered in isolation (100% sensitivity and 92% specificity). 
 
5.6. Concluding comments 
 
Advances in understanding the molecular genetic basis of PCD have been made in recent 
years, to the extent that genetic testing is now able to detect ∼65% of PCD cases. However, 
genetic testing for PCD is not yet available in the UK except as a research tool (135). As 
more genes are identified, genetic testing by multi-gene panel (135) will make genotyping a 
cost-effective approach. Characterisation of ciliary structure and function will continue to 
have a place within diagnostic processes, similar to the need for functional tests to confirm 
the diagnosis of cystic fibrosis (154). Moreover, a thorough definition of disease phenotype 
by cilia ultrastructure, cilia beat pattern, nNO production rate will be extremely helpful in 
guiding genetic analyses in this genetically heterogeneous disease. The English public 
healthcare system does not fund immunofluorescence (IF) staining of ciliary proteins as a 
diagnostic test. This method is currently only able to detect abnormalities that are evident by 
TEM, and would therefore not improve our diagnostic accuracy. However, we anticipate that 
as more antibodies become available, IF will prove a time and cost efficient diagnostic test. 
 
There is no single diagnostic test that can be used universally to diagnose PCD. Recent 
reports of PCD-causing genes (RSPH1) associated with subtle HSVMA and TEM 
abnormalities with normal nNO demonstrate the skill and expert microscopists needed for 
accurate diagnoses (149, 150, 155). Importantly, the conduct and reporting of tests used to 
diagnose PCD are not standardised.  We believe that the time is right to develop consensus 
standards for equipment, staff experience and protocols.
 112 
 
Figure 7: PCD diagnostic pathway for patients and samples. Diagnostic tests included: 
nasal nitric oxide (nNO), high-speed video microscopy analysis (HSVMA) and 
transmission electron microscopy (TEM). Not all patients underwent all tests.  
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Figure 8: The diagnostic investigations and outcomes of patients seen (A) at the 
diagnostic centre UHS or (B) having had samples couriered to UHS from a satellite 
respiratory clinic.  Patients were diagnosed as PCD-positive, PCD-negative or valid-
inconclusive (VI).  Invalid-inconclusive (II) results due to inadequate samples or data 
are shown but subsequently excluded from accuracy analyses.  Diagnostic tests 
included: nasal nitric oxide (nNO), high-speed video microscopy analysis (HSVMA) and 
transmission electron microscopy (TEM).  
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Figure 9: Receiver operating characteristic (ROC) curve analysis for ciliary beat 
frequency (CBF) and nasal nitric oxide (nNO) for predicting a diagnosis of primary 
ciliary dyskinesia (PCD) (using multidisciplinary diagnosis as the reference standard). 
ROC curve analysis showed that nNO ≤30 nL·min−1 (area under the curve (AUC) 0.97, 
95% CI 0.94–1.00) was superior to CBF (AUC 0.92, 95% CI 0.79–1.00) as predictors of 
a PCD-positive diagnosis. 
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Table 7: Clinical characteristics of the referral population grouped by positive, negative, valid-inconclusive and invalid-inconclusive 
diagnostic outcomes  
 
  TOTAL (n=868, 100%) Positive (n=75, 9%) Negative (n=566, 65%) VI (n=13, 2%) II (n=214, 25%) 
  
Yes No Unknown Yes No Unknown Yes No Unknown Yes No Unknown Yes No Unknown 
Gender (Male) 362 (42%) 393 (45%) 113 (13%) 34 (45%) 36 (48%) 5 (7%) 249 (44%) 278 (49%) 39 (7%) 7 (54%) 6 (46%) 0 (0%) 72 (34%) 73 (34%) 69 (32%) 
Full term gestation 346 (40%) 102 (12%) 420 (48%) 66 (88%) 7 (9%) 2 (3%) 242 (43%) 80 (14%) 244 (43%) 8 (61%) 2 (15%) 3 (23%) 30 (14%) 13 (6%) 171 (80%) 
Sibling with PCD  32 (4%) 792 (91%) 44 (5%) 18 (24%) 55 (73%) 2 (3%) 9 (2%) 529 (93%) 28 (5%) 0 (0%) 
11 
(85%) 
2 (15%) 5 (2%) 197 (92%) 12 (6%) 
Neonatal unit 138 (16%) 694 (80%) 35 (4%) 46 (61%) 25 (33%) 4 (5%) 77 (14%) 466 (82%) 23 (4%) 3 (23%) 9 (69%) 1 (8%) 12 (6%) 194 (91%) 8 (4%) 
Situs abnormality  70 (8%) 788 (91%) 10 (1%) 33 (44%) 42 (56%) 0 (0%) 22 (5%) 537 (95%) 7 (0%) 4 (31%) 9 (69%) 0 (0%) 11 (5%) 200 (93%) 3 (1%) 
Cardiac 
abnormality 
20 (2%) 848 (98%) 0 (0%) 6 (8%) 69 (92%) 0 (0%) 10 (2%) 556 (98%) 0 (0%) 0 (0%) 
13 
(100%) 
0 (0%) 4 (2%) 210 (98%) 0 (0%) 
Respiratory 
symptoms  
710 (82%) 158 (18%) 0 (0%) 72 (96%) 3 (4%) 0 (0%) 488 (86%) 78 (14%) 0 (0%) 
12 
(93%) 
1 (7%) 0 (0%) 138 (64%) 76 (36%) 0 (0%) 
Rhinitis 477 (55%) 389 (45%) 2 (0%) 61 (81%) 14 (19%) 0 (0%) 325 (57%) 239 (42%) 2 (1%) 9 (69%) 4 (31%) 0 (0%) 82 (38%) 132 (62%) 0 (0%) 
Sinusitis                       192 (22%) 663 (76%) 13 (2%) 21 (28%) 53 (71%) 1 (1%) 138 (24%) 416 (74%) 12 (2%) 5 (38%) 8 (62%) 0 (0%) 28 (13%) 186 (87%) 0 (0%) 
 
Data are presented as n (%). Patients with invalid-inconclusive (II) outcomes were excluded from the study population for analyses. VI: Valid 
inconclusive 
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Table 8: The diagnostic accuracy of nasal nitric oxide (nNO), high-speed video 
microscopy analysis (HSVMA) and transmission electron microscopy (TEM) analysis to 
diagnose primary ciliary dyskinesia. Data were analysed for patients with conclusive 
positive or negative results (n=641) who underwent the individual tests.   
 
  
nNo  
(≤30nL/min) 
HSVMA TEM 
Total  
n (%) /641 
301 
(47%) 
625 
(98%) 
368 
(57%) 
Positive patients            
 n (%) /75 
34 
(45%) 
60 
(80%) 
71 
(95%) 
Negative patients          
 n (%) /566 
267 
(47%) 
565 
(100%) 
297 
(52%) 
True positive (n) 31 60 56 
True negative (n) 257 526 297 
False positive (n) 10 39 0 
False negative (n) 3 0 15 
Sensitivity                   
 (95% CI) 
0.91                  
 (0.76-0.98) 
1.00                         
 (0.94 - 1.00) 
0.79                                
(0.68-0.88) 
Specificity                   
(95% CI) 
0.96            
 (0.93-0.98) 
0.93                         
(0.91-0.95) 
1.00                         
 (0.99-1.00) 
PPV                                  
(95% CI) 
0.76             
(0.60-0.88) 
0.61                         
 (0.50-0.70) 
1.00                        
 (0.94-1.00) 
NPV                                     
(95% CI) 
0.99            
 (0.97-1.00) 
1.00                         
 (0.99-1.00) 
0.95                           
(0.92-0.97) 
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Table 9: The diagnostic accuracy of nasal nitric oxide (nNO), high-speed video 
microscopy analysis (HSVMA) and transmission electron microscopy (TEM) analysis to 
diagnose primary ciliary dyskinesia. Analyses were stratified by A. patients seen at 
University Hospital Southampton (UHS) and B. samples from patients sent by courier 
to UHS. They were stratified further by age (i) <5 years at time of assessment and (ii) ≥5 
years. 
 
 
A (i) UHS <5 years  
n=126 
A (i) UHS >5 years 
n=355 
B (i) Courier <5 years 
n=80 
B (i) Courier >5 years 
n=80 
  HSVMA TEM 
nNO (≤30 
nL/min) 
HSVMA TEM HSVMA TEM HSVMA TEM 
Total                
  n (%)  
 
125  
(99%) 
 
67 
(53%) 
301 
(85%) 
353 
(99%) 
212  
(60%) 
71 
(89%) 
48 
(60%) 
76 
(95%) 
41 
(51%) 
Positive              
  n (%) 
8 
 (6%) 
7 
(10%) 
34 
(11%) 
34 
(10%) 
33  
(16%) 
8 
(11%) 
17 
 (35%) 
10 
 (13%) 
14  
(34%) 
Negative           
 n (%)  
117  
(94%) 
60  
(90%) 
267 
(89%) 
319  
(90%) 
179  
(84%) 
63  
(89%) 
31  
(65%) 
66  
(87%) 
27  
(66%) 
True positive  (n) 8 6 31 34 22 8 15 10 13 
True negative 
(n) 
111 60 257 297 179 59 31 59 27 
False positive (n) 6 0 10 22 0 4 0 7 0 
False negative 
(n) 
0 1 3 0 11 0 2 0 1 
Sensitivity                     
(95% CI) 
1.00         
(0.63-
1.00) 
0.86        
(0.42-
0.98) 
0.91         
(0.76-
0.98) 
1.00             
(0.90-
1.00) 
0.67        
(0.48-
0.82) 
1.00        
(0.63-
1.00) 
0.88        
(0.64-
0.98) 
1.00        
(0.69-
1.00) 
0.93         
(0.66-
0.99) 
Specificity                     
(95% CI) 
0.95        
(0.89-
0.98) 
1.00         
(0.94-
1.00) 
0.96         
(0.93-
0.98) 
0.93        
(0.90-
0.96) 
1.00        
(0.98-
1.00) 
0.94        
(0.85-
0.98) 
1.00            
(0.89-
1.00) 
0.89        
(0.79-
0.96) 
1.00        
(0.87-
1.00) 
PPV                                    
(95% CI) 
0.57         
(0.29-
0.82) 
1.00         
(0.54-
1.00) 
0.76        
(0.60-
0.88) 
0.61         
(0.47-
0.74) 
1.00        
(0.84-
1.00) 
0.67        
(0.35-
0.90) 
1.00        
(0.78-
1.00) 
0.59        
(0.33-
0.81) 
1.00        
(0.75-
1.00) 
NPV                                      
(95% CI) 
1.00        
(0.97-
1.00) 
0.98       
(0.91-
1.00) 
0.99         
(0.97-
1.00) 
1.00        
(0.99-
1.00) 
0.94        
(0.90-
0.97) 
1.00        
(0.94-
1.00) 
0.94        
(0.80-
0.99) 
1.00        
(0.94-
1.00) 
0.96        
(0.82-
0.99) 
Data are presented as n or n (%), unless otherwise stated. PPV: positive predictive value; NPV: 
negative predictive value. 
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Table 10: Sensitivity and specificity of high-speed video microscopy (HSVMA), ciliary 
beat pattern (CBP), nasal nitric oxide (nNO) and transmission electron microscopy 
(TEM) applied as single or combined tests, using simultaneous or sequential testing. 
*The net sensitivity and specificity was calculated for combined tests. 
 
  A.     Single testing B. Simultaneous testing C. Sequential two stage testing 
  nNO HSVMA TEM 
nNO  
+  
HSVM
A 
HSVM
A 
+ 
TEM 
nNO 
+ 
HSVM
A 
+ 
TEM 
 
1. nNO    
n=180               
2. 
HSVMA 
 n=36 
1. nNO   
n=180                
2. TEM 
n=36 
 
1. nNO 
+HSVM
A  
n=180       
  2. TEM 
 n=51 
 
1. 
HSVMA  
n=180                       
2. TEM 
n=43 
 
Total (n) 
 
180 180 180 180 180 180 36 36 51 43 
 
Total positive 
(n) 
 
31 31 31 31 31 31 28 28 31 31 
Total 
negative (n) 
149 149 149 149 149 149 8 8 20 12 
True positive 
(n) 
28 31 20 31 31 31 28 19 20 20 
True negative 
(n) 
141 137 149 129 137 129 8 8 20 12 
False positive 
(n) 
8 12 0 20 12 20 0 0 0 0 
False 
negative (n) 
3 0 11 0 0 0 0 9 11 11 
Sensitivity 0.90 1.00 0.65         
    
(95% CI) 
(0.74-
0.98) 
(0.89-
1.00) 
(0.45-
0.81) 
        
    
Specificity  0.95 0.92 1.00         
    
(95% CI) 
(0.90-
0.98) 
(0.86-
0.96) 
(0.98-
1.00) 
        
    
PPV  0.78 0.72 1.00         
    
(95% CI) 
(0.61-
0.90) 
(0.56-
0.85) 
(0.83-
1.00) 
        
    
NPV  0.98 1.00 0.93         
    
(95% CI) 
(0.94-
1.00) 
(0.97-
1.00) 
(0.88-
0.97) 
      
  
  
  
*Net 
sensitivity 
  
  
1.00 1.00 1.00 0.90 0.61 0.65 0.65 
*Net 
specificity 
      0.87 0.92 0.87 1.00 1.00 1.00 1.00 
Data are presented as n, unless otherwise stated. PPV: positive predictive value; NPV: negative 
predictive value 
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6.1. Abstract  
Background: Symptoms of primary ciliary dyskinesia (PCD) are nonspecific and guidance 
on whom to refer for testing is limited. Diagnostic tests for PCD are highly specialised, 
requiring expensive equipment and experienced PCD scientists. This study aims to develop a 
practical clinical diagnostic tool to identify patients requiring testing.  
Method: Patients consecutively referred for testing were studied. Information readily 
obtained from patient history was correlated with diagnostic outcome. Using logistic 
regression, the predictive performance of the best model was tested by receiver operating 
characteristic curve analyses. The model was simplified into a practical tool (PICADAR) and 
externally validated in a second diagnostic centre.  
Results: Of 641 referrals with a definitive diagnostic outcome, 75 (12%) were positive. 
PICADAR applies to patients with persistent wet cough and has seven predictive parameters: 
full-term gestation, neonatal chest symptoms, neonatal intensive care admittance, chronic 
rhinitis, ear symptoms, situs inversus and congenital cardiac defect. Sensitivity and 
specificity of the tool were 0.90 and 0.75 for a cut-off score of 5 points. Area under the curve 
for the internally and externally validated tool was 0.91 and 0.87, respectively.  
Conclusion: PICADAR represents a simple diagnostic clinical prediction rule with good 
accuracy and validity, ready for testing in respiratory centres referring to PCD centres. 
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6.2. Introduction 
 
Primary ciliary dyskinesia (PCD) is a rare heterogeneous disorder characterised by abnormal 
ciliary function and associated with abnormal ciliary ultrastructure in 70% of cases (16, 40). 
Consequences of PCD include impaired mucociliary clearance of the airway causing upper 
and lower respiratory tract symptoms which usually present soon after birth. Neonatal 
manifestations range in severity from mild transient tachypnoea to significant respiratory 
failure requiring prolonged respiratory support (1-3). Patients continue to have chronic, 
progressive symptoms of persistent wet cough and recurrent chest infections that almost 
invariably lead to bronchiectasis. Upper airway problems include rhinosinusitis and recurrent 
otitis media with hearing impairment (99). Motile embryonic nodal cilia are important for 
left-right asymmetry; approximately half of PCD patients exhibit situs inversus, and 6-12% 
heterotaxic syndromes which may be associated with complex congenital cardiac defects (8, 
156).  Male Infertility is common since sperm flagella have a similar ultrastructure to cilia; 
the incidence of female infertility is less clear but can be explained by immotile fallopian 
tube cilia (157). 
 
The prevalence, burden of disease and prognosis of PCD patients is difficult to determine due 
to limited representative international data. Reported prevalence varies from 1:2,000 to 
1:40,000 reflecting true variability as well as differences in access to diagnostic facilities (10, 
11, 110). A survey of 26 European countries found that PCD is under-diagnosed or diagnosed 
late particularly in countries with low health-care expenditure (110). In addition to expecting 
to improve respiratory prognosis (4, 12, 64), early diagnosis facilitates appropriate 
management; management is different to non-PCD related serous otitis media for example 
(21). Diagnosis also allows genetic counselling for the family. 
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There is currently no “gold standard” test to diagnose PCD (13). European guidelines 
recommend that PCD should be confirmed in a specialist centre using appropriate diagnostic 
testing (22).  PCD diagnostic investigations are complex, requiring expensive infrastructure 
and an experienced team of clinicians, scientists and microscopists (13, 19, 20). Various 
models exist to deliver diagnostic services for this rare disease, generally with a network of 
satellite screening centres accessing a specialist centre (14, 20, 21). The symptoms of PCD 
are non-specific and secondary care physicians need guidance of whom to refer for diagnostic 
testing (21). To promote early diagnosis without overburdening specialist services, screening 
tools such as nasal nitric oxide (nNO) are used and has been proved to be an excellent 
screening measures (14, 53, 158). This however requires expensive equipment and trained 
technicians to obtain reliable measurements. 
 
The aim of this study was to utilise easily available clinical information from a large 
prospective population to produce a scoring tool to predict whether symptomatic patients 
have PCD: PICADAR (PrImary CiliARy DyskinesiA Rule). We aimed to develop a tool that 
would be quick and easy to use by general respiratory and ear, nose and throat specialists. 
PICADAR’s accuracy was externally validated in a second PCD diagnostic centre. 
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6.3. Methods 
This research was approved by the National Research Ethics Service (NRES-06/Q1702/109). 
 
6.3.1. Study population 
6.3.1.1. Derivative group 
We analysed data from 641 consecutive patients with a definitive diagnostic outcome from 
the University Hospital Southampton (UHS) PCD diagnostic centre (2007–2013). A 
proforma was used to collect patient data, completed by a clinician through a clinical 
interview prior to diagnostic testing. 
 
6.3.1.2. External validation group 
We used data from a sample of 187 patients (93 PCD-positive and 94 PCD-negative) referred 
for testing to the Royal Brompton Hospital (RBH) to validate the score. An equal number of 
positive and negative referrals were randomly selected from the overall population of patients 
referred between 1983 and 2013. Using a similar protocol to UHS, a clinical history proforma 
was completed before diagnostic testing. 
 
6.3.2. Diagnostic testing 
The diagnostic criteria used in the UK (UHS and RBH) have previously been described in 
detail in Jackson et al.(101) and Lucas and Leigh (13). In brief, a positive diagnosis is usually 
based on a typical clinical history with at least two abnormal diagnostic tests (“hallmark” 
transmission electron microscopy (TEM), “hallmark” ciliary beat pattern (CBP), nNO ⩽30 
nL·min−1 ). Occasionally patients with a strong history (e.g. sibling with PCD, “full” clinical 
 125 
 
phenotype (e.g. neonatal respiratory distress at term followed by daily wet cough, persistent 
rhinitis and glue ear), are diagnosed based on either “hallmark” TEM or repeated high-speed 
video microscopy analysis (HSVMA) consistent with PCD. CBP was only considered 
positive if the pattern was typical of PCD rather than secondary ciliary dyskinesia either from 
two brushing biopsies or from one brushing biopsy with reanalysis following air–liquid 
interface culture. 
6.3.3. Clinical Data 
Data was collected on gender, date of birth, age at assessment and ethnicity. Neonatal data 
collected included admittance to a special care babies unit, neonatal respiratory support, 
neonatal rhinitis or chest symptoms. Data on the presence of situs abnormalities, congenital 
cardiac defect, chronic (>3 months) cough, rhinitis, sinusitis, ear problems, history of 
pneumonia and bronchiectasis was collated. Family history of PCD, bronchiectasis, hearing 
problems, asthma and consanguinity were included. Data on clinical history was coded as 
yes=0, no=1 or missing=99. For the adult population, subfertility was recorded if the patient 
had difficultly conceiving but had children, used in vitro fertilisation or if they stated they 
were never able to conceive. 
 
6.3.4. Model development 
Potential predictors were restricted to information readily available in a nonspecialist setting. 
From the derivation group, 27 potential variables were identified. Two-tailed parametric (t-
test) or nonparametric (Mann–Whitney) tests, Chi-squared test or Fisher’s exact test (as 
appropriate) were used to compare the characteristics of positive and negative referrals.  
Logistic regression analysis was used to develop a simplified practical prediction tool. First, 
potential predictors were entered into the model individually using forward step-wise 
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methods. This allowed us to identify and select the significant predictors for PCD and assess 
their influence on a positive PCD diagnosis. Sensitivity, specificity and overall accuracy (the 
weighted average of the models sensitivity and specific) from selected significant predictors 
were interpreted (159).  
 
6.3.5. Model performance 
The model’s ability to discriminate between those with and without PCD was assessed by 
plotting receiver operating characteristic (ROC) curve and calculating the area under the 
ROC curve (AUC). Discrimination was considered moderate if AUC was 0.6 to 0.8 and good 
if >0.8 (160). The Hosmer Lemeshow goodness-of-fit-test was used to assess the calibration 
of the model, i.e. how well the predicted probabilities agreed with the prevalence of the 
outcome in patient subgroups. A Hosmer Lemeshow goodness-of-fit-test (161) result of 
<0.05 indicates that the predicted probabilities and the actual outcome agree poorly (162). 
Subjects with missing data were excluded on a case-wise basis; however, to confirm the 
model’s accuracy, multiple imputation was used to check for any biases that can occur in 
complete case analysis along with a substantial loss of power and precision (163, 164).  
 
6.3.6. Clinical prediction tool  
The best model from the logistic regression allowed for the calculation of a diagnostic 
predictive tool (PICADAR) to estimate the probability of a positive PCD diagnosis based on 
total score. The score for each predictor corresponds to their regression coefficient rounded to 
the nearest integer. A ROC curve was plotted to assess the predictive performance of 
PICADAR for comparison with the original model. Each score has a corresponding accuracy 
(i.e. sensitivity and specificity) of predicting a positive or negative diagnosis. 
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6.3.7. Validation in external population  
The discriminative ability of the scores in the validation population was assessed using ROC 
curve analysis. All analyses were performed by using SPSS Statistics for Windows version 
21.0 (IBM, Armonk, NY, USA). 
 
6.4. Results 
6.4.1. Study population 
Of 641 consecutive participants in the derivation group, 75 (12%) were diagnosed with PCD 
and 566 (88%) had a negative diagnosis. Median (range) age at assessment was 9 (0–79) 
years and 44% of patients were male.  
The validation group was selected to include similar numbers of positive and negative 
diagnoses. The participants were younger than the derivation group; they were also more 
likely to be non-white and from a consanguineous background, reflecting the different 
populations served by UHS and RBH (Table 11). 
6.4.2. Clinical and family characteristics 
Both PCD-positive and PCD-negative groups had a high prevalence of a persistent daily wet 
cough throughout life (PCD-positive 93.3%, PCD negative 85.1%, p=0.069). PCD-positive 
patients were more likely to report neonatal problems requiring admittance to a neonatal unit 
(61.3%, 13.6%, p<0.001), neonatal rhinitis (26.6%, 6.5%, p<0.001) and neonatal chest 
symptoms (e.g. wet cough, tachypnoea, oxygen requirement) (74.6%, 17.1%, p<0.001). 
Symptoms were higher among the PCD-positive group for persistent perennial rhinitis 
(81.3%, 57.4%, p<0.001), serous otitis media (glue ear) (57.3%, 19.2%, p<0.001) and hearing 
loss (49.3%, 15.9%, p<0.001). Situs abnormalities (41.3%, 3.9%, p <0.001) and congenital 
 128 
 
cardiac defects (9.3%, 2.1%, p=0.001) and were also more common in the PCD-positive 
group. Fertility data was available for 152 referrals, with significantly higher percentage 
reporting subfertility in PCD-positive group (90%, 18.4%, p<0.001). Family history of PCD 
in siblings (24%, 1.6%, p<0.001), or in other family members (5.3%, 1.1%, p=0.012), was 
significantly higher among the PCD-positive group. Consanguinity (16.0%, 1.4%, p<0.001), 
was more common in PCD-positive group. Clinical characteristics of the derivation group are 
summarised in Table 12, and of the validation group in Appendix 3: Table A5. 
 
6.4.3. Development of PICADAR score 
Of the 27 binary variables considered for selection, the best logistic regression model 
included seven significant predictors. In order of importance (based on their corresponding 
odds ratio) these predictors were situs inversus, birth at full term, neonatal chest symptoms, 
admission to a neonatal unit, congenital cardiac defect, rhinitis, and ear and hearing 
symptoms (Table 13). Similar results were found when multiple imputation was applied 
(Appendix 3: Table A6). The overall accuracy of this model was 90%, and the sensitivity and 
specificity were 71% and 94%, respectively. The discriminant ability (AUC) of this model 
was 0.92 (Figure 10). The Hosmer–Lemeshow test showed good agreement between the 
predicted probabilities and the actual outcome (p=0.64). 
PICADAR (Figure 11) was designed as an easily scored predictive tool based on the seven-
variable-predictor model. The presence of each clinical factor contributed to the total score 
following adjustment of its regression coefficient values to an integer between 1 and 4. This 
adjustment had little effect on discriminative ability (model AUC 0.92, PICADAR AUC 
0.91) (Figure 10). 
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The likelihood of a patient having PCD can be estimated by comparing their score to the 
probability curve (Figure 11b) or cut-offs could be used. The highest combined sensitivity 
and specificity (0.90 and 0.75, respectively) was at the cut-off value of 5 points (Table 14). 
The maximum PICADAR score was 14. This corresponded to a 99.80% probability of having 
PCD, a score >10 had a probability of 92.6%, and a score >5 had a probability of 11.10% 
(Figure 11b and Appendix 3: Table A7). Sensitivity and specificity of the tool were 0.90 and 
0.75 for a score of >5 points (Table 14). In the UHS derivation group, of the PCD positive, 
6.0% had scores <5, 58.0% had scores 6-9 and 36.0% had scores >10. In the PCD-negative 
group, 79.4% had scores <5, 20.2% had scores 6-9 and only 0.4% had scores >10 (Table 15). 
 
 
6.4.4. Validation of the PICDAR score 
Validation of PICADAR used data from an independent set of 93 randomly selected PCD-
positive patients and 94 PCD-negative patients from RBH. Data for all PICADAR predictors 
were available in 157/187 (84%) of the validation group, all of whom were <18 years of age. 
The remaining 30 were excluded due to missing symptom data. Positive cases accounted for 
79 (50%) of the population, 79 (50%) were male; mean age at assessment was 4 years. Scores 
in the validation group ranged from 0 to 14 (mean±SD 5.9 ±3.3). The mean±SD PICADAR 
score was higher in the PCD-positive group (PCD-positive 7.9±2.8, PCD-negative 3.8±2.3; 
p<0.01) and distribution of the scores differed between groups (Appendix 3: Figure A4). 
ROC curve analysis confirmed the performance of the score with AUC 0.87 (95% CI 0.81–
0.94) (Figure 12). In the validation group, 18.7% of the PCD-positive group had a score ⩽5, 
53.3% had a score 6–9 and 29.1% had a score ⩾10. For the PCD-negative group, 75.6% has a 
score ⩽5, 20.5% had a score of 6–9 and 3.8% had a score ⩾10 (table 5). 
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A second predictive tool, PICADAR+S, which includes the variable “siblings with PCD” was 
developed and validated for patients with one of more siblings. When validated, this tool was 
also shown to discriminate between positive and negative referrals (AUC 0.94, 95% CI 0.90–
0.97) (see Appendix for full description). 
 
6.5. Discussion  
6.5.1. Statement of principle findings 
We have developed an easy-to-use predictive score for determining the likelihood of an 
individual having a diagnosis of PCD. The score accurately predicts a positive or negative 
test result in patients with daily lower respiratory tract symptoms throughout life. PICADAR 
was developed and validated in patients referred to specialist diagnostic centres; at this stage 
we would not aim for it to be used in primary care, but anticipate that it could be used by 
respiratory centres to guide referral to specialist PCD centres. PICADAR should raise 
awareness of symptoms associated with PCD, and stimulate discussion and research to 
further refine the tool. PCD centres could use PICADAR to identify patients who should be 
investigated further following inconclusive or equivocal PCD tests. In resource limited 
countries with no diagnostic facilities the tool could be used to attach a PCD-likelihood to the 
patients; this is important for international research registries and metacohorts.  
There is no gold standard test for PCD, and testing is restricted to centres with the 
infrastructure and expertise to analyse and interpret HSVMA or TEM images and genotype 
data (13, 20, 165).  
Measurement of nasal nitric oxide (nNO) provides a good screening tool (14, 53) to 
differentiate PCD-positive and non-PCD in patients with symptoms. In the study population 
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which contributed to the development of PICADAR, we previously reported in Jackson et 
al.(101) that a cut-off of 30 nL·min
−1
 was both sensitive (0.91, 95% CI 0.76–0.98) and 
specific (0.96, 95% CI 0.93–0.98); of 301 consecutive referrals for diagnostic testing 
including nNO, 31/34 (91%) of PCD-positive patients had low nNO (true positive), 10/267 
(3%) of PCD-negative patients had low nNO (false positive) and 3/34 (9%) of PCD-positives 
had nNO >30 nL·min
−1
 (false negative). However, the equipment for measuring nNO is not 
widely available outside specialist centres and needs trained technicians to obtain reliable 
readings. We designed PICADAR for use outside specialist diagnostic centres. Our data 
suggests similar accuracy in comparison with nNO, e.g. a cut-off score of ⩾5 using 
PICADAR had 90% sensitivity and 75% specificity to differentiate PCD-positive and PCD-
negative patients in the derivation group, and had 86% sensitivity and 73% specificity in the 
validation group. If patients with a score ⩽4 had not proceeded to further testing, 167 
(70.2%) and 57 (73.1%) negative patients would have avoided formal testing at the 
diagnostic centres; however, two (4.0%) positive patients in the derivation group and 11 
(13.9%) in the validation group would have been missed (table 5). The tool therefore should 
not be used in isolation when deciding who to refer. We believe that promotion of the tool is 
likely to raise awareness of the most common symptoms associated with PCD. Although 
PICADAR will “miss” some patients when used in isolation, since diagnosis is currently 
commonly missed due to lack of physician awareness, widespread use of PICADAR would 
inevitably increase the number of actual diagnoses.  
 
6.5.2. Strengths and limitations of the study  
PICADAR comprises seven predictive variables including full-term gestational age, 
admittance to a neonatal unit, neonatal chest symptoms, persistent perennial rhinitis, chronic 
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ear and hearing symptoms, situs abnormalities, and presence of a cardiac defect; such items 
are easily ascertained and quick to compute in any clinical setting. We did not specify cardiac 
defects associated with laterality defects within the score because we want PICADAR to be 
used by nonspecialists. PICADAR was derived in a specialist PCD centre (UHS) and 
validated externally in another centre (RBH). Although these two diagnostic centres are both 
situated in Southern England, they have different demographic populations in terms of 
ethnicity, consanguinity and age at assessment. Good discriminant ability was maintained 
when used in the validation group with AUC 0.87. The process of developing a clinical 
prediction rule includes four stages before ever being implemented in routine practice 
(derivation, internal validation, external validation and impact analysis). If an external 
validation is done directly in another setting, internal validation is not necessary. Therefore, 
as of now, we have completed all three of the requested stages of the rule development. Once 
these results are published, further validations can be done in other countries and settings, by 
other investigators, so that they can provide additional evidence for its validity for further 
implementation in practice (166).  
PICADAR was developed in a large clinically relevant population. Consecutive patients with 
a diagnostic outcome were included. Patients had been referred based on symptoms and/or 
family history. Diagnosis was based on a combination of tests including nNO measurements, 
HSVMA to assess ciliary function and TEM to assess ciliary ultrastructure (12, 21). A 
detailed clinical proforma was completed by health professionals before diagnostic testing 
was started, thus reducing bias. Using PICADAR, patients with a score ⩾10 had a >90% 
probability of testing positive for PCD. Those with a score ⩾5 had a >11% chance of being 
diagnosed PCD-positive (Figure 11b and Appendix 3: Table A7). We believe that this 
guidance will support appropriate referrals of patients for specialist testing, particularly where 
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patients are geographically remote from a diagnostic centre. Clinicians using the score need 
to be aware that individuals with low risk scores might still have PCD (table 5). It should be 
noted that persistent wet cough is not included in the score because virtually all positive and 
negative referrals had chronic cough; therefore, the score is for use in patients with chronic 
cough as a precondition. A potential limitation is that a significant amount of data was 
missing for some variables. For example, a large proportion of the adult population did not 
know their gestational age and none of the children would yet know their fertility status. 
Complete case analysis was used to deal with missing data; however, this can lead to bias. To 
overcome this obstacle, multiple imputation was used to replace missing values within the 
model’s significant variables (163, 164). The pooled result obtained from five imputed 
datasets showed the best model is accurate (Appendix 3: Table A6). Importantly, it must also 
be emphasised that PICADAR was developed using a population already referred for 
diagnostic testing. It was developed with the aim of identifying appropriate patients for 
referral from secondary care and will now require validation in this setting. Finally, patients 
with equivocal results were excluded from the derivation and validation populations. This 
may artificially improve the tool’s performance; however, good discrimination was found 
when the tool was validated in a second diagnostic centre.  
 
6.5.3. Future research  
The scores were derived using combined data from adults and children, but we expect that 
separate scores for adults and children might further improve accuracy. We therefore propose 
further research in large cohorts of children and adults to derive separate scoring systems. 
PICADAR includes a number of predictors based in early life, including gestational age and 
neonatal chest symptoms, which may be difficult to recall in adulthood. Similarly, subfertility 
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was more common in the PCD-positive group and is likely to be a strong predictor for adult 
diagnoses. While the derivation group consisted of a wide range of age groups, the majority 
of referrals in the external validation group were children. Furthermore, the scores were 
developed and validated in UK specialist diagnostic centres, but referrals originate from 
nonspecialist services, and therefore future validation will be needed in referral centres and in 
centres outside of the UK.  
6.6. Conclusions  
PICADAR provides the first validated tool to aid appropriate referral of patients for 
diagnostic testing. It was designed to be easily applied in a nonspecialist setting to determine 
which patients with chronic chest symptoms require PCD diagnostic testing. PICADAR is a 
simple cost-effective score suitable for use in all clinical settings. The tools are now available 
for validation in a variety of clinical settings. 
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Figure 10: PICADAR: receiver operating characteristics curve for the best prediction 
model (AUC= 0.92; CI 0.87-0.95) and the prediction tool (AUC=0.91; CI 0.87-0.95) in 
the derivation group.  
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Figure 11: PICADAR is a predictive score with 7 simple questions to predict likelihood 
of having PCD. It can be used in any patients with chronic respiratory symptoms 
starting in early childhood. The total score is calculated and the individual probability 
of having PCD diagnosis can be estimated from Figure 11b. 
PICADAR 
Does the patient have a daily wet cough that started 
in early childhood? 
Yes- complete PICADAR 
 
No- STOP. PICADAR is not designed for 
patients without a wet cough 
 
 
Was the patient born preterm or full term? Term 2 
Did the patient experience chest symptoms in the 
neonatal period (eg. tachypnoea, cough, pneumonia)? 
Yes 2 
Was the patient admitted to a neonatal unit? Yes 2 
Does the patient have a situs abnormality (situs 
inversus or heterotaxy)? 
Yes 4 
Does the patient have a congenital heart defect? Yes 2 
Does the patient have persistent perennial rhinitis Yes 1 
Does the patient experience chronic ear or hearing 
symptoms (e.g. glue ear, serous otitis media, hearing 
loss, ear perforation)   
Yes 1 
Total Score =   
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(b) 
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Figure 12: Receiver operating characteristics curve for the prediction tool PICADAR 
(AUC= 0.87; CI 0.81-0.94) in the validation group.  
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Table 11: Demographical characteristics of the two study populations: the derivation 
and the validation group.* 
 Derivation group (UHS) Validation group (RBH) 
 Total 
n=641 
PCD positive  
n=75  
PCD 
negative 
n=566  
Total 
n=157  
PCD positive  
n=80 
PCD 
negative 
n=77 
Age at assessment   
(median, range) 
9 (0-79) 6 (0-67) 9 (0-79) 3 (0-18) 6 (0-17) 2 (0-12) 
Male (n= %) 283 (44%) 34 (45%) 249 (44%) 78 (50%) 38 (48%) 40 (52%) 
Gestational age (mean ±SD) 39 (2.6) 39.6 (1.6) 38.9 (2.7)  39 (2.3) 39 (2.0) 39 (2.5) 
Preterm  
(n= %) 
87 (14%) 7 (9%) 80 (14%) 17 (11%) 7 (9%) 10 (13%) 
Siblings with PCD  
(n= %) 
27 (4%) 18 (24%) 9 (2%) 27 (17%) 24 (30%) 3 (4%) 
Other family with PCD  
(n= %) 
10 (2%) 4 (5%) 6 (1%) 8 (5%) 7 (9%) 1 (1%) 
Consanguinity 
(n= %) 
20 (3%) 12(16%) 8 (1%) 38 (24%) 35 (44%) 3 (4%) 
Ethnicity       
White 482 (75%) 57 (76%) 425 (75%) 90 (57%)  31 (39%)  59 (77%) 
Other 55 (9%) 17 (23%) 38 (7%) 57 (36%) 39 (49%) 18 (23%) 
Ethnicity not stated 104(16%) 1 (1%) 103 (18%) 10 (7%) 10 (12%) 0 (0%) 
*Missing values not presented 
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Table 12: Clinical symptom characteristics of the derivation group (n=641)  
  
Total                         
n=641 (%) 
PCD positive 
 n=75 (%) 
PCD negative  
n=566 (%) 
Odds ratio p-value 
Neonatal 
symptoms 
      
 
  
Neonatal 
respiratory support  
72 (11.2%) 31 (41.3%) 41 (7.2%) 
9.77  
(5.53 - 17.26) 
<0.001 
Neonatal chest 
symptoms  
153 (23.0%) 56 (74.6%) 97 (17.1%) 
13.56  
(7.60 - 24.11) 
<0.001 
Neonatal rhinitis 57 (8.9%) 20 (26.6%) 37 (6.5%) 
5.53 
(2.99 - 10.23) 
<0.001 
Respiratory 
symptoms 
      
 
  
Persistent daily 
wet cough  
552 (86.1%) 70 (93.3%) 482 (85.1%) 
2.38  
(0.93-6.07) 
0.069 
Recurrent wheeze  254 (39.6%) 36 (48.0 %) 218 (38.5%) 
1.39  
(0.86-2.26) 
0.176 
Previous 
pneumonia  
227 (35.4%) 31 (41.3 %) 196 (34.6%) 
1.14 
(0.69-1.88) 
0.585 
Bronchiectasis  202 (31.5%) 22 (29.3%) 180 (31.8%) 
0.94 
(0.54-1.61) 
0.83 
Upper airway 
and ear 
symptoms 
      
 
  
Perennial 
persistent rhinitis   
386 (60.2%) 61 (81.3%) 325 (57.4%) 
3.20  
(1.75 - 5.86) 
<0.001 
Chronic sinusitis  159 (24.8%) 21 (28.0%) 138 (24.3 %) 1.19 (0.69-2.05) 0.52 
Hearing loss  127 (19.8%) 37 (49.3%) 90 (15.9%) 
5.90 
(3.52 - 9.98) 
<0.001 
Chronic acute 
otitis media  
165 (25.7%) 25 (33.3%) 140 (24.7 %) 
1.41                     
(0.85 - 2.32) 
0.117 
Serous otitis 
media  
152 (23.7%) 43 (57.3%) 109 (19.2%) 
3.24                    
  (2.11 - 4.96) 
<0.001 
Chronic ear 
perforation  
59 (9.2%) 9 (12.0%) 50 (8.8%) 
5.90                  
   (3.52 - 9.98) 
0.398 
Ear surgery  105 (16.3%) 24 (32.0%) 81 (14.3%) 
2.81                  
 (1.64-2.83) 
<0.001 
Other clinical 
characteristics 
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Neonatal Unit 123 (19.2%) 46 (61.3%) 77 (13.6%) 
11.13                   
(6.46 -  19.17) 
<0.001 
Situs abnormality  53 (8.2%) 31 (41.3%) 22 (3.9%) 
17.19                   
 (9.18 - 32.19) 
<0.001 
Congenital cardiac 
defect 
19 (2.9%) 7 (9.3%) 12 (2.1%) 
4.75                     
 (1.81 - 12.48) 
0.001 
Hydrocephalus   7 (1.1%) 1 (1.3%) 6 (1.0%) 
1.14                          
(0.13-9.61) 
0.903 
Developmental 
delay* 
43 (6.7%) 8 (10.6%) 35 (6.2%) 
1.68                          
(0.75-3.82) 
0.197 
Family history of 
disease 
      
 
  
Family history 
PCD in siblings  
27 (4.2%) 18 (24.0%) 9 (1.6%) 
19.23                    
 (8.24 - 44.87) 
<0.001 
Family history 
PCD in extended 
family  
10 (1.5%) 4 (5.3%) 6 (1.1%) 
5.22                     
 (1.44 - 18.98) 
0.012 
Family history of 
asthma  
206 (32.1%) 12 (16.0%) 194 (34.2%) 
0.35                  
  (0.18 - 0.67) 
0.002 
Family history 
bronchiectasis  
28 (4.3%) 3 (4.0%) 25 (4.4%) 
0.99                        
(0.29-3.40) 
0.998 
Family history 
otitis media 
65 (10.1%) 5 (6.6%) 60 (10.6%) 
0.69  
(0.26 - 1.80) 
0.456 
Subfertility 
(n=152)† 
36 (23.6%) 10 (90%) 26 (18.4%) 
44.23    
 (5.42-360.91) 
<0.001 
 
  * Developmental delay includes those who present with gross motor delay, social delay or 
language delay 
   †Subfertility is based on a total of 152 referrals. Subfertility data is available for positive 
referrals n= 11 and negative referrals n=141 
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Table 13: Factors for the prediction of PCD selected by stepwise logistic regression 
 RC OR  (95% CI) p-value *Simplified RC 
tool 
Situs inversus 3.54  34.48 (11.6 to 101.8) <0.001 4 
Gestational age (full term) 2.20 9.06 (2.9 to 27.4) <0.001 2 
Neonatal chest symptoms 1.91  6.79 (2.7 to 16.7) <0.001 2 
Neonatal unit 1.90  6.70 (2.7-16.3) <0.001 2 
Congenital cardiac defect 1.57  4.83 (1.1-22.2) 0.043 2 
Rhinitis 1.22  3.40 (1.2 to 8.9) 0.013 1 
Ear and hearing symptoms 0.95  2.59 (1.2 to 5.8) 0.021 1 
RC, Regression coefficient; OR, Odds ratio 
*Regression coefficients of the main model are rounded to the nearest integer 
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Table 14: Performance measures including sensitivity, specificity, positive predictive 
value (PPV) and negative predictive value (NPV) of the PICADAR prediction tool for 
different cut-off values calculated from the derivation group and validation group. 
 
 
 Derivation group (UHS) Validation group (RBH) 
Cut-off  ≥: Sensitivity Specificity PPV NPV Sensitivity Specificity PPV NPV 
0 
>0.99 <0.01 0.12 NA >0.99 <0.01 0.51 0.00 
1 
>0.99 0.01 0.12 1.0 - - - - 
2 
>0.99 0.04 0.12 1.0 >0.99 0.01 0.51 1.00 
3 
0.97 0.20 0.14 0.98 0.99 0.35 0.61 0.97 
4 
0.97 0.48 0.20 0.99 0.93 0.63 0.72 0.90 
5 
0.90 0.75 0.32 0.98 0.86 0.73 0.77 0.83 
6 
0.89 0.83 0.41 0.98 0.81 0.76 0.78 0.79 
7 
0.76 0.94 0.63 0.97 0.73 0.89 0.79 0.79 
8 
0.63 0.96 0.68 0.95 0.53 0.90 0.85 0.65 
9 
0.34 0.99 0.82 0.92 0.35 0.96 0.90 0.59 
10 
0.31 >0.99 0.80 0.92 0.29 0.96 0.88 0.57 
11 
0.19 >0.99 0.72 0.90 0.25 0.99 0.96 0.56 
12 
0.13 >0.99 1.0 0.90 0.13 0.99 0.93 0.52 
13 
0.01 >0.99 1.0 0.88 0.05 >0.99 1.00 0.50 
14 
<0.01 >0.99 NA 0.88 0.01 >0.99 1.00 0.49 
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TABLE 15: The distribution of scores (⩽5, 6–9 and ⩾10) in primary ciliary dyskinesia 
(PCD) positive and PCD-negative participants using PICADAR in the derivation group 
(n=288) and in the validation group (n=157) (only children <18 years included) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Derivation group 
n=288 
 
Validation group 
n=157 
 
 <5 
n (%) 
6-9 
n (%) 
>10 
n (%) 
 
<5 
n (%) 
6-9 
n (%) 
>10 
n (%) 
PCD+  
(n=50) 
3 (6.0%) 29 (58.0%) 
18 
(36.0%) 
PCD+  
(n=79) 
15 (18.7%) 42 (53.3%) 22 (28.0%) 
PCD-  
(n=238) 
189 (79.4%) 48 (20.2%) 1 (0.4%) 
PCD-  
(n=78) 
59 (75.6%) 16 (20.5%) 3 (3.8%) 
 145 
 
7. ACCURACY OF DIAGNOSTIC TESTING FOR PRIMARY CILIARY 
DYSKINESIA: RESPONSE TO CORRESPONDENCE  
 
 
JANE S LUCAS 
BORISLAV DIMITROV 
LAURA BEHAN 
CLAUDIA KUEHNI 
 
THIS LETTER WAS PUBLISHED IN THE EUROPEAN RESPIRATORY JOURNAL IN 
2016 
 
 
 
 
 
 
 
 
 
 
 146 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Correspondence: Diagnostic testing in primary ciliary dyskinesia 
 Israel Amirav
1
, Patrick M. Boussuyt
2
 
1. Pediatric Department, University of Alberta, Edmonton  
2. Department of Clinical Epidemiology and Biostatistics, Academic Medical Center, University of 
Amsterdam, The Netherlands 
 
To the Editor:  
The PCD group in Southampton UK, led by Dr Lucas are to be applauded for their recent efforts to improve the 
accuracy of diagnosing PCD.  
In two recent articles published by the group in this journal (1,2), a large number of PCD referral cases were 
analyzed and various conclusions were drawn regarding diagnostic accuracy as well as derivation of a clinical 
prediction rule which was suggested to aid in further referral and investigations for PCD. 
The major problem with these data however is that the authors have not essentially evaluated diagnostic accuracy.  
In diagnostic accuracy studies, the ability of one or more tests to correctly identify patients with the target condition 
is typically expressed as the sensitivity and specificity of the test(s). These are estimated by comparing the test results 
against the results of the reference standard, the best available method for correctly identifying patients with the 
target condition. 
Diagnostic accuracy studies can be at risk of bias, and several sources of bias have been described (3,4). Studies at 
risk of bias because of design deficiencies typically overestimate the indicators of test performance but also limit the 
applicability of the study findings. Unfortunately, these recent PCD studies are not at low risk of bias. The authors 
did not notify the readers of two design deficiencies. The first is that the diagnostic criteria in the Jackson's study 
(the reference criteria) include the index tests measured (2). This was also done in the prediction rule study (1). The 
resulting bias is known as incorporation bias, and is known to lead to inflated estimates of accuracy, and to generous 
conclusions about test performance.  
Furthermore, the calculated estimates of specificity and sensitivity were based on the number of participants who 
were diagnosed as PCD (or not) by the reference criteria. However, as no gold standard exist in PCD, exclusion of 
the disease (true negative) is almost impossible to achieve in that situation. This is exemplified in genetic tests, where 
a negative finding of a PCD causing mutation does not necessarily confirm that the patient has no PCD, as only 60—
70% of the mutations are known.  
We feel that the best (and probably only) diagnostic performance indicator that can be meaningfully discussed in 
these studies is the positive predictive value of the various tests. To associate these tests with the conventional 
accuracy statistics, sensitivity and specificity, still needs to wait, as indeed suggested (for other reasons) by Haarman 
and Schmidts in their editorial (5) to one of the papers.  
Until we have some reference tests that are better than the current bronze or silver standards, diagnostic accuracy 
cannot be meaningfully evaluated, nor claimed. 
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We thank Drs Amirav and Boussuyt for their interest in our manuscripts. We agree that our 
two studies (101, 167) have some limitations, caused by the lack of a “gold standard” test for 
diagnosing PCD, but we strongly disagree with their claim that we “did not notify the readers 
of these design deficiencies”. Instead, we had taken great care to highlight these uncertainties 
and risks of bias. Our first manuscript evaluates the accuracy of different tests used to 
diagnose PCD: nasal nitric oxide (nNO), high-speed video microscopy analysis (HSVMA) 
and transmission electron microscopy (TEM), used alone or in combination, against an expert 
diagnostic consensus based on information from all available tests (101). This was clearly 
described in the methods section; and several sensitivity analyses tested the robustness of our 
results by varying different parameters. Most notably, we began the discussion section (101) 
by describing the lack of a single ‘gold reference standard’ (second paragraph) as the major 
limitation of our study. We highlighted that we used a surrogate reference standard, which 
was an expert multidisciplinary consensus, based on results from all available diagnostic tests. 
We also cautioned that since each test contributed to the final diagnostic decision, our 
sensitivity and specificity estimates of the single tests might be overestimated. Their letter is 
helpful as it highlights the challenges of investigating diagnostic accuracy for diseases where 
there is no ‘gold standard’. This is typical for many diseases, including rare ones like PCD 
(13), and common ones like asthma. It complicates research, but should not impede it; or else 
we will never progress. Guidance recommends that in situations without a ‘gold standard’ 
researchers can consider constructing a reference standard from multiple test results or use an 
imperfect reference (168). In our clinical practice, a multidisciplinary panel of specialists 
considers results of multiple tests to develop a consensus diagnosis of PCD, based on pre-
determined rules. In the paper, we used this composite diagnostic outcome as the study’s 
reference standard. Pre-specified rules for deciding the composite diagnostic outcome makes 
the method transparent and easy to use. 
 148 
 
An alternative approach(168) is to use an imperfect reference standard and then adjust the 
calculated sensitivity and specificity based on existing data about the imperfections. For 
example, we could have used TEM alone as a single reference standard, and calculated the 
accuracy of the other tests compared to TEM, taking into consideration that the latter has 
excellent specificity but limited sensitivity (70-90%). For completeness, we did this for TEM 
and for HSVMA (Appendix 2: Table A4) (101)), but given that this was not our primary 
approach and that pre-existing data about the degree of imperfection were highly variable, we 
decided not to make any adjustments. As discussed in our manuscript (101) and the 
accompanying editorial by Haarman and Schmidts (169), generalisability of our findings 
should be considered with caution. Accurate analysis of ciliary function by HSVMA and of 
ultrastructure by TEM depends on expertise. The UK PCD reference centres regularly audit 
each other’s analyses, and discuss difficult cases (21). We routinely analyse de novo cilia 
following culture of the original sample at air liquid interface allowing us to differentiate 
primary and secondary functional and structural defects (139). These methods are technically 
demanding and not available in many centres. In centres without similar infrastructure subtle 
cases of PCD are more likely to be missed, and secondary defects incorrectly attributed to 
PCD; even with these facilities, we may misdiagnose some patients. Introduction of new tests 
is likely to advance the accuracy of diagnostic decisions; we did not include data on genotype 
and immunofluorescence because these methods were introduced relatively recently and were 
not available during the study period. The second manuscript that Amirav and Boussuyt refer 
to describes the PICADAR tool, a 7-item prediction rule aimed at identifying patients 
needing referral for diagnostic testing (167). The tool uses information on clinical symptoms 
at presentation to predict the likelihood (or, risk) of a final PCD diagnosis. As diagnostic 
outcome, we used the same composite reference standard as in the first study (101)  based on 
results from all available diagnostic tests. A standardised clinical history was taken from all 
 149 
 
referred patients, prior to performing any of the diagnostic tests. As detailed in the manuscript, 
diagnosis was based on positive test results, but not on the clinical history. Symptoms were 
not part of the composite diagnosis, so there was no incorporation bias in this study. In 
addition to the published analyses, as strategy to assess potential model overfitting, we 
performed a bootstrapping testing of the receiver operator characteristic curves of the 
derivation population, which indicated an expected shrinkage of <3% (Appendix 4). This 
suggests that there is no significant overestimation for the ROC curves as produced within the 
predictive logistic regression models. We further published the external validation using an 
independent patient cohort (167) but pointed out that PICADAR should be further validated, 
and if necessary modified, in different study populations, in general respiratory clinics and 
different countries. In summary, we agree that current methods for diagnosing PCD and for 
assessing diagnostic accuracy are imperfect and require further development and scrutiny. 
However, we confirm that our manuscripts, which were very transparent about diagnostic 
pathways, diagnostic and statistical methods, and their limitations, are an acceptable way 
forward whilst we establish better methods. The two publications are not intended as the 
definitive answer, but as significant steps in the plight to develop an evidence-base to 
diagnostic testing. Waiting for a ‘gold standard’ will not allow us to move forward in the near 
future. 
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8.1. Abstract 
Background: Primary ciliary dyskinesia (PCD) is characterised by chronic suppurative lung 
disease, rhino-sinusitis, hearing impairment and sub-fertility. We have developed the first 
multidimensional measure to assess health-related quality of life (HRQoL) in adults with 
PCD (QOL–PCD). 
Method: Following a literature review and expert panel meeting, open-ended interviews with 
patients investigated the impact of PCD on HRQoL in the UK and North America (n=21). 
Transcripts were content analysed to derive saturation matrices. Items were rated for 
relevance by patients (n=49). Saturation matrices, relevance scores, literature review, 
evaluation of existing measures, and expert opinion contributed to development of a 
preliminary questionnaire. The questionnaire was refined following cognitive interviews 
(n=18). 
Results: Open-ended interviews identified a spectrum of issues unique to adults with PCD. 
Saturation matrices confirmed comprehensive coverage of content. QOL–PCD includes 48 
items covering the following seven domains: Physical Functioning, Emotional Functioning, 
Treatment Burden, Respiratory and Sinus Symptoms, Ears and Hearing, Social Functioning, 
and Vitality and Health Perceptions. Cognitive testing confirmed that content was 
comprehensive and the items were well-understood by respondents. 
Conclusion: Content validity and cognitive testing supported the items and structure. QOL–
PCD has been translated into other languages and is awaiting psychometric testing. 
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8.2. Introduction 
Primary ciliary dyskinesia (PCD) is a rare disease (∼1 in 15 000 people) inherited in a 
genetically heterogeneous, autosomal recessive pattern (20, 21, 170). It is characterised by 
chronic infection of the upper and lower airways caused by impaired mucociliary clearance 
as a consequence of abnormal function of motile cilia. In healthy individuals, cilia clear 
airway mucus, bacteria and debris by coordinated beating. The ciliary dysfunction in PCD 
leads to a daily wet cough, recurrent chest infections and rhino-sinusitis. By adulthood, 
bronchiectasis is invariable and many patients develop respiratory failure (1). Motile cilia are 
important in organ systems besides the airways, such as the embryonic node, sperm flagella 
and the female reproductive tract. Therefore, patients frequently have problems caused by 
non-respiratory dysmotile cilia, e.g. serous otitis media (“glue ear”) leading to hearing 
impairment and immotile sperm causing infertility). The cilia of the embryonic node, 
responsible for left–right asymmetry of organs, are similar in structure to respiratory cilia. 
Dysfunction of embryonic nodal cilia in PCD causes laterality defects, including situs 
inversus (chest and abdominal organs are mirror image of normal; seen in approximately 40% 
of cases) and situs ambiguous (disturbance of the usual left and right distribution of the 
thoracic and abdominal organs which does not entirely correspond to mirror image; seen in 
approximately 10% of cases) and can be associated with congenital heterotaxic heart disease 
in approximately 2–3% of cases (8). 
 
Monitoring of disease progression and evaluation of therapeutic options has been hampered 
by a lack of disease-specific outcome measures. Spirometry is an insensitive marker of 
progressive lung disease, which is evident using high-resolution computed tomography 
(HRCT)(66). Although HRCT is a useful staging test, it is an impractical monitoring tool. 
Lung clearance index (LCI), measured by multiple breath washout, has been investigated as a 
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potential tool for monitoring at specialist centres using sulphur hexafluoride (SF6) as a tracer 
gas (73, 76). However, contrary to findings in cystic fibrosis (CF), LCI does not appear to be 
a sensitive test of airway disease in advanced PCD (73). Furthermore, physiological measures 
provide information on objective indicators of health to patients and clinicians, but these 
measures do not reflect the patient perceptions of the impact of the disease on symptoms as 
well as physical, social and emotional functioning. 
Thus, measures are needed to assess the impact of PCD, from the patient's perspective, on all 
domains of patient functioning (24, 90, 171). Health-related quality of life (HRQoL) 
measures have become a vital and necessary component of patient-reported outcomes (PROs) 
in populations with chronic disease (172). The US Food and Drug Administration (FDA) 
define HRQoL as the patient's perception of how they “survive, feel, and function” (94). We 
used a model for HRQoL originally proposed by Wilson and Cleary (173) and revised by 
Ferrans et al. (174). There is extensive agreement that assessment of HRQoL should 
encompass, at minimum, physical, social and emotional well-being and symptoms which 
allow for a multidimensional, systematic measure of how the illness and its treatment impact 
symptoms and other domains of functioning. 
 
Existing PROs do not assess the disease-specific effects of PCD on daily symptoms and 
functioning. Most studies have utilised either generic (e.g. Short Form 36 Health Survey) or 
broad-based respiratory questionnaires, such as the St George's Respiratory Questionnaire 
(SGRQ)(77, 107, 113, 118) and two additional studies have utilised qualitative interview 
methods (78, 79). These PROs have a number of limitations for assessing HRQoL in adults 
with PCD. For example, the SGRQ was developed for patients with chronic obstructive 
airways disease and, thus, has a limited number of respiratory symptoms, no items relevant to 
ear, nose and throat disease or fertility problems, long and variable recall periods and 
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considerable respondent burden (e.g. nearly an hour to complete). Thus, there was an urgent 
need to develop a disease-specific measure for adults with PCD. These tools can be used to 
document the progression of disease, monitor patients clinically and serve as an outcome 
measure for clinical trials of new therapies. 
 
Our ultimate goal is to develop a PCD-specific HRQoL instrument for use as a primary or 
secondary outcome measure in large, randomised clinical trials. To recruit adequate numbers 
of participants, multi-centre and multi-national collaboration was required. Therefore, 
researchers from the UK, North America and Ireland worked closely to develop age-specific 
questionnaires (child, adolescent, parent-proxy and adult) using guidance developed by the 
FDA and European Agency for the Evaluation of Medicinal Products (EMEA)(92-94). 
Development of the child, adolescent and parent-proxy versions will be reported in a separate 
manuscript. This manuscript describes the development process for the QOL–PCD Adult 
version which included the following phases: 1) literature review and expert panels; 2) open-
ended interviews with patients in in UK, USA and Canada; 3) item generation; 4) cognitive 
testing; and 5) refinement of the draft measure. QOL–PCD is now being validated in Europe, 
USA and Canada; the psychometric reliability and validity will be reported when these 
studies are complete. 
 
8.3. Methods 
The protocol for development of the QOL–PCD complied with FDA requirements. The study 
was approved by Southampton and South West Hampshire Research Ethics Committee 
(Southampton, UK) A 07/Q1702/109 and by the University of Miami Institutional Review 
Board (Miami, FL, USA). Informed consent was obtained prior to interviews. 
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8.3.1. Literature review and expert panel 
First, a systematic literature review was conducted to identify key symptoms and effects of 
PCD on patient functioning. MEDLINE and EMBASE were searched, and additional 
references were sought through citations in the identified studies. Abstracts were reviewed 
and manuscripts sourced for research investigating the effects of PCD on adults. 
In the next step, expert clinicians, allied health professionals and researchers met to discuss 
their own perceptions of the impact of PCD on adults, based on their clinical experiences. 
These sources of information contributed to a long list of items patients rated for relevance. 
These items also informed the development of the open-ended interview guide. 
8.3.2. Participants 
In the UK, participants for the open-ended and cognitive interviews were recruited from PCD 
clinics and from an advert through the PCD Family Support Group UK. A list of potential 
items was sent to the Family Support Group in the UK to rate their relevance. Participants in 
North America were recruited from a cohort of PCD patients evaluated at the University of 
North Carolina, as well as from the US PCD Foundation's registry of patients. Expert opinion 
was also sought during the item generation and item reduction phases from members of the 
European PCD Group. 
Criteria for participation in the open-ended and cognitive interviews included age ≥18 years 
with a diagnosis of PCD. Patients were recruited from English-speaking countries: UK, USA 
and Canada. UK participants had an existing diagnosis from one of the English diagnostic 
centres (21, 141) based on clinical phenotype plus high-speed video analysis of ciliary 
function and/or assessment of ciliary ultrastructure by electron microscopy. North American 
participants were diagnosed at a specialised PCD research center, based on: a compatible 
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clinical phenotype plus defect in ciliary ultrastructure and/or identification of biallellic 
disease-causing mutations in one of the PCD genes. 
8.3.3. Open-ended interviews 
In-depth interviews were conducted either in-person or by phone to elicit the effects of PCD 
from the patients' perspective. Interviews were conducted in the UK by L. Behan and in USA 
and Canada by A.L. Quittner, A. Alpern and A.M. Morris. All participants were fluent in 
English. We attempted to interview patients who were geographically representative and 
clinically stable. The audio of all interviews was recorded and transcribed for content analysis 
using either NVivo (version 8 2008; QSR International Pty Ltd, Daresbury, UK) in the UK or 
Atlas.ti (Version 7.0; Scientific Software Development, Corvallis, OR, USA) in the USA. 
Thematic coding was used to identify key symptoms and psychosocial impacts. Two 
members of each research team coded the interview transcripts using consensus coding. 
When there was a discrepancy, this was discussed and resolved within the pair of coders. We 
did not calculate percentage agreement since we used a consensus coding process. These data 
were then analysed to identify critical items based on frequency of endorsement. Content 
analysis of these transcripts yielded saturation and indicated that the measure was 
comprehensive and that all relevant items were included. 
8.3.4. Item generation 
Questions from the literature review, expert panel and open-ended interviews were also sent 
by post to respondents of an advert circulated to members of the PCD Support Group and to 
adult patients at PCD clinics in the UK. A pre-paid envelope and covering letter was included. 
Participants rated each item using a 5-point Likert scale (1: “not relevant”; to 5: “highly 
relevant”). 
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Items for the initial QOL–PCD measure were based primarily on the patient-based content 
analysis. We discussed these results in a series of teleconferences chaired by J.S. Lucas. Each 
meeting included clinicians, psychologists and interviewers from Ireland, the UK and the 
USA. Decisions made using a modified Delphi approach guided by two main principles. The 
primary criterion for including an item was its impact on HRQoL, measured by the frequency 
with which items were mentioned across patients and in relation to other items mentioned. 
There was no pre-determined frequency required for inclusion of an item, but the researchers 
considered the frequency each item was mentioned relative to the other items in that domain. 
They also considered the importance interviewees placed on these items. Secondly, patients' 
ratings of relevance from the UK survey were considered. For each item, decisions were 
made to include an item based on our discussion. When there was initial disagreement, the 
chair invited each individual to explain their rationale. Unanimous agreement was achieved 
within two rounds of discussion. Finally, we determined that all of the content had been 
identified based on saturation matrices in the UK and US, which showed that no new content 
emerged after six patients, on average, in each country. We included at least four items on 
each subscale to ensure adequate internal consistency. 
8.3.5. Construct of prototype questionnaire 
Agreement on item selection and wording was achieved during multi-disciplinary, 
multinational conference calls. Selected items were written using patient language obtained in 
the qualitative interviews and then combined into scales (e.g. frequency and severity of 
respiratory symptoms, perceptions of treatment burden). Where appropriate, the items were 
formulated into questions based on the Cystic Fibrosis Questionnaire-Revised (CFQ-R), 
which has been well-validated(172, 175). Some example CFQ-R items that were adapted to 
the PCD HRQoL measure include: “Did you cough during the day?” and “How often does 
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CF get in the way of meeting your school, work, or personal goals?” Items were written to 
ensure conceptual, cultural and linguistic equivalence for North America, the UK and Ireland, 
by researchers from the USA, England and Ireland. We also adhered to both the FDA and 
EMEA Guidance (92-94). The FDA guidelines for developing PROMs for use in clinical 
trials (83) recommend an iterative process consisting of: (1) hypothesising the conceptual 
framework, (2) adjusting conceptual framework and draft instrument, (3) confirming the 
conceptual framework and accessing other measurement properties, (4) collecting analysing 
and interpreting data, and (5) modifying the instrument.  
8.3.6. Cognitive interviews 
Cognitive interviews were conducted prior to formal psychometric validation of 
questionnaires to evaluate how respondents process the question and rating options 
cognitively; i.e. What “meaning” do these items have for respondents? Is this the same 
meaning we intended? What were they considering when rating frequency or impact? 
Specifically, we wanted to identify any problems with the instructions, organisation of the 
questionnaire, item interpretation, memory retrieval, decision-making processes and response 
selection. A “think aloud” procedure was used to investigate the participants' comprehension 
of the instructions, items and rating scales. They were asked clarifying questions, such as: 
“What were you thinking of when answering that question?” and “What does X word mean 
to you?” For example, “What does feeling ‘well’ mean to you?”, “What would have made 
you endorse a higher/lower frequency for that question?”, “How relevant/important is this 
question for you?”, “Are the rating options clear to you?” and “Are they easy to use?” 
 
Participants were first asked to complete the prototype questionnaire independently. Next, 
they were interviewed using specific cognitive probes, which focused on the clarity of the 
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question, its meaning, relevance and importance, and what would have shifted their response 
to an adjacent answer. The audio of all interviews was recorded and transcribed. The results 
were discussed during a series of teleconferences to determine whether revisions were 
required for the format, instructions or items. The measure was refined based on the cognitive 
interviews and then finalised. 
 
8.4. Results 
8.4.1. Item generation 
Items were generated by the expert panel and the qualitative, open-ended interviews with 
patients. Characteristics of participants who completed the open-ended interviews (n=21) are 
shown in Table 16. The majority of participants were female, and among US participants, 
most were between 18 and 35 years of age. As expected, nearly all adults described a chronic 
cough and sino-nasal symptoms. Eight (38%) participants described themselves as infertile or 
had required assisted fertilisation, but 10 (48%) participants had not yet tried to conceive or 
had their fertility status checked. Selected patient quotes from the open-ended interviews 
conducted with UK and North American participants are presented in Table 17. 
8.4.2. Content analysis and item reduction 
Content analysis of the transcripts yielded the most important items for each of the 10 
domains based on the frequency with which they were mentioned across adults. Saturation of 
content, across domains, was confirmed when no new themes emerged (Figure 13). Our 
results indicated that this was achieved by the 5–7th interview, depending on the specific 
content area. We also harmonised the content across UK and North America to identify the 
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most important topics. The items that were considered most important and relevant by the 
participants who performed the open-ended interviews were also scored as highly relevant by 
the 49 adult members of the PCD UK support group who completed the survey. Thus, 
content analysis of the interviews concurred with results of the survey (Appendix 5: Table 
A12). 
 
8.4.3. Cognitive testing 
Cognitive interviews were conducted with 15 adults (UK n=9, USA n=6). Review of these 
transcripts indicated that patients found the items clear, important and relevant and had no 
difficulty with the response options. Six items were added, based on patient input, after the 
cognitive testing phase (Table 18). These topics included: making plans for the future 
(vacation, attending family events), treatment burden, intimacy, and pain associated with 
sinus disease. Thus, the final prototype instrument contained 48 items (QOL–PCD v1.2). 
Following this iterative process, the draft version of the QOL–PCD v.1.2 is ready to be tested 
in a psychometric validation study. 
 
8.5. Discussion 
This process, conducted in the UK and North America, yielded the first HRQoL instrument 
for adults with PCD, the QOL–PCD. It was developed following the guidelines published by 
the major regulatory bodies in Europe and the USA (i.e. EMEA and FDA) (92-94) and will 
be submitted to these agencies for consideration as an outcome measure for clinical trials. 
The most important principle governing its development was our reliance on patient input 
and their perspective at each phase. Thus, this tool systematically reflects how an adult with 
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PCD “survives, feels, or functions” (94). Given the rarity of this chronic disease, we 
developed the content cross-culturally in English-speaking countries (UK, USA and Canada) 
and found no discrepancies in content across countries. Additional input was obtained from 
the current literature and from medical experts across Europe and North America. 
 
Open-ended interviews highlighted the importance not only of patients' respiratory symptoms, 
but the effects of sinus disease and hearing problems on daily functioning. Although sinus 
disease is also problematic for patients with CF and non-CF bronchiectasis, patients with 
PCD emphasised the additional impact of their upper respiratory tract symptoms. This 
highlights that PCD has distinct features from other bronchiectatic diseases (23), and 
deserves individualised management. Thus, a number of items assessing rhino-sinus and ear 
symptoms appear on the final instrument, differentiating it from disease-specific HRQoL 
measures for adults with CF or non-CF bronchiectasis (172, 176). 
 
The study population was not fully representative of the PCD population. In common with 
many previous studies, it was more difficult to recruit men than women with only three men 
(14%) participating in the interviews. Approximately 6% of patients with PCD have 
cardiovascular disease (8). None of the 21 interviewees in this study had cardiovascular 
disease, but even if we had designed the study population to be representative of the PCD 
population we would have aimed to have only one patient. Moreover, we would not be able 
to recruit patients with the diverse spectrum of cardiac disease e.g. complex cyanotic heart 
disease versus simple cardiac anomaly. It is therefore a limitation of the questionnaire that it 
does not include items relevant to patients with cardiac disease. 
A reliable patient-reported outcome measure for PCD is particularly important, given that 
physiological measures such as forced expiratory volume in 1 s and LCI are not sensitive or 
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predictive, and HRCT is not suitable for repeat testing due to radiation exposure. Importantly, 
the QOL–PCD provides a measure of the multidimensional effects of PCD on adults, from 
their own perspective including its impact on the upper and lower respiratory systems, 
treatment burden and social and emotional functioning. Reliability and validity studies are 
currently in process and will be reported in due course. 
8.6. Conclusion 
In summary, the QOL–PCD was developed and has undergone cognitive testing in adults 
from several English-speaking countries. It has been translated into Dutch, German, and 
Danish, with plans to develop translations from major European countries and the Middle 
East. A multi-national, psychometric field-study is now planned to assess several forms of 
reliability and validity. Similar processes have been used to develop age-specific HRQoL 
measures for children and adolescents with PCD and parent caregivers. These instruments 
will also be translated into other languages and validated in future studies. 
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Figure 13: Saturation grids for UK and US participants: respiratory symptoms, sinus 
symptoms, and ear and hearing symptoms. Vertical lines indicate saturation was 
reached. All items above the horizontal lines were retained for the final questionnaire. 
Shaded cells refer to the first time the item was mentioned.  
#
: participants did not indicate adverse effects of difficulty smelling; therefore it was not 
included in the final questionnaire. 
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Table 16: Demographics and clinical characteristics of participants 
 Study population  UK  USA  
Participant n   21  11  10 
Sex     
Male   3 (14) 1 (9) 2 (20)  
Female 18 (86) 10 (91) 8 (80)  
Age (years) 
18-35 years 
36-50 years 
51-65 years 
Over 65 years 
 
12 (57) 
4 (19) 
3 (14) 
2 (10) 
 
5 (45)  
1 (9)    
3 (27)  
2 (18)  
 
7 (70)  
3 (30)  
Age at diagnosis 
<5 years 
5-12 years 
12-18 years 
>18 years 
 
4 (19) 
4 (19) 
1 (5) 
12 (57) 
 
1 (9)  
0 
1 (9)  
9 (82)  
 
3 (30)  
4 (40)  
0 
3 (30)  
Race/ethnicity 
     UK 
     White British 
     British Asian 
     Asian 
     USA 
     Caucasian 
Hispanic 
White non-Hispanic 
  
 
9 (82) 
1 (9) 
1 (9) 
 
 
 
 
 
 
10 (100) 
9 (90) 
1 (10) 
Symptoms 
Chronic wet cough 
Persistent runny nose 
Recurrent sinus disease 
Infertility 
Situs abnormalities 
   
21 (100) 
20 (95) 
16 (76) 
8 (38) 
12 (57) 
 
11 (100)  
11 (100)  
8 (72)  
4 (36)  
8 (72)  
 
10 (100)  
9 (90)  
8 (80) 
4 (40)  
4 (40)  
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Cardiac disease 0 0 (0)  0 (0)  
FEV1 %  predicted # 
Range 
Mean±SD 
  
31-98 
64±21 
 
29-102 
65±25 
Employment status 
In paid employment 
Student 
Retired due to age 
Retired/left work due to PCD 
Carer for dependents 
Other 
 
 
11 (52) 
4 (19) 
1 (5) 
4 (19) 
1 (5) 
0  
 
4 (36)  
2 (18)  
1 (9)  
3 (27)  
1 (9)  
0 
 
 
7 (70)  
2 (20)  
0 
1 (10) 
0 
0 
Marital status 
Single 
Living with partner/ spouse 
Separated from partner/ spouse  
Widowed 
 
5 (24) 
16 (76) 
 
3 (27)   
8 (73)  
0 
0 
 
2 (20)  
8 (80)  
0 
0 
Fertility  
Conceived naturally 
Conceived through IVF 
Infertility 
Not yet known  
  
3 (27%) 
1 (9%) 
3 (27%) 
4 (36%) 
 
0 (0%) 
2 (20%) 
2 (20%) 
6 (60%) 
Data are presented as n (%), unless otherwise stated. #: forced expiratory volume in 1 s 
(FEV1) is based on n=5 participants in the UK and n=8 in North America; data were 
unavailable for telephone interviews. 
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Table 17. Participant quotes by topic 
Topic  Quote Country of 
interviewee/gender/ 
age band (in years) 
Impact of respiratory 
symptoms 
 “I had to tell the group…not to worry because I start 
huffing and spluttering as I’m walking…”  
 
“When I listen to myself breathe I always wheeze.” 
UK/female/36-50  
 
 
US/female/18-35 
Impact of sinus 
symptoms 
“...I’m always blowing my nose…doesn’t matter what 
weather it is.  
 
“I always have to blow my nose before I eat if I wanna 
taste anything.” 
UK/female/36-50  
 
US/female/36-50 
 
Impact of ear 
symptoms/ hearing 
loss 
“You have to ask people to repeat themselves…so 
many times, they’re just like oh don’t worry about it.” 
 
“I can’t go white water rafting because I have tubes in 
my ears and my ears can’t get wet.” 
UK/male/18-35  
 
 
US/female/18-35 
  
Impact of fertility 
issues 
“Finding out that I possibly can’t have kids…that’s 
when it…started to panic me a little bit.”  
 
“I’m still very uncertain if I ever wanna have children 
because I don’t know how me having this illness will 
affect them.” 
UK/male/18-35  
 
 
US/female/18-35 
Impact of treatment 
burden 
“…I don’t really want to do it, it’s kind of boring and 
it’s not fun and… I’d rather do something else.  But 
obviously you have to do it.”  
 
“I think it just requires more planning…I need to wake 
up earlier…or…start getting ready for bed earlier, I 
need to come home from work and do this…it’s just 
more planning.” 
UK/female/18-35  
 
 
 
US/female/18-35 
Emotional functioning “I’m so frustrated with this illness, I just want it to go 
away, but…unfortunately that’s how I have to live.”  
 
“…if you go to the doctor [and] you’re feeling pretty 
good and you know your numbers are not good…that 
UK/male/18-35  
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can be a big cause of anxiety.” US/female/18-35 
 
Social functioning “It has had such a huge impact on my life, and 
certainly I think it’s…contributed to the breakup of my 
first marriage.” 
 
“…there have been times where I’ve had to cancel 
things because I I’ve gotten sick…getting sick can 
happen overnight…you’re fine one day and the next 
day you feel awful…”  
UK/female/50-64  
 
 
US/female/18-35 
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Table 18. Summary of modifications to QOL-PCD after cognitive testing 
Issues Modifications after cognitive testing 
Items added to 
scales 
Respiratory Symptoms: 
Wheezing 
Chest tightness 
Sinus Symptoms: 
Post-nasal drip 
Sinus pain 
Physical Functioning: 
Carrying heavy things, such as books and shopping bags 
Health Perceptions: 
I feel healthy 
Emotional functioning: 
Felt depressed 
Felt lonely 
Social Functioning: 
Stay at home more often than would like 
Feel comfortable coughing in front of others 
Feel comfortable blowing nose in front of others 
Intimacy with a partner (kissing, hugging, sexual activity) 
Worried about being exposed to others who are sick 
Comfortable doing treatments (airway clearance, physiotherapy) in front of 
others 
Treatment Burden 
Physiotherapy/airway clearance made you feel tired quickly 
Items deleted 
from scales 
Health Perceptions: 
I feel in control of my PCD 
Emotional Functioning: 
Felt angry 
Felt limited 
Felt self-conscious 
Social Functioning 
Self-conscious coughing and blowing my nose in public 
Treatment Burden: 
Treatments made you feel better  
Physiotherapy is hard work 
Wording 
modifications 
Emotional Functioning: 
“Felt anxious” changed to “felt worried” 
“Felt frustrated” changed to “felt frustrated about doing your daily treatments” 
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9.1. Abstract  
Background: QOL-PCD is the first disease-specific, health-related quality of life instrument 
for primary ciliary dyskinesia. The aim of this study is to perform a psychometric validation 
of QOL-PCD assessing the performance of this measure in adults, including its reliability, 
validity and responsiveness to change.  
Method: Seventy-two adults with primary ciliary dyskinesia completed the 49-item QOL-
PCD and generic quality of life measures: SF-36, SNOT-20 and SGRQ-C. Thirty-five 
participants repeated QOLPCD 10-14 days later to measure stability or reproducibility of the 
measure, with 10 patients repeating it during respiratory exacerbations to assess 
responsiveness.  
Results: Multi-trait analysis was used to evaluate how the items loaded on 10 hypothesised 
scales: Physical, Emotional, Role and Social Functioning, Treatment Burden, Vitality, Health 
Perceptions, Upper-Respiratory Symptoms, Lower-Respiratory Symptoms, and Ears and 
Hearing Symptoms. This analysis of item-to-total correlations led to 9 items being dropped; 
the validated measure is comprised of 40 items. Each scale had excellent internal consistency 
(0.74 to 0.94). Two-week test-retest demonstrated stability for all scales (intra-class 
coefficients 0.73 to 0.96). The QOL-PCD was responsive to exacerbations, with decreased 
mean scores on several scales. Significant correlations were obtained between QOL-PCD 
scores and age and FEV 1. Strong associations were also found between QOL-PCD scales 
and corresponding generic questionnaires e.g. Lower-Respiratory Symptoms and SGRQ-C 
(r=0.72, p<0.001), whilst correlations between measures of different constructs were poor.  
Conclusion: QOL-PCD has demonstrated good internal consistency, test-retest reliability, 
convergent and divergent validity, and responsiveness to exacerbations. QOL-PCD is short 
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and easy to use, offering a promising tool for evaluating new therapies and for measuring 
symptoms, functioning and quality of life during routine care. 
9.2. Introduction  
PCD is a rare, heterogeneous genetic disorder characterised by impaired mucociliary 
clearance due to abnormal ciliary function. Individuals with PCD usually present with 
unexplained neonatal respiratory symptoms in the first few days of life (3, 167), have early 
onset of persistent sino-pulmonary infections, bronchiectasis during childhood (66) and a 
progressive decline in lung function(4). This can lead to end stage lung disease with a report 
that 25% of adult PCD patients in the US required long-term oxygen or lung transplantation 
(1). Male infertility is common since sperm flagella have a similar ultrastructure to cilia; the 
incidence of female infertility and of ectopic pregnancy is unclear and is explained by 
immotile fallopian tube cilia. Motile embryonic nodal cilia contribute to left-right asymmetry 
and nearly half of PCD patients’ exhibit situs inversus, and 12% heterotaxic syndromes, 
sometimes associated with complex congenital cardiac defects (8). Outcome measures that 
have been used to assess disease severity in PCD include spirometry (4), chest computed 
tomography (66, 71), magnetic resonance imaging (5) and lung clearance index (73-76). 
These physiological and radiological measures all have limitations in terms of their 
sensitivity or feasibility to monitor disease progression. The Food and Drug Administration 
(FDA) and the European Medicines Agency (EMA) strongly endorse the use of outcome 
measures in clinical trials, assessing the impact of the disease on the patient’s daily symptoms 
and functioning (e.g., physical, respiratory, social) in addition to physiological measures (92-
94). Treatment strategies for PCD have necessarily been applied from other diseases (22, 23), 
particularly cystic fibrosis (CF), since no medications have specifically been tested and 
approved for PCD. A major obstacle to evaluating new treatments and monitoring disease 
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progression is the lack of a disease-specific outcome measure (24). Thus, we developed 
health-related quality of life (HRQoL) measures to assess the impact of PCD for children, 
teenagers and adults from the patient perspective (103). Here we present the psychometric 
validation of the English version of QOL-PCD in adults from United Kingdom, United States 
of America and Canada.  
9.3. Method  
9.3.1. Participants  
Participants were recruited from PCD diagnostic centres across the UK, USA and Canada. 
Adults (>18 years) with a positive diagnosis of PCD were eligible to participate. Information 
about the study was provided at a clinic appointment or by telephone. The following 
inclusion criteria had to be met by patients: (1) diagnosis of PCD in one of the specified 
diagnostic centres, (2) age ≥18 years and (3) ability to read and speak English fluently. UK 
participants had been diagnosed at one of the English diagnostic centres (21, 141) based on 
clinical phenotype plus high-speed video analysis of ciliary function and/or assessment of 
ciliary ultrastructure by electron microscopy. North American participants were diagnosed at 
a specialised PCD research center, based on: a compatible clinical phenotype plus defect in 
ciliary ultrastructure and/or identification of biallellic disease-causing mutations in one of the 
PCD genes.  
9.3.2. QOL-PCD scales  
The QOL-PCD Adult version consisted of 49 items (103), which were self-completed 
electronically at home or in the clinic, where possible; ‘pen and paper’ copies were provided 
to those without access to internet. Participants were provided with a unique study number 
and a link to the online survey. No identifiable information was included, and the data were 
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captured on a server of University of Southampton. Most responses used a four-point Likert 
scale: "not at all true” to “very true” or “never” to “always". The first time QOL-PCD was 
completed, participants also completed generic questionnaires: Short-Form 36 Health Survey 
(SF-36), the shortened St George Respiratory Questionnaire (SGRQ-C), and a measure 
focusing on rhino-sinus symptoms: SNOT-20. Further details on this protocol and these 
measures can be found in Appendix 6.  
 
9.3.3. Statistical analysis  
Statistical analyses were conducted using the SPSS Statistics (IBM SPSS Statistics for 
Windows, Version 21.0. Armonk, NY: IBM Corp). P<0.05 was considered significant. 
Firstly, we assessed the distribution of responses for each item and each scale to look for 
floor and ceiling effects. Next, we used multitrait analysis to examine the relationships 
between items and their proposed scales. These analyses assessed the extent to which items 
correlated with their hypothesised versus competing scales; we required item-to-scale 
correlations ≥ 0.40 with the intended scale and lower correlations with competing scales (177, 
178). We considered floor and ceiling effects, using <15% of participants as the threshold for 
the highest and lowest scores for a scale (179).  
9.3.3.1 Reliability  
Internal consistency of the QOL-PCD scales were investigated by Cronbach’s α values. 
Cronbach's α gives a score of between zero and one, a value of >0.70 indicating good internal 
consistency. Items were removed if this led to higher internal consistency (i.e. higher 
Cronbach’s α) to increase the parsimony and efficiency of the instrument (180, 181). 
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The distributions of responses and multi-trait analyses were reviewed in a series of 
teleconferences to decide which items could be removed, allowing us to shorten QOL-PCD, 
taking reliability and clinical relevance into consideration. Test-retest reliability was assessed 
using intra-class correlation coefficients (ICC) in stable patients who completed the QOL-
PCD a second time, 10 to 14 days after completing the baseline measures. An ICC value 
of >0.60 provided evidence of good stability and >0.75 excellent stability for each scale.  
9.3.3.2. Validity  
For a questionnaire to be construct valid, all items together should represent the underlying 
construct (HRQoL). Construct validity can be determined by testing the instrument against 
hypotheses. We hypothesised a priori that clinical features (age, gender, FEV1 and 
Pseudomonas status) would correlate with specific scales (e.g. FEV1 would correlate with 
Physical Functioning and Upper Respiratory Symptoms (construct validity). Cohen’s 
guidelines for the interpretation of correlation coefficients were used; correlations between 
0.50 and 1.00 were interpreted as strong, correlations between 0.30 and 0.50 as moderate, 
correlations between 0.10 and 0.30 as small and correlations <0.1 as weak (182). We also 
predicted that QOL-PCD scales would have moderate correlations (>0.3), using Spearman’s 
Correlation, with generic scales (SF-36, SGRQ-C and SNOT20) measuring similar constructs 
(convergent validity). We hypothesised small or weak correlations (<0.3) with scales 
measuring different constructs (divergent validity). Details of the hypothesised correlations 
are provided in Tables 22 and 23.  
9.3.3.3. Responsiveness  
Participants who contacted the study team towards the start of an exacerbation were asked to 
complete the questionnaire whilst unwell. An exacerbation was defined as respiratory tract 
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symptoms leading to prescription of antibiotic treatment, or a decline in FEV1% predicted ≥ 
10%. For patients who had experienced more than one exacerbation, the first exacerbation 
was used for analyses. For patients who repeated the measure during an exacerbation, we 
used paired sample t-tests to compare scores when the patient was stable and unwell.  
9.3.4. Ethical approval  
The study was approved by the National Research Ethics Service, UK (UK 07/Q1702/109), 
the Research Ethics Board at the Hospital for Sick Children in Toronto, Canada and the 
Institutional Review Boards at the University of North Carolina, Chapel Hill. Written consent 
was obtained prior to participation. 
 
9.4. Results  
9.4.1. Participants  
Between April 2014 and March 2016, 72 adults were recruited. Participant characteristics are 
shown in Table 18. The 49-item prototype took a mean time of 8 minutes (SD 5) to complete.  
9.4.2. Development of scales  
We used a multi-trait analysis to generate ten hypothesised scales: Physical, Emotional, Role 
and Social Functioning, Treatment Burden, Vitality, Health Perceptions, Upper Respiratory 
Symptoms, Lower-Respiratory Symptoms, and Ears and Hearing Symptoms. Examination of 
the distribution of responses to items and the multi-trait analyses enabled us to shorten the 
questionnaire by removing nine items which were redundant, not strongly endorsed or did not 
correlate strongly with its designated scale. (Appendix 6: Table A14). The final QOL-PCD 
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comprised of 40 items on ten scales which were subjected to further psychometric analysis 
(Table 20).  
Analyses of the 40-item QOL-PCD confirmed that all items had strong correlations (>0.63) 
with their intended scales. Few floor and ceiling effects were observed with the exception of: 
1) floor effects on the Social Functioning scale (16.7% of respondents had low scores) and 2) 
ceiling effects were found on the Physical Functioning and Ears and Hearing scales, with 
23.9% and 18.1% of respondents scoring the highest values, respectively. 
9.4.3. Reliability: Internal consistency and test-retest reliability  
The QOL-PCD scales had moderate to strong internal consistency (0.74 to 0.94) (Table 21). 
Thirty-five participants repeated QOL-PCD after 10-14 days, providing evidence of stability 
across all scales with intraclass correlation coefficients ranging from 0.73 to 0.96. (Table 21)  
 
9.4.4. Validity  
We had hypothesised that older age groups would report worse Physical Functioning, poorer 
Vitality, and more symptoms (Table 22). Mean Physical Functioning scores were 
significantly worse in those who were older; average scores for the 18-22 years age group 
was 88.21 (SD= 15.81), decreasing to 49.33 (SD= 34.88) in the >55 year old group (p<0.001). 
Lower Respiratory Symptoms scores were highest in the youngest (18-22 Year; M=58.76 
(SD= 16.72) and oldest age groups (>55 years (M=55.00 (SD= 24.21)) and worst in the 37-55 
years age group (M=36.30 SD= 19.90). For patients with reported Pseudomonas aeruginosa, 
lower mean scores were reported for Physical Functioning and Lower and Upper Respiratory 
Symptoms however these did not reach statistical significance. For lung function, Physical 
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Functioning scores were significantly lower in those with poor lung function, however, no 
significant associations were found on the Upper and Lower Respiratory Symptoms scores.  
As hypothesised, females reported significantly worse Lower Respiratory Symptoms 
(p=0.004) (Table 22). Although mean Treatment Burden scores were higher in males, this did 
not reach statistical significance (p=0.052). There was also no significant difference between 
males and females on the Social Functioning scale (Table 22). 
Convergent validity was tested by examining correlations between scales measuring similar 
constructs on the QOL-PCD with other validated scales: SNOT-20 (upper airway), the SF-36 
(generic health status) and the SGRQ-C (lower respiratory) (Table 23). As expected, strong 
associations were found between the QOL-PCD Upper Respiratory symptoms and the 
SNOT- 20 total score (r=0.60, p<0.01). Strong correlations were also found between QOL-
PCD Lower Respiratory Symptoms and SGRQ-C Symptoms (r=0.69, p<0.001). On the SF-
36, as hypothesised we found strong correlations between Physical Functioning and QOL-
PCD Physical scale (r=0.83, p<0.001), Role-physical and QOL-PCD Role Functioning 
(r=0.83, p<0.001) and Mental health with QOL-PCD Emotional Functioning scale (r= 0.73, 
p<0.001). In contrast, as hypothesised, much weaker relationships were found between the 
QOL-PCD scores and generic questionnaires that measured dissimilar constructs (divergent 
validity) For example, the Ear and Hearing Symptoms on the QOL-PCD correlated weakly 
with Role Functioning (r=0.39, p<0.001) on the SF-36 (Table 23). Similarly the QOL-PCD 
Lower Respiratory Symptoms scale correlated more strongly than the Upper Respiratory 
Scale, which focused on sinus symptoms, with SGRQ-C Symptoms.  
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9.4.5. Responsiveness 
Ten patients completed the measure both while stable and when they experienced a 
respiratory exacerbation. Median time from completing the QOL-PCD when stable to 
exacerbation was 54 days (range: 3-172 days). A significant reduction in scores with large 
effect sizes was found for all scales except Emotional and Social Functioning and Ear and 
Hearing Symptoms (Table 24). Changes in scores were mapped for each individual for 
Physical Functioning and Lower Respiratory Symptom scales (Figure 14). Most participants 
reported a large decrease in scores between stable and exacerbation periods with some 
individuals’ scores remaining stable. 
 
9.5. Discussion  
We have shown that QOL-PCD (Adult version) is a valid instrument to measure health 
related quality of life in patients with PCD. Psychometric testing confirmed our measure to 
be robust, reliable, responsive and valid. QOL-PCD was developed in the UK and North 
America to ensure cross-cultural equivalence in English-speaking countries (103). The QOL-
PCD has already been translated into Danish, Dutch, German (developed and linguistically 
validated for Germany and Switzerland), Greek and French; translations are progressing well 
in Turkish, Arabic, Spanish (European), Italian and Spanish (Latin America). This 
international approach is important for rare diseases since multinational clinical trials are 
needed to recruit sufficient patients. 
Our study involved the recruitment of 72 PCD patients from centres in North America (n=38) 
and the UK (n=34). All age groups were represented in the study, and participants had a 
range of disease severity (FEV1% predicted: 26%-115%). This collaborative effort allowed us 
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to recruit sufficient participants with this rare disease. However, given the modest size of the 
study population, we conducted a multi-trait analysis to develop the scales rather than an 
exploratory factor analysis, which would require over 200 patients. The multi-trait analysis 
supported the conceptual foundations of 10 scales with 40 items and has been recommended 
for use in the development of HRQoL measures which are expected to have correlations 
across domains (e.g., increased respiratory symptoms are likely to lead to decreased physical 
functioning). QOL-PCD had excellent item-to-total correlations and strong internal 
consistency across all scales (Cronbach's α 0.74 to 0.94). 
All scales were stable in an analysis of test-retest reliability over 10 to 14 days. Despite the 
small numbers of patients who completed QOL-PCD during an exacerbation (n=10) most 
scales evidenced worse mean scores than in comparison to these patients’ stable state. Scores 
for three sub-scales did not change during exacerbations (Ears and Hearing Symptoms, Social 
and Emotional Functioning) perhaps suggesting that chest exacerbations have minimal effects 
on these domains of functioning. QOL-PCD correlated with generic HRQoL measures (SF-
36, SGRQ, SNOT-20). As expected there were stronger relationships between scales 
assessing similar than dissimilar constructs.  
The QOL-PCD was generally sensitive to the changes that have been reported to occur with 
increasing age and disease severity. As hypothesised Physical Functioning scores were 
highest for those with FEV1>75% predicted and those who have never been identified with 
Pseudomonas aeruginosa although this did not reach statistical significance. Worsening 
quality of life with age has previously been described in a PCD study using generic measures 
(113) and decreases with age group were also found in this study for both Physical 
Functioning and Lower Respiratory Symptoms. Unexpectedly, the lowest QOL-PCD score in 
the Upper and Lower Respiratory Symptom scales were in our 37-55 years age group, with 
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scores increasing again in the ≥55 year age group. This may reflect specific challenges for 
this age group in comparison to those who are older e.g. lack of time to fit in treatments due 
to careers and families, or perhaps a survivor effect i.e. those who have survived to 55 years 
may have milder disease. This highlights the kinds of information that can be derived from 
HRQoL measures, reflecting the impact of disease management (i.e., adherence to prescribed 
treatments) and progression of disease. 
QOL-PCD has advantages over physiological or radiological assessments of disease. By 
facilitating discussion on issues that are of importance to patients, clinicians can focus 
attention on their patient’s perceptions of their illness, facilitating collaborative care and 
shared medical decision-making. Moreover, patient’s perceptions of improved functioning 
that are not reflected in other physiological outcomes may be important factors in promoting 
adherence to treatments. 
QOL-PCD has also been developed for children (aged 6-12 years), adolescents (aged 13-17 
years) and for parents (proxy) of children aged 6-12 years. QOL-PCD has been translated 
into six conceptually and linguistically equivalent language versions; a number of further 
translations are in progress, each following a protocol-led process of forward and back 
translation followed by cognitive testing. Validation of the remaining age-specific tools and 
different languages is underway. Studies will also be needed to demonstrate equivalence 
between computerised and paper administrations. As the QOL-PCD is used in clinical trials 
we will need to determine the minimal clinical important difference score to allow for 
interpretation of changes in scores. 
The adult version of QOL-PCD is ready for use in clinical trials to assess the benefits of 
medications or non-pharmacological interventions. It can also be used to understand the 
natural course and progression of the disease in terms of its effects on physical, emotional, 
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role and social functioning. We propose QOL-PCD as a tool to be used at annual assessments, 
providing a broad assessment of well-being, as perceived by the patient.  
 
9.6. Conclusion 
In summary, we have developed (103) and validated the first health-related quality of life 
instrument specific for PCD. QOL-PCD is valid and reliable; it is short and easy for patients 
to complete and provides a promising outcome measure for use in clinical trials and clinical 
practice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 185 
 
Figure 14: Change in Quality of Life-Primary ciliary dyskinesia (QOL-PCD) from 
stable time point to day of exacerbation. A, Lower Respiratory Symptoms scores B, 
Physical Functioning. (n=10) 
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Table 19: Participant characteristics by country of residence 
 United Kingdom 
N=34 
USA and Canada 
N=38 
 
Female n (%) 
 
20 (58.8) 
 
29 (76.3) 
Age, mean in years (SD)  
Range 
18-32 years n (%) 
33-55 years n (%) 
>55 years n (%) 
34.8 (17.3) 
18-79 
22 (64.7) 
4 (11.8) 
8 (23.5) 
31.0 (12.9) 
18-65 
24 (63.2) 
12 (31.6) 
2 (2.6) 
 
FEV1 % predicted, mean (SD) 
Range 
Missing n (%) 
 
72 (26) 
26-115 
1 (3) 
 
66 (19) 
33-101 
1 (3) 
 
FEV1 % predicted >80%, n (%) 
Missing n (%) 
 
12 (35) 
1 (3) 
 
8 (21) 
1 (3) 
 
Past/current growth of pseudomonas aeruginosa, n (%) 
Missing n (%) 
 
 
11 (32) 
2 (6) 
 
 
23 (61) 
1 (3) 
 
Education, n (%) 
Second level or less 
Some college 
College graduate/post graduate 
Missing 
 
 
11 (32) 
4 (12) 
16 (47) 
3 (9) 
 
 
8 (21) 
7 (19) 
21 (55) 
2 (5) 
 
Working status, n (%) 
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Part time or full time employment 
Full time homemaker 
Attending education courses outside the home 
Attending education courses inside the home 
Not working due to health 
Not working for other reason 
Retired 
18(52.9) 
1 (2.9) 
7(20.6) 
0 (0) 
3 (8.8) 
3 (8.8) 
2 (5.9) 
 
7 (18.4) 
13 (34.2) 
6 (15.8) 
3 (7.9) 
2 (5.3) 
6 (15.8) 
1 (2.6) 
 
Ethnicity, n (%) 
White 
Black 
Hispanic 
Asian 
Other 
Missing 
 
 
32 (94.1) 
0 (0) 
0 (0) 
0 (0) 
2 (5.9) 
0 (0) 
 
 
31 (81.65) 
0 (0) 
2 (5.3) 
2 (5.3) 
1 (2.6) 
2 (5.3) 
 188 
 
Table 20: Multi-trait analysis of QOL-PCD scales showing item to scale correlations: 
Physical Functioning, Emotional Functioning, Treatment Burden, Social Functioning, 
Role Functioning, Health Perception, Vitality, Upper Respiratory Symptoms, Lower 
Respiratory symptoms and Ear and Hearing Symptoms (n = 72, adults>18 years). We 
required item to scale correlations >0.40 with the intended scale (shaded) and much 
lower correlations with the competing scales. 
 
 
Physical Emotional Treatment Social Role Health Vitality 
Upper 
Respirator
y 
Lower 
Respirator
y Hearing 
Physical 1 0.880 0.502 0.463 0.408 0.705 0.728 0.527 0.387 0.715 0.474 
Physical 2 0.873 0.471 0.445 0.393 0.762 0.688 0.465 0.243 0.542 0.364 
Physical 3 0.863 0.445 0.424 0.328 0.629 0.672 0.508 0.229 0.590 0.315 
Physical 4 0.801 0.323 0.315 0.266 0.562 0.528 0.371 0.154 0.461 0.359 
Physical 5 0.906 0.515 0.573 0.196 0.742 0.711 0.471 0.430 0.659 0.395 
Emotional 1 0.495 0.766 0.343 0.247 0.523 0.623 0.514 0.299 0.402 0.239 
Emotional 2 0.428 0.782 0.281 0.316 0.408 0.466 0.374 0.267 0.453 0.300 
Emotional 3 0.309 0.723 0.281 0.121 0.361 0.452 0.390 0.265 0.273 0.196 
Emotional 4 0.307 0.629 0.366 0.220 0.404 0.450 0.295 0.368 0.306 0.345 
Emotional 5 0.418 0.757 0.444 0.161 0.416 0.527 0.539 0.471 0.512 0.330 
Treatment 1 0.397 0.198 0.598 0.137 0.542 0.497 0.244 0.217 0.259 0.164 
Treatment 2 0.423 0.330 0.805 0.236 0.527 0.550 0.409 0.288 0.414 0.333 
Treatment 3 0.280 0.308 0.730 0.211 0.407 0.312 0.462 0.381 0.318 0.313 
Treatment 4 0.368 0.505 0.736 0.262 0.522 0.596 0.628 0.445 0.472 0.239 
Social 1 0.273 0.161 0.284 0.814 0.357 0.452 0.324 0.055 0.286 0.055 
Social 2 0.151 0.231 0.220 0.861 0.185 0.306 0.367 0.015 0.138 -0.006 
Social 3 0.431 0.206 0.157 0.710 0.447 0.364 0.327 0.100 0.193 0.250 
Role 1 0.562 0.336 0.434 0.204 0.731 0.431 0.225 0.432 0.498 0.389 
Role 2 0.741 0.508 0.668 0.305 0.868 0.774 0.594 0.359 0.535 0.354 
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Role 3 0.647 0.493 0.588 0.406 0.899 0.751 0.521 0.382 0.541 0.417 
Role 4 0.717 0.548 0.598 0.314 0.812 0.746 0.629 0.372 0.664 0.395 
Health 1 0.529 0.506 0.563 0.541 0.628 0.808 0.580 0.328 0.427 0.263 
Health 2 0.608 0.563 0.435 0.293 0.686 0.784 0.442 0.388 0.666 0.386 
Health 3 0.697 0.642 0.662 0.391 0.725 0.923 0.678 0.307 0.585 0.396 
Health 4 0.704 0.524 0.560 0.301 0.582 0.781 0.653 0.364 0.628 0.386 
Vitality 1 0.577 0.576 0.458 0.382 0.394 0.533 0.893 0.337 0.410 0.269 
Vitality 2 0.681 0.377 0.428 0.400 0.549 0.647 0.749 0.271 0.463 0.396 
Vitality 3 0.354 0.526 0.618 0.240 0.526 0.594 0.836 0.322 0.380 0.290 
Upper Resp 1 0.311 0.316 0.274 0.041 0.366 0.307 0.221 0.836 0.484 0.281 
Upper Resp 2 0.315 0.406 0.462 0.085 0.402 0.373 0.352 0.827 0.452 0.439 
Upper Resp 3 
0.210 0.322 0.227 
-
0.074 
0.321 0.222 0.267 0.762 0.374 0.287 
Upper Resp 4 0.249 0.342 0.366 0.129 0.347 0.380 0.288 0.821 0.456 0.470 
Lower Resp 1 0.513 0.428 0.467 0.194 0.543 0.599 0.391 0.472 0.821 0.429 
Lower Resp 2 0.463 0.460 0.380 0.079 0.522 0.501 0.362 0.507 0.717 0.414 
Lower Resp 3 0.343 0.127 0.323 0.162 0.400 0.352 0.230 0.250 0.649 0.267 
Lower Resp 4 0.367 0.240 0.314 0.351 0.336 0.458 0.298 0.281 0.679 0.286 
Lower Resp 5 0.461 0.488 0.355 0.144 0.443 0.452 .346 0.503 0.751 0.496 
Lower Resp 6 0.711* 0.546 0.490 0.263 0.615 0.643 0.467 0.455 0.694 0.448 
Ear and Hear 
1 
0.416 0.415 0.315 0.107 0.443 0.478 0.424 0.434 0.538 0.931 
Ear and Hear 
2 
0.364 0.232 0.292 0.073 0.357 0.289 0.221 0.408 0.435 0.886 
†Item-scale correlation to intended scale 
* item correlation with competing scale higher than its correlation with its own scale. 
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Table 21: QOL-PCD scales’ internal consistency measured by Cronbach’s alpha and 
test-retest reliability measured by intraclass coefficients (ICC). Cronbach’s alpha >0.7 
indicates good internal consistency. ICC >0.6 indicates good stability and >0.75 
excellent stability of the scales. 
QOL-PCD (Adult) Scales No. of 
Items 
Mean (SD) 
of scales 
Cronbach’s 
α 
N=72 
ICC (95% CI) 
N=35 
 
 
Physical Functioning 
 
5 
 
70.51 (30.37) 
 
0.94 
 
0.94 (0.89-0.97) 
Emotional Functioning 5 73.68 (19.56) 0.83 0.91 (0.82-0.95) 
Treatment Functioning 4 60.80 (23.70) 0.75 0.92 (0.82-0.96) 
Social Functioning 3 38.11 (29.47) 0.74 0.73 (0.47-0.87) 
Role Functioning 4 64.23 (28.98) 0.86 0.94 (0.88-0.97) 
Health Perception 4 51.16 (26.32) 0.83 0.91 (0.82-0.95) 
Vitality 3 53.76 (21.93) 0.79 0.88 (0.75-0.94) 
Upper Respiratory Symptoms 4 45.83 (26.76) 0.83 0.91 (0.81-0.95) 
Lower Respiratory Symptoms 6 47.30 (15.49) 0.83 0.92 (0.85-0.96) 
Eat and Hearing Symptoms 2 61.81 (28.59) 0.79 0.96 (0.87-0.97) 
 
 
 
 
 
 191 
 
Table 22: QOL-PCD scales mean scores and standard deviations (SD) for participant characteristics where we had hypothesised an 
association a priori. 
 Physical 
Functioning 
 
Social Functioning Vitality Treatment 
Burden 
Upper 
Respiratory 
Symptoms 
Lower 
Respiratory 
Symptoms 
Gender 
Male (n=23) 
Female (n=49) 
 
_ 
 
 
43.96 (32.74) 
35.37 (27.74) 
p=0.284 
 
_ 
 
 
69.61 (19.75) 
57.62 (24.37) 
p=0.052 
 
_ 
 
 
58.70 (15.32) 
43.20 (20.36) 
p=0.004 
Age 
18-22 years (n=26) 
23-36 years (n=21) 
37-55 years (n=15) 
>55 years (n=10) 
 
88.21 (15.81) 
69.21 (29.63) 
56.88 (32.35) 
49.33 (34.88) 
p<0.001 
 
_ 
 
58.55 (20.50) 
52.91 (20.20) 
46.66 (20.30) 
48.88 (23.54) 
p=0.355 
 
_ 
 
46.47 (23.35) 
43.25 (30.80) 
42.22 (27.72) 
55.00 (26.41) 
p=0.655 
 
58.76 (16.72) 
40.21 (19.63) 
36.30 (19.90) 
55.00 (24.21) 
p=0.001 
Pseudomonas 
Yes (n=34) 
No (n=35) 
 
63.92 (33.43) 
76.38 (26.78) 
p=0.092 
 
_ 
 
_ 
 
_ 
 
43.63 (26.75) 
48.57 (27.08) 
p=0.448 
 
44.12 (20.51) 
52.22 (21.86) 
p=0.117 
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FEV1 % pred 
<40 (n=11) 
≥40<60 (n=14) 
≥60<75 (n=16) 
≥75 (n=29) 
 
41.82 (30.12) 
63.81 (32.94) 
77.33 (29.04) 
80.46 (23.70) 
p<0.02 
 
_ 
 
_ 
 
_ 
 
59.09 (24.28) 
45.83 (26.90) 
41.67 (28.87) 
43.68 (26.51) 
p=0.364 
 
44.44 (26.99) 
42.86 (25.17) 
48.88 (17.21) 
51.92 (19.49) 
p=0.563 
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Table 23: Convergent validity testing: Spearman’s rank correlation coefficients between scales from QOL-PCD and generic health 
related quality of life measures (SNOT-20, SGRQ-C and SF-36). We a priori hypothesised scales that would have stronger correlations 
(closer to 1 or -1); these correlations are shadowed grey. 
 SNOT-
20 
SGRQ-C SF-36 
 
Scales of 
QOL-PCD  
 Total Symptoms Activity Impacts Physical 
function
ing 
Role- 
Physica
l 
Bodily 
pain 
General 
health 
Vitality Social 
functio
ning 
Role 
functio
ning 
Mental 
health 
Total 
Physica
l score 
Total 
Mental 
score 
                
Physical 0.51 -0.83 -0.78 -0.85 -0.74 0.83 0.79 0.54 0.79 0.65 0.62 0.49 0.46 0.84 0.37 
Emotional -0.48 -0.52 -0.04 -0.47 -0.54 0.47 0.55 0.60 0.63 0.61 0.67 0.60 0.73 0.57 0.69 
Treatment -0.61 -0.67 -0.61 -0.54 -0.65 0.54 0.67 0.78 0.66 0.54 0.50 0.54 0.38 0.71 0.36 
Social -0.21 -0.43 -0.40 -0.28 -0.48 0.34 0.35 0.32 0.42 0.46 0.28 0.27 0.34 0.39 0.27 
Role -0.60 -0.80 -0.73 -0.67 -0.78 0.73 0.84 0.68 0.79 0.69 0.72 0.44 0.47 0.86 0.43 
Health -0.64 -0.84 -0.76 -0.72 -0.84 0.71 0.79 0.76 0.87 0.79 0.76 0.50 0.62 0.87 0.56 
Vitality -0.46 -0.63 -0.67 -0.49 -0.59 0.59 0.56 0.60 0.72 0.75 0.52 0.43 0.39 0.69 0.43 
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Upper  
respiratory 
-0.60 -0.39 -0.31 -0.31 -0.39 0.36 0.51 0.54 0.48 0.35 0.42 0.37 0.39 0.48 0.35 
Lower 
respiratory 
-0.53 -0.72 -0.69 -0.61 -0.69 0.59 0.69 0.58 0.75 0.67 0.59 0.43 0.49 0.69 0.49 
Ear and 
Hearing 
-0.57 -0.47 -0.40 -0.36 -0.49 0.51 0.49 0.46 0.66 0.55 0.51 0.39 0.46 0.56 0.47 
 
SGRQ = St. George Respiratory Questionnaire (higher score indicates worse HRQoL) and SF-36 = Medical Outcome Survey Short Form-36 (higher score 
indicates better health status).  
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Table 24: Responsiveness to change was measured, paired t-tests compared scores (SD) 
for each scale in 10 patients who completed QOL-PCD whilst stable and during an 
exacerbation. 
 
 Stable 
Mean (SD) 
Exacerbation 
Mean (SD) 
Mean Difference 
(95% CI) 
P-value Effect size 
Physical 
41.33 (37.55) 26.00 (34.20) 15.33 
(1.47-29.20) 
0.03 0.43 
Emotional 
67.33 (27.12) 63.33 (23.63) 4.00 
(-6.35-14.35) 
0.41 0.16 
Treatment 
49.16 (26.77) 39.16 (23.58) 10.00 
(0.05-20.05) 
0.05 0.40 
Social 
38.88 (26.31) 43.33 (21.24) -4.44 
(-20.42-11.54) 
0.54 0.19 
Role 
45.83 (36.05) 31.66 (30.63) 14.16 
(4.41-23.92) 
0.01 0.42 
Health 
38.33 (27.8) 27.50 (20.80) 10.83 
(20.58-1.08) 
0.03 0.44 
Vitality 
45.55 (25.89) 27.77 (22.98) 17.77 
(3.66-31.91) 
0.02 0.73 
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Upper respiratory 
45.83 (22.65) 36.66 (26.11) 9.16 
(0.34-18.67) 
0.05 0.38 
Lower respiratory 
38.88 (24.14) 28.33 (19.67) 10.56 
(0.74-20.37) 
0.03 0.48 
Ears and Hearing 
41.66 (29.65) 43.33 (28.54) -1.66 
(-14.78 - -11.45) 
0.78 0.06 
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10. General Discussion 
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This thesis has led to major advances in the field of PCD; from diagnosis to the treatment and 
management of patients. The development and validation of the first predictive score for 
diagnosing PCD based on clinical symptoms will lead to earlier referral of patients and 
improved awareness among medical practitioner of the signs and symptoms of PCD. The 
development and validation of QOL-PCD has provided the first patient-reported outcome 
measure for this illness for use in clinical trials assessing new and existing treatments.  The 
systematic review, international survey and series of interviews have provided a detailed 
insight into patient perspectives and experiences with PCD. Based on the results and tools 
developed in this thesis, a model has been developed showing how the findings link together 
under the biopsychosocial framework (Figure 15). 
 
10.1. Main findings 
10.1.1. Diagnosing PCD 
10.1.1.1. Delayed diagnosis 
The results presented in the thesis showed that PCD was diagnosed late among study 
participants. Furthermore, patients attributed their late diagnosis to the widespread lack of 
PCD awareness among medical practitioners. Patients who suffer from rare diseases often 
encounter particular difficulties that those diagnosed with more prevalent and common 
diseases do not. These include barriers in scientific knowledge, organisational barriers, 
financial barriers, and personal barriers. A report by EURORDIS (Rare Disease Europe) on 
the experiences and expectations of patients with rare diseases, has shown that a lack of 
awareness of the clinical manifestations of a rare disease may lead to diagnostic delay, failure 
of diagnosis, and misdiagnosis (183). In the European Organisation of Rare Diseases, 
summarised in The Lancet (184), diagnostic delay has been shown to lead to loss of 
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confidence in the health-care system, feelings of rejection and marginalisation, confusion, 
worry, and fear. These findings have certainly been echoed in our findings.  
Delayed diagnosis in PCD has been well documented in previous studies (25, 109, 110), 
however the reasons for and the implications of a delayed diagnosis from the patient’s 
perspective has not been presented until now. In Chapter 3, patients discussed the journey to 
referral in a series of semi-structured interviews (112). A delayed diagnosis was primarily 
recognised as being due to a lack of PCD awareness by medical professionals. This was also 
reflected in the survey, with 37% of PCD international respondents reporting that they visited 
their doctor on >40 occasions for PCD-related symptoms before it was considered a possible 
diagnosis. Nearly all parent interviewees (92%) reported that their child had respiratory 
distress at birth and neonatal symptoms, but only 27% were referred at this stage for testing.  
Participants diagnosed later in life felt that the underlying cause of their symptoms was not 
considered nor was their past medical history taken into account when presenting to their 
medical practitioner with symptoms. All adult interviewees were diagnosed late in life (>30 
years of age) and felt that their current state of health might have been better had they been 
diagnosed earlier. These findings were supported in the systematic review (Chapter 4), where 
two studies reported that later PCD diagnosis was associated with poorer subsequent health-
related quality of life (107, 113). To prevent a delayed diagnosis, participants felt that 
medical professionals need to be better educated about PCD, its signs and symptoms, and the 
need to take past medical history into account, i.e. neonatal symptoms. This study shows a 
clear need to educate non-expert clinicians on guidelines published a quarter of a century ago 
which stated that individuals with chronic upper and lower airway symptoms should be 
investigated for PCD, particularly if symptoms began early in life (102).  
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In order to address the lack of PCD awareness among physicians, PICADAR was developed 
(Chapter 6) (167). It is hoped that the development and validation of this clinical predictive 
rule will raise awareness of the clinical features associated with PCD and will aid appropriate 
referral of patients for diagnostic testing. PICADAR is the first validated tool to predict the 
probability of a PCD diagnosis based on clinical symptoms. The score applies to patients 
with persistent wet cough and has seven predictive parameters: full-term gestation, neonatal 
chest symptoms, neonatal intensive care admittance, chronic rhinitis, ear symptoms, situs 
inversus and congenital cardiac defect.  It is designed to be easily applied in a non-specialist 
setting to determine which patients, with chronic chest symptoms, should be referral for PCD 
diagnostic testing. As it has been developed in a tertiary care centre, it is not aimed for use in 
primary care, however it could serve to raise awareness among general practitioners and 
neonatologists of the signs and symptoms associated with PCD. It could be then used by 
respiratory centres as a cost effective tool to guide referral of high risk patients to specialist 
PCD centres.  
PICADAR, when using a cut-off score of ⩾5 had 90% sensitivity and 75% specificity to 
differentiate PCD-positive and PCD-negative patients. When validated in a second centre, it 
had 86% sensitivity and 73% specificity. If patients with a score ⩽4 had not proceeded to 
further testing, 167 (70.2%) and 57 (73.1%) negative patients in the development and 
validation group respectively would have avoided formal testing at the diagnostic centres. 
However, it would have also resulted in two (4.0%) positive patients in the developmental 
group and 11 (13.9%) in the validation group being missed. The tool should not be used in 
isolation when deciding who to refer; however widespread use of PICADAR would 
inevitably increase awareness and lead to an increase in the number of actual diagnoses.   
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Since the publication of PICADAR, a study from Leigh et al (185) has developed a clinical 
screening tool for children and adolescents that is also based on symptoms. Experts defined a 
priori and tested 5 clinical features apparent in early childhood, and found 4 to be alone or in 
combination predictive of PCD: (1) unexplained neonatal respiratory distress with 
supplemental oxygen requirement more than 24 hours in term infants; (2) early-onset, year-
round, wet cough; (3) early-onset, year-round nasal congestion; and (4) laterality defects. 
Sensitivity and specificity is based on the number of clinical features. This showed that the 
presence of 4 features had a sensitivity and specificity of 0.21 and 0.99, respectively. Three 
features had sensitivity and specificity of 0.50 and 0.96, respectively and 2 features was 0.80 
sensitive and 0.72 specific. Adapting PICADAR using these more detailed and extended 
questions may improve the specificity of our tool; however it is also possible that the 
sensitivity could be reduced. 
PICADAR has been included in European Respiratory Society (ERS) Taskforce Guidelines 
for diagnosing PCD, for which I was a junior member. These guidelines have recently been 
submitted to the European Respiratory Journal (ERJ) (Appendix 8). It has been recommended 
as a tool to be used in identifying patients for diagnostic testing but should only be used in 
isolation in certain circumstances i.e. specialist respiratory centres.   
 
10.1.1.2. Screening for PCD 
To improve early diagnosis in PCD, screening has been explored in a number of studies. 
Nasal nitric oxide has been shown to provide a good screening tool (14, 53) to differentiate 
between symptomatic patients with and without PCD. The technique, however, is 
insufficiently standardised, with different centres using their own reference values and 
proposed cut-off values range from 25 to 126 nL-min·1(53). nNO is not 100% sensitive, 
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ranging between 75% and 100% in different studies using different cut-off values (53). The 
equipment for measuring nNO is not widely available outside specialist centres and it 
requires trained technicians to obtain reliable readings.   
In Chapter 5, nasal nitric oxide was examined as a screening test in a referral population of 
symptomatic patients (101). Using the arbitrary cut-off value of 30 nL·min
−1
, sensitivity and 
specificity were found to be 0.91 and 0.96, respectively. This shows that 9% of PCD cases 
could have been missed if this test was completed in isolation. If a higher cut-off value was 
used, for example the value of 77 nL·min
−1
 as recommended by Leigh et al (14); sensitivity 
in our sample would have improved to 96%, but specificity would have reduced to 83%. 
When nNO was tested using a higher cut-off value, it had a greater sensitivity but showed 
that still 4% of cases could be missed.  
If nNO were to be used more widely as a screening test for PCD, greater guidance would be 
needed to ensure a cost effective approach and to prevent it from overburdening diagnostic 
services. In Chapter 5, the positive predictive value (PPV) and negative predictive value 
(NPV) of nNO at the cut of value of 77 nL·min
−1 
were found to be 42.6% (95% CI 30.2% to 
54.5%) and 99.1% (96.6% to 99.9%) respectively. This means that approximately 60% of 
patients with a positive test did not have the disease.  
In order to investigate the possible consequences of screening in different populations, I 
participated in a further study to model PPV and NPV of nNO in several theoretical scenarios 
(186) (Appendix 11).  The prevalence of PCD in the general population is around 1:10 000. 
Predictive values are dependent on the prevalence of the disease in the tested population.  If 
PCD was universally screened using nNO, the PPV would only be 0.1%, making it 
impractical as a screening tool.  Previous data from children have suggested that the 
prevalence of PCD in those with recurrent wet cough is 5% (187), which would give a PPV 
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of 23.6% and NPV of 99.6%, indicating that this group could a target population for nNO 
screening. It is also suggested that patients with non-cystic fibrosis bronchiectasis could be 
targeted for screening with a systematic review of 989 patients showing 9% of this population 
had PCD (186, 188). PICADAR (Chapter 6) has a similar PPV (49%) to that of nNO at 77 
nL·min
−1
 when used in a specialist centre. If PICADAR were used as a screening tool in the 
general population, it would also prove to be an impractical screen (PPV 0.1%). 
Another approach could be to use PICADAR to provide guidance on who to refer for nNO 
screening. In resource limited countries with no diagnostic facilities, both methods used in 
combination could be used to attach a PCD-likelihood to the patients. I have conducted the 
analysis to establish the sensitivity and specificity of using both methods simultaneously 
(Abstract accepted European Respiratory Congress 2016, (Appendix 10). At a cut-off value 
of >5 points, PICADAR alone had sensitivity 0.88 and specificity of 0.95. Accuracy varied 
when combined with nNO thresholds and sensitivities were 0.94, 0.94 and 1.0 using cut-off 
values of 30 nL min
−1
 , 77nL min
−1
  and 100nL min
−1
  nNO.  Respective specificities were 
0.89, 0.78 and 0.73 using 30 nL min
−1
 , 77 nL min
−1
 and 100 nL min
−1
. Using a combined 
approach, PICADAR and nNO testing can provide a highly sensitive method for patient 
selection with a 100nl/min nNO threshold giving a sensitivity (and hence NPV) of 100%. The 
PPV of this method is 0.50. This approach could greatly improve the effective use of PCD 
diagnostic resources. 
 
10.1.1.3. The importance of combination diagnostic testing  
There is no ‘gold standard’ reference test for diagnosing PCD. In Chapter 5, the importance 
of combination diagnostic testing was highlighted (101). Data from patients who had 
undergone all tests; nNO, HSVMA and TEM (n=180) were used to calculate the accuracy for 
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possible combinations of tests. Two-stage testing based on nNO pre-screening followed by 
TEM potentially missed approximately 40% of PCD cases showing that 33 nL min
−1
 cut-off 
is probably too low for use as a screening threshold and that HSVMA needs to be taken into 
account. Using all three tests simultaneously (where any abnormal test leads to a positive 
result), sensitivity was 100% and specificity was 87%. This showed the importance of the 
multidisciplinary combination approach where no test was considered in isolation.  
The results from this study have contributed to the new ERS Taskforce Guidelines (Appendix 
8). The guidelines are based on an assessment of the following diagnostic techniques: clinical 
presentation, nasal nitric oxide, analysis of ciliary beat frequency by high-speed video 
microscopy analysis, transmission electron microscopy, genotyping, and 
immunofluorescence through a systematic review of the literature. Assessment of the 
evidence was conducted using the GRADE (Grading of Recommendations, Assessment, 
Development and Evaluation) (189, 190) approach. Subsequently, an algorithm was 
developed for the use of diagnostic tests to definitively confirm and exclude the diagnosis of 
PCD. Using modified Delphi approach (191), consensus agreement was reached that a 
conclusive positive diagnosis can only be determined if a patient has a supportive history of 
PCD, shows a confirmatory hallmark ciliary ultrastructure defects for PCD through TEM or 
has mutations in PCD causing genes. It must be stressed, however, that these tests will miss a 
minority of positive cases. Consensus was not reached (<80% consensus) that any other test 
in isolation or in combination could provide a conclusive positive diagnosis. A ‘highly likely’ 
diagnosis can be provided in patients with: a combination of a compatible history of PCD, 
very low nNO and HSVMA findings (static or circling cilia) consistently suggestive of PCD 
on three occasions,  or have very low nNO plus HSVMA findings consistent with PCD 
following cell culture.   
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Good communication between patients and the diagnostic team is of high importance here 
highlighting the inter-relatedness of biophysical, social and psychological factors.  When 
diagnosis is ‘highly likely’ but not conclusive, patients must be told that the diagnosis is 
likely but not 100% certain and they may need to receive additional confirmation when better 
tests become available. Patients should also have other causes for their symptoms excluded 
and should be treated as if they have PCD.  
 
10.1.1.4. Inconclusive diagnosis 
An inconclusive diagnosis in any disease can generate feelings of uncertainty, self-doubt, 
stress and distress (192). A qualitative study by Nettleton et al. (2004) explores the narratives 
of patients who live with medically unexplained symptoms and who have not secured a 
diagnostic label. It found that patients represent their illness in terms of "chaos narratives" 
characterised by "confusion and uncertainty" and "a merry-go-round of hope and despair". It 
also suggests that a prolonged pre-diagnostic period is stressful and traumatic and may 
produce serious repercussions on the mental health of the patients involved (193).  
According to the European Taskforce Guidelines (Appendix 8), an inconclusive diagnosis 
can be determined if a patient was found to have equivocal results following nNO, HSVMA, 
TEM, genetics and repeated HSVMA following cell culture. In the UHS longitudinal 
database, of the 868 referrals, 13 (1%) had an inconclusive diagnostic outcome despite 
adequate samples (Chapter 5). Many cases can remain inconclusive despite expert testing 
because both TEM and genetics are not sufficiently sensitive, and HSVMA and ALI cultures 
are often unclear due to poor health of the cells causing secondary defects.  
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In Chapter 3, participants who experienced an inconclusive diagnostic result endorsed the 
sentiments described by Nettleton; that of uncertainty, self-doubt and stress (112). The 
practical constraints of such an outcome were also discussed. These were often country-
specific with participants from countries such as the USA having difficulties accessing 
insurance for treatments without a definitive diagnosis. The impact of receiving a 
confirmatory positive diagnosis following years of having an inconclusive label led to a 
profound sense of validation and relief; a label had finally been provided.   
Disbelief that diagnostic testing in PCD cannot always provide a confirmatory positive or 
negative diagnosis was evident from the interviews. This frustration relating to inconclusive 
results has been found in other diseases e.g. genetic testing for BRCA1 and BRCA2, which 
causes increased risk of breast and ovarian cancer (192).  Based on the themes that emerged 
from Chapter 3, it would seem that the needs of patients who have received inconclusive 
results are not always met. A number of suggestions for improved care of patients with 
inconclusive results can be adapted from diseases outside PCD. Hallowell et al. (194), 
recommended that all persons who were informed that they had an inconclusive test result 
should have a follow-up session with a clinician either by telephone or in person. Ardern-
Jones et al. (192) suggested annual telephone contact be provided to inconclusive patients to 
update them on advances in diagnostic testing status. This has also been suggested in recent 
European Consensus Guidelines (Appendix 8) which expresses the importance for PCD 
clinicians to recall inconclusive patients for further testing as advances in PCD diagnostics 
are made.  As PCD is often diagnosed through outreach clinics where professionals may not 
immediately be aware of new developments in diagnostics, Ardern-Jones et al. (192) 
advocates that health professionals caring for patients with inconclusive diagnostic results be 
also updated continuously on new scientific discoveries.  
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10.1.2.  Prevalence and impact of symptoms  
The prevalence of each of the 26 clinical features published in Chapters 5 and 6 (101, 167) 
were presented for both positive and negative referrals. Persistent daily wet cough (93%) and 
persistent perennial rhinitis (83%) were the most prevalent symptoms reported by positive 
PCD patients. In a recent systematic review and meta-analysis of clinical manifestations in 
PCD (37), prevalence of wet cough varied between 14-100%; however the weighted mean 
was 88%. Rhinitis, rhinorrhoea or nasal congestion ranged in prevalence from 9-100%, 
against the weighted mean of 75%. In the UHS dataset, the prevalence of hearing loss was 
49%. Again heterogeneity was reported in the meta-analysis where prevalence ranged from 8 
to 100% (weighted mean 36%).  
A number of reasons could account for such heterogeneity. It could be attributed to 
differences in the definition of symptoms in each study. It could also be related to differences 
in diagnostic protocol, study design, or selection of study populations. As most studies 
originated from specialised clinics, it is expected that patients with more severe 
manifestations were included and these study populations cannot be considered representative 
for all PCD patients. The type of clinic and where the study population originated from i.e. 
from pulmonologists, ENT specialist or fertility specialist, can also influence the prevalence 
of reported symptoms. 
 
In Chapter 6, situs abnormalities were found in 44% of patients and congenital cardiac 
defects in 8% of the positive group. The prevalence of situs anomalies in the 43 eligible 
studies in the systematic review ranged from 11-90% (weighted mean: 49%). Situs 
abnormalities were reported to be more common in adult patients, probably due to the fact 
that adults without situs anomalies or severe lung disease were underdiagnosed, especially in 
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the past. The prevalence of congenital heart disease has less heterogeneous across studies 
with a range of 3-8%, likely due to the lower possibility of misclassification bias. Fertility 
data was only available for 23% of the total referrals in UHS because a large proportion was 
children or young adults. In those with available data, infertility or subfertility was reported 
in 90% of patients; however this was not stratified by sex. In the systematic review it ranged 
from 15-79%. Again this could be higher in older study group or with some studies applying 
the application of sensitive testing for detection e.g. spermatozoa analysis (37).  
 
The clinical findings reported in Chapter 5 and 6, has also been included in the systematic 
meta-analysis to inform the ERS Taskforce Guidelines. A recommendation (labelled a 
‘strong’ recommendation) has been made to refer patients for testing if they have several of 
the following features; persistent wet cough; situs anomalies; congenital cardiac defects; 
persistent rhinitis; chronic middle ear disease with or without hearing loss; a history in term 
infants of neonatal upper and lower respiratory symptoms or neonatal intensive care 
admittance.  
 
Here we can see how biological factors can influence the social and psycholoical domains. 
 
 Open-ended interviews with adults, children, teenagers, and parents conducted during the 
development of the HRQoL measures (QOL-PCD) in Chapter 8 (and Appendix 7) confirmed 
the burdensome nature of symptoms such as wet productive cough, runny nose and hearing 
impairment (103). Adults also reported that these symptoms can sometimes impact on their 
sense of taste and smell. The impact of symptoms on physical functioning was well 
documented among adult interviewees who reported the physical difficulty of keeping up 
with family and friends. Impact on physical functioning has previously been reported in the 
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paediatric population where children reported not being able to run as fast as other children, 
not being able to keep up with peers in sports, needing to take regular breaks, and having to 
stop to cough when engaging in activities (78, 124). All age groups described the impact of 
respiratory symptoms and the constant need to cough. Getting out of breath from physical 
activity and from coughing was discussed as well as difficulty breathing when experiencing 
an exacerbation. For both adults and children, hearing problems were discussed and both 
groups described the social impact of having to constantly ask people to repeat themselves. 
Children also reported having ear infections and the embarrassment of ear drainage. All age 
groups described the impact of upper respiratory symptoms, with children describing rhinitis 
as ‘a constant sniff’ and sinus pain as ‘a pain that stings and feels like somebody's pushing 
down on my sinuses’. Among older adults, the decline in respiratory health over the years 
was reflected upon. Younger adults expressed their worry on the possibility of infertility, 
while older adults discussed the personal and social impact infertility has had or continues to 
have on their lives. 
The impact of these symptoms on HRQoL has been shown for the first time in the validation 
of the QOL-PCD (195) (Chapter 9). This manuscript has been submitted to the American 
Journal of Respiratory and Critical Care Medicine (AJRCCM) and is currently under review. 
Adults had low mean scores for upper and lower respiratory symptoms at 46/100 and 47/100 
points. We did not expect that reported mean scores for respiratory symptoms would be lower 
(indicating worse quality of life) than mean score reported by cystic fibrosis patients who 
completed the validation for the cystic fibrosis HRQoL questionnaire (CFQ-R). In the 
validation of the CFQ-R, respiratory symptoms mean scores ranged between 50-70 across the 
mild to severe disease groups (172). Lower respiratory symptoms scores were also lower than 
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non-cystic fibrosis bronchiectasis patients who had scores ranging between 52-60 points in 
the validation of the HRQoL questionnaire for non-cystic fibrosis bronchiectasis (176).  
This study also shows the range of severity and heterogeneity in PCD. FEV1 % predicted 
ranged from 26% to 113%. As hypothesised, Physical Functioning mean scores were highest 
(indicating better HRQoL) in those with FEV1>75% predicted, and in patients who have 
never grown Pseudomonas Aeruginosa in the past (although this did not reach statistical 
significance). Worsening HRQoL in PCD patients  has been shown to correlate with 
increasing age (using generic HRQoL measures) (113). This was also found in the validation 
of QOL-PCD study in Chapter 9. However, the lowest QOL-PCD scores in the Upper and 
Lower Respiratory Symptom scales were found in the 37-55 years age group, with scores 
increasing again in the ≥55 year age group. This may reflect specific challenges for this age 
group in comparison to older age groups e.g. lack of time to fit in treatments due to careers 
and families. These findings highlight that quality of life is a multi-faceted measure 
influenced by other factors (e.g. age, treatment adherence). 
 
10.1.3. Psychological impact of PCD 
The psychological impact of symptoms has been described above, but also presented in this 
thesis (103) (Chapters 4 and 8) (Appendix 7) (124). The paediatric groups reported feeling 
anxious and fearful about getting sick and about the chronic nature of their symptoms. In 
addition, a sense of injustice and sadness about having this condition when their peers and 
siblings were healthy was reported. The systematic review also found that PCD children were 
more likely to be withdrawn, experience anxiety or depression, and internalise more problems 
than the healthy population (77). PCD was found to also affect the parent with significantly 
higher stress being reported in mothers of children with PCD compared to mothers of health 
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children. While anxiety and depression have not yet been measured in the adult population, in 
the validation of QOL-PCD in adults, mean scores for emotional functioning were higher 
than other scales at 73.68 (SD: 19.56). Emotional functioning in adults was found to be 
similar to the mean scores reported in the validation of the HRQoL questionnaire for cystic 
fibrosis (CFQ-R) which ranged from ~68-81 across mild, moderate and severe disease status 
groups (172).      
 
10.1.4. Social impact of PCD 
Concealing PCD symptoms and embarrassment from symptoms such as coughing and 
blowing nose in public was reported in the semi-structured interviews with adults and 
children. In the validation of this measure, social functioning was found to have low mean 
scores (mean 38.11, SD29.47), lower than mean social functioning scores reported in the 
validation of the cystic fibrosis HRQoL questionnaire where scores ranged from ~65-80 
across mild , moderate and severity groups (172). Embarrassment from symptoms and 
concealment was reported across all age groups in the systematic review (78, 79). Children 
and teenagers were found to be reluctant to disclose their PCD diagnosis to teachers and 
peers. Adult patients were reluctant to disclose to work colleagues and those outside their 
family and close friends. Such concealment of symptoms and illness disclosure has been 
reported in other chronic illnesses (128-131). Chronic illness has been shown to have a 
negative impact on relationships with friends, families and peers. Results from a cystic 
fibrosis study (131) also found patients were more likely to disclose to romantic partners and 
close friends than to casual friends, bosses, or co-workers. It reported that disclosure was 
associated with higher social support, social functioning, and medication adherence self-
efficacy.  In the systematic review (Chapter 4), many of the papers document a sense of 
isolation and mistrust in medical care among PCD patients which is heightened by a lack of 
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PCD awareness by the patient’s general practitioner (79). Participants were concerned about 
the effect the delayed diagnosis has had on their health. Such mistrust of medical 
practitioners was echoed in our findings described in Chapter 3 (196).   
 
This thesis has aimed to contribute to the biopsychosocial model of PCD which states that the 
workings of the body, mind and environment all affect, and are affected by each other. This 
theory suggests that each one of these factors is not sufficient in itself to bring about the 
optimum outcome for this condition in terms of health and well-being; it is the interaction 
between them that determines the impact. In effect, the biopsychosocial model suggests that 
it is important to address all three aspects together. Based on the findings in the present series 
of studies, Figure 15 shows how the findings of this study link together under this 
biopsychosocial framework. 
 
10.2. Strengths and Limitations 
The strengths and limitations of the six papers in this thesis have also been acknowledged and 
addressed in the previous chapters. This section provides an overall synopsis of the strengths 
and limitations using a systematic approach. Checklists for systematic reviews that have been 
employed to guide the assessment of the quality of these studies i.e. STROBE (The 
Strengthening the Reporting of Observational Studies in Epidemiology)(197), QUADAS 
(quality assessment of studies of diagnostic accuracy included in systematic reviews)(198), 
CASP: Diagnostic Test Study Checklist (199); TRIPOD (Transparent reporting of a 
multivariable prediction model for individual prognosis or diagnosis) and CASP: Evaluating 
a Clinical Prediction Rule Checklist (50). 
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10.2.1.  Strengths 
This thesis has addressed a number of timely and relevant research questions in PCD today. 
The European Taskforce Guidelines (2009)(22) called for the urgent need for further research 
in PCD. The findings from this thesis have contributed to these needs but have also attributed 
to new consensus diagnostic guidelines from an ERS Taskforce (Appendix 8).  The findings 
from the PCD diagnostic accuracy study (Chapter 5) and the data collected and presented for 
the development of PICADAR (Chapter 6) has been included in the systematic reviews to 
inform these European Taskforce Guidelines for diagnosing PCD. The results from the 
survey and interviews conducted on the international diagnostic patient experience (Chapter 
3), have been used to inform all decisions reached in these guidelines.  
Chapter 3 is the first international study to be completed on the experience of patients 
referred for PCD diagnostic testing. Questions for the survey were comprehensively 
translated into 9 languages and the expertise of an international panel of PCD experts and 
patient representatives was sought on how the diagnostic experience could be fully captured. 
This is also the first study to report on the perspectives of patients referred for PCD testing 
but who were found to have a negative or inconclusive diagnostic outcome. Subgroup 
analysis per country was applied to further interpret the results and examine interactions i.e. 
differences between countries were assessed in terms of established diagnostic facilities and 
government health expenditure.  
Chapter 5 and 6 conducted analyses of consecutive referrals within a national diagnostic 
programme. This is a pragmatic study that reflects the real patient journey. High levels of 
expertise standardisation, and multidisciplinary consensus was applied in this analyses. We 
can therefore be confident these results yield the most valid estimates of diagnostic accuracy. 
Confidence in the strength of PICADAR as a predictive tool is evident through the external 
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validation in a separate diagnostic centre in the Royal Brompton Hospital in London. Good 
discriminant ability of the tool was maintained when applied to this sample with an AUC 
0.87. Although both diagnostic centres are situated in Southern England, they have different 
demographic populations in terms of ethnicity, consanguinity and age at assessment.  
Chapter 8 and Chapter 9 detail the development and validation of the adult HRQoL measure 
(QOL-PCD). The strength of this study is that QOL-PCD measure was developed using FDA 
recommended guidelines for developing patient reported outcomes for use in clinical trials 
(83). This involved a detailed iterative process which included most facets of Guyatt’s ‘Rolls-
Royce’ model (95). QOL-PCD was found to be a valid instrument to measure HRQoL when 
validated in 72 PCD adults with psychometric testing confirming the measure to be robust, 
reliable, responsive and valid. Now that the measure is complete, it will be submitted to the 
FDA and EMEA for consideration as an outcome measure for clinical trials. The most 
important principle governing the development of QOL-PCD was our inclusion of patient 
input and their perspective at each phase. A unique strength of this study is that this English 
version has been developed using a cross-cultural approach through close collaboration with 
PCD centres in the US and Canada. Thus, this tool systematically reflects how an adult with 
PCD “survives, feels, or functions” not only in English speaking patients from the UK and 
Ireland but across English speaking countries i.e. USA and Canada. 
The 2009 Taskforce Guidelines for diagnosing PCD expressed the need for high-quality 
randomised controlled multicentre trials to investigate the effect of different treatments on 
symptoms, lung function, quality of life and long-term progression of PCD. By developing 
and validating age-specific HRQoL measures, a disease-specific outcome measure is now 
available for patients with PCD. Its development will facilitate the assessment of long-term 
outcomes, spectrum and severity of clinical disease, and functional limitations of PCD. It will 
 215 
 
also allow for sensitive capture of change following an intervention or trial. Comprehensive 
translation of this HRQoL measure has been performed by the author so that QOL-PCD is 
now available in five European languages (Appendix 10). These measures are currently being 
used as an outcome measure in the BESTCILIA international randomised control trial in 
azithromycin; the first international clinical trial in PCD.  
10.2.2. Limitations 
This thesis has a number of limitations.  
In Chapter 3, a survey was distributed internationally and this was followed by a series of 
interviews assessing the diagnostic experiences of patients referred for PCD testing. Selection 
bias is possible with the main percentage of respondents originating from countries with 
established diagnostic centres i.e. UK, US, Germany and France. Bias could also have been 
introduced as only those with access to the internet, or ‘informed’ participants contacted by 
ELF and patient support groups, completed the survey. It is therefore possible that the results 
of the survey section of the study may not truly reflect the opinions of referrals from 
countries with less established diagnostic services or countries without any services available. 
The survey aimed to include patients who were referred and still waiting for results, who 
were negative for PCD or who had been found to be inconclusive for PCD and were still 
going through testing, however the majority of survey respondents (74%) were PCD positive 
with PCD negative representing only 5%, inconclusive 8%, and still waiting 3%. It is 
especially low considering that international results have found that between 11.5%-18.6% of 
referrals are eventually diagnosed with PCD (29, 58, 101, 108). This limits our capacity to 
assess the perspective of the population with an inconclusive or negative outcome. Although 
participants were asked about the tests that had been performed, their results cannot be 
verified and there is therefore diagnostic uncertainty. In addition, a number of participants’ 
 216 
 
diagnoses were based on tests that are not considered robust, e.g. the saccharine test. It is 
therefore likely that some patients may have been diagnosed who do not have PCD and vice 
versa. Since we were interested in the experiences and outcomes of patients from diverse 
clinical settings it was important to include groups where diagnostic status was uncertain. 
This inherently means that allocation of patients to diagnostic outcome groups was defined 
by the participants’ understanding rather than the diagnosis that might be provided by a 
highly specialist centre; this is at the same time a strength and a weakness of the study.   
PCD is a rare disease with considerable heterogeneity in prevalence rates, therefore no pre-
study considerations of statistical power were completed nor was response rate measured. 
However, the survey was translated into 9 languages to ensure as much inclusiveness at 
possible. In the qualitative section, the main limitation was that no feedback was provided 
back to the interviewees to confirm and further clarify the themes reported.  
 
In the review in Chapter 4, papers included were limited to those published in the English 
language. It is possible that there are relevant studies published in other languages. Overall 
the evidence of this review is based on a small number of heterogeneous studies (n=14) that 
are limited in size. The quality assessment of the quantitative studies revealed them to be of 
low quality with scores no greater than 8 points. Until recently, no disease-specific age 
appropriate HRQoL measures were available for PCD patients (103, 124) and to date, studies 
have used general HRQoL tools such as the SF-36 and disease specific tools for cystic 
fibrosis and COPD. These studies have also included child participants to complete measures 
that are not age appropriate without psychometric validation. Studies have included results 
where young children had help from a parent to complete these measures which may lead to 
bias (129). Only one of the studies performed analyses with and without the children who 
needed help completing the questionnaire. In addition, limited psychometric data was 
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presented on the validity of the HRQoL used, with some studies reporting validity but never 
for all of the scales. As with any review, the quality of studies included can only be assessed 
by what was reported in the final manuscript; e.g. missing information on any of the adopted 
criterion might reflect unclear reporting as opposed to a limitation in study design.  
 
With no established ‘gold standard’ for diagnosing PCD, in both Chapter 5 and Chapter 6, a 
positive PCD diagnosis was based on a surrogate reference standard. This surrogate reference 
standard consisted of an expert multidisciplinary consensus based on results from all 
available diagnostic tests. In Chapter 5, where the accuracy of each diagnostic test was 
measured in isolation and combination, it is possible that since each test contributed to the 
final diagnostic decision, our sensitivity and specificity estimates of the single tests might be 
overestimated. However, guidance does recommend that in situations without a ‘gold 
standard’, researchers can consider constructing a reference standard from multiple test 
results or can use an imperfect reference (168). There is also a risk of population bias as these 
tests were completed in highly specialised centre referrals; these results may not be 
generalisable to non-specialist settings. A final limitation in this chapter is that not all 
participants received all of the three diagnostic tests being assessed (199). To overcome this 
limitation however, further analysis was conducted examining the accuracy in the subsample 
of patients (n=180) that received all three tests. 
 
In Chapter 6, PICADAR, a predictive model for diagnosing PCD was developed and 
validated. This paper fulfils the majority of the 22 criteria recommended by recently 
published guidelines for reporting the development and validation of multivariable prediction 
models for diagnosis or prognosis (TRIPOD)(200). One discrepancy was that the researcher 
was not blinded to the diagnostic outcome when collecting the predictors for the validation 
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population. This may inflate the predictive accuracy of the predictors. Further limitations of 
PICADAR can be identified from the CHARMS checklist: critical appraisal and data 
extraction for systematic reviews of prediction model studies(201). These include the 
previously discussed limitation of not having an established diagnostic ‘gold standard’ test 
for defining the outcome. A report on how the sample size was arrived at was also not 
provided. For studies validating prediction models, a minimum of 100 events and 100 non-
events have been suggested (201). For the validation of PICADAR, this sample size was 
sought however approximately 10% had to be excluded due to missing data. A significant 
amount of data was missing for some variables. For example, a large proportion of the adult 
population did not know their gestational age and none of the children could yet know their 
fertility status. Complete case analysis was used to deal with missing data which can lead to 
bias. To overcome this obstacle, multiple imputation was used to replace missing values 
within the model’s significant variables and the pooled result obtained from five imputed 
datasets showed the best model is accurate (199).  
 
In Chapter 8, there are some limitations in the development and validation of the HRQoL 
measure. Guyatt et al (95) stated that sampling should be conducted of the complete spectrum 
of disease severity under consideration, and inclusion of patients from all subclasses (e.g., 
those of age, sex and duration of disease). In this study, it was more difficult to recruit men 
than women with only three men (14%) participating in the interviews. Approximately 6% of 
patients with PCD have cardiovascular disease however none of the 21 interviewees in the 
developmental stage had cardiovascular disease. It is therefore a limitation of the measure 
that it does not include items relevant to patients with cardiac disease. However, if the study 
population had been designed to be representative of the PCD population, only one patient 
with cardiovascular disease would have been included. While efforts were made to include all 
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ranges of severity, it is possible that not all ranges were covered without sensitive tools to 
measure disease progression. Guyatt et al.(95) also suggested that between 50-100 patients 
would ideally be interviewed and 50 patients should take part in the second round of 
interviews, as PCD is a rare disease, recruiting a sample of this size was not feasible in this 
study. Saturation was reached early in the study, which was followed by a further number of 
interviews to ensure saturation.  
In Chapter 9, this study involved the recruitment of 72 PCD patients from centres in North 
America (n=38) and the UK (n=34). All age groups were represented in the study, and 
participants had a range of disease severity (FEV1 % predicted: 26%-115%). This 
collaborative effort allowed us to recruit sufficient participants with this rare disease. 
However, given the modest size of the study population, we conducted a multi-trait analysis 
to develop the scales rather than an exploratory factor analysis (which would require >200 
patients), or more complex analysis such as Rasche analysis (which would require >100 
patients) (202). The multi-trait analysis supported the conceptual foundations of 10 scales 
with 40 items and has been recommended for use in the development of HRQoL measures 
which are expected to have correlations across domains (e.g., increased respiratory symptoms 
are likely to lead to decreased physical functioning). QOL-PCD had excellent item-to-total 
correlations and strong internal consistency across all scales (Cronbach's α 0.74 to 0.94). A 
more complex analysis including factor analysis and Rasche analysis may be an option in 
future studies if we are able to recruit larger sample sizes.  
 
10.3. Future research recommendations  
In the area of PCD, there are many opportunities to build on the existing research, projects 
and networks. This research has, and will continue to, contribute to networks of excellence 
 220 
 
that focus on research infrastructure such as the COST Action project BEAT-PCD, the 
international PCD Registry, the iPCD cohort and The Genetic Disorders of Mucociliary 
Clearance Consortium (GDMCC). This research has and will provide disease-related 
information at EU level and beyond (through guidelines, diagnosis, and patient experience). 
These research findings will increase translation of chronic disease understanding into drug 
development and healthcare innovation. Findings will contribute to the understanding on 
innovative diagnostic methods, and will lead to the improvement and further validation of 
existing methods. It is intended that these findings will contribute to guidelines for medical 
and psychosocial care in patients with PCD (including those patients who have received 
inconclusive results). Finally, it is anticipated that the findings will lead to future research on 
the impact of culture, demographics, sex and age in terms of needs, concerns and support. 
 
The results from the systematic review on the PCD patient experience and HRQoL in Chapter 
3 illustrates the need for further qualitative studies to be conducted in order to reflect 
different ethnicities and cultures. This will establish the needs and opinions specific to these 
groups and will facilitate effective management and treatment. Further explorations are also 
needed on the psychological effects of PCD on intra-familiar relationships and stress related 
to PCD across the developmental pathway and in different age groups. Chapter 3 has 
highlighted the limitations of using  generic and non-PCD specific HRQoL measures in PCD 
studies and highlighted the need for large multi-national and longitudinal studies to be 
conducted using disease-specific HRQoL measures. 
Chapter 4 presented the experiences of patients and parents referred for PCD diagnostic 
testing. The opinions and perspectives from patients presented in Chapter 4 provide a number 
of future recommendations to improvement PCD diagnosis. These include the need for 
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samples to be analysed by PCD experts, the need for results to be delivered by a PCD expert, 
and the importance for patients to have the opportunity to discuss their results with a PCD 
expert. Patients recommended that measures must be introduced to prevent late diagnosis, 
such as better knowledge of PCD by medical practitioners including relevance of past 
medical history. A resolution to the ‘inconclusive’ diagnosis result status and research to 
improve diagnostic methods were highlighted an importance factors for future guidelines. 
Patients also expressed the need to establish a patient support group in each country and to 
have online translated information on PCD available in all European languages. 
 
Findings from Chapter 5 have highlighted the importance of combination testing since no 
individual diagnostic test was 100% accurate when used in isolation. It also highlighted the 
need for tests to be standardised in both the way in which they are conducted, and in the way 
they are reported.  Data from Chapter 5 has already contributed to Taskforce diagnostic 
guidelines where consensus agreement has stated that conclusive positive diagnosis can only 
be determined if a patient has a supportive history of PCD, showed a confirmatory hallmark 
ciliary ultrastructure defects for PCD through TEM or had mutations in PCD causing genes. 
A ‘highly likely’ diagnosis is to be provided in patients with a combination of a compatible 
history of PCD, very low nNO and HSVMA abnormalities, or very low nNO plus HSVMA 
findings consistent with PCD following cell culture. Chapter 5 highlights the importance of 
characterisation of ciliary structure and function and the need for this to continue to have a 
place within diagnostic processes.  
 
The development of PICADAR (Chapter 6) demonstrates the use of a prospective cohort 
study of patients referred for PCD diagnostic testing in whom clinical features are assessed in 
a standardised way before they are diagnosed. As PICADAR was derived using combined 
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data from adults and children, there is a need for analyses to be completed stratified by age as 
it is expected that separate scores for adults and children might further improve accuracy. 
PICADAR includes a number of predictors based in early life, including gestational age and 
neonatal chest symptoms, which may be difficult to recall in adulthood. Similarly, subfertility 
was more common in the PCD-positive group and is likely to be a strong predictor for adult 
diagnoses.  
Future work on PICADAR must also take into account the settings in which it is used to refer 
patients. The sensitivity of the tool is likely to differ between patients attending different 
specialised clinics. For instance, while chronic cough will not distinguish between patients 
with and without PCD in a pulmonology clinic, chronic ENT symptoms will not be 
distinctive in an ENT clinic, where (nearly) every patient has these complaints, and cardiac 
defects will not distinguish in a cardiology setting.  Finally, as PICADAR was developed and 
validated in a UK specialist diagnostic centres, but referrals originate from non-specialist 
services, future validation will be needed in referral centres and in centres outside of the UK. 
Chapter 8 and 9 have facilitated some of the recommendations put forward in Chapter 2 by 
developing, validating and translating QOL-PCD into five European languages.  The 
measures are currently in the process of inclusion in an international PCD registry developed 
as part of the BESTCILIA FP7 study, providing an international platform to systematically 
collect data. Data in this registry is also being collected on clinical presentation and 
effectiveness of treatment (65). This will increase our understanding of the natural course and 
progression of the disease in terms of its effects on physical, emotional, role and social 
functioning (65). QOL-PCD measures are currently being included in the first international 
randomised control trial on prophylactic azithromycin. Once the analysis of the randomised 
control trial is complete, analysis will facilitate the generation of the minimum clinically 
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important difference (MCID), which is defined as the smallest difference in score on the 
HRQoL instrument that patients perceive as beneficial and that would mandate, in the 
absence of troublesome side effects and excessive cost, a change in the patient’s management 
(203). This will provide a useful means for future clinical trials to assess the benefits of 
medications or non-pharmacological interventions and will allow for comparative analysis 
across different studies and in multiple sites. Finally, it is important that QOL-PCD will also 
be used a tool at annual assessments, providing a broad assessment of well-being, as 
perceived by the patient. 
 
11. Conclusion  
Findings from this thesis have demonstrated the physical, psychological and social impact of 
PCD. The author has used a mixed method approach to address some of the identified gaps in 
knowledge on PCD that fit well with the tenets of the biopsychosocial framework (Figure 15). 
The work has led to an international study evaluating PCD patients’ experiences and their 
perspective on the diagnostic process, the findings of which were used to advise the ERS 
Task Force (TF-2014-04) on their development of clinical practice guidelines for diagnosing 
or refuting a diagnosis of PCD. The author has provided a detailed analysis of the diagnostic 
pathway in UHS to determine the accuracy of different diagnostic strategies. To overcome 
some of the barriers to being referred for diagnostic testing identified by patients, the author 
conducted a detailed analysis of the UHS database and developed the first validated tool to 
aid appropriate referral of patients for diagnostic testing. PICADAR is a simple cost-effective 
score suitable for use in referral settings, which will raise awareness among clinicians and 
lead to earlier referral. The importance of the patient perspective in the assessment of new 
treatments has led to the development of the first HRQoL measure for PCD (QOL–PCD). 
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The author has coordinated the translation of these measures for use in major European 
countries and in the Middle East. QOL-PCD has good reliability, construct validity, internal 
consistency, stability and responsiveness. QOL-PCD is short and easy to use, offering a 
promising tool for evaluating new therapies and for measuring symptoms and functioning 
during routine care.  It is hoped that the contributions made in this thesis will lead to 
improved health-related quality of life and better outcomes for PCD patients around the 
world. 
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Figure 15: Venn diagram of the biopsychosocial model showing how biophysical, psychological and social factors can influence health in PCD. 
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